Roles of the Epigenetic Modifier EZH2 in Melanoma by Zingg, Daniel Kaspar
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Roles of the Epigenetic Modifier EZH2 in Melanoma
Zingg, Daniel Kaspar
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-122963
Dissertation
Published Version
Originally published at:
Zingg, Daniel Kaspar. Roles of the Epigenetic Modifier EZH2 in Melanoma. 2015, University of Zurich,
Faculty of Science.
 Roles of the Epigenetic Modifier EZH2 in Melanoma 
 
 
 
Dissertation 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
 
von 
 
Daniel Kaspar Zingg 
von Zürich ZH 
 
Promotionskomitee 
Prof. Dr. Lukas Sommer (Vorsitz / Leitung der Dissertation) 
Prof. Dr. Konrad Basler 
Prof. Dr. Gerhard Christofori 
 
 
Zürich, 2015 

 I 
Acknowledgements 
 
I would like to express my gratitude to the following persons: 
Prof. Dr. Lukas Sommer, 
for giving me the opportunity to conduct my doctorate in his research group. You have been a 
tremendous mentor during this long journey. You have provided a very motivating and enjoyable 
scientific environment, which has taught independence and has promoted innovative ideas. 
Prof. Dr. Konrad Basler and Prof. Dr. Gerhard Christofori, 
for accepting to be members of my PhD committee, for co-reviewing my PhD thesis, and for the 
scientific inputs during my doctorate. 
All the members of the Sommer Lab, 
for contributing to an excellent scientific spirit and for being extraordinary friends over the last five 
years. Without you guys, my doctorate would have been barely as much fun as it was! 
Dr. Olga Shakhova, 
for the competent supervision during my doctorate. 
Nicole Bachelin and Monika Jenny, 
for being a great administrative team. You have always been supportive, whether it concerned 
administrative issues as much as moral encouragement, such as offering Prosecco on a New Year’s Eve 
afternoon in the Lab. 
Prof. Dr. Reinhard Dummer and Dr. Phil Cheng, 
for the extensive scientific advice concerning the clinical facet of melanoma and, Phil, for being a great 
friend. 
Prof. Dr. Raffaella Santoro and Sandra Frommel, 
for their tremendous help in performing ChIP on melanoma samples. 
Prof. Dr. Onur Boyman, Dr. Rodney A. Rosalia, and Natalia Arenas-Ramirez, 
for the stimulating collaboration on and the insights into immunoediting in melanoma. 
My family, 
especially my parents, Sabina Zingg-Trieb and Ulrich Zingg, for their encouraging and open-minded 
support and sympathy throughout my doctorate. 
Steffi, 
for being with and caring about me during my doctorate. You have brought the invaluable 
counterbalance into my science-driven life. Thank you! 
 II 
 
 
 
  
 III 
Table of contents 
 
Acknowledgements ......................................................................................................... I 
Table of contents .......................................................................................................... III 
Table of figures and tables .......................................................................................... IX 
1. Summary ................................................................................................................. 1 
2. Zusammenfassung .................................................................................................. 3 
3. Introduction ............................................................................................................ 5 
3.1. Epigenetic mechanisms ............................................................................................................... 5 
3.1.1. DNA methylation ................................................................................................................... 5 
3.1.2. Post-translational histone modifications ................................................................................ 6 
3.1.3. Histone deacetylases .............................................................................................................. 8 
3.1.4. Histone methyltransferases .................................................................................................... 9 
3.1.4.1. EZH2 function in ESCs ................................................................................................. 10 
3.1.4.2. EZH2 function in development and tissue homeostasis ................................................ 11 
3.1.4.3. EZH2 function in hematopoietic malignancies ............................................................. 12 
3.1.4.4. EZH2 function in solid cancers ..................................................................................... 14 
3.1.5. Histone demethylases ........................................................................................................... 16 
3.1.6. Histone modification readers ............................................................................................... 17 
3.2. The neural crest and its derivatives ........................................................................................ 19 
3.2.1. The embryonic neural crest .................................................................................................. 19 
3.2.2. Neural crest stem cells .......................................................................................................... 21 
 IV 
3.2.3. The melanocytic lineage ....................................................................................................... 22 
3.2.4. Adult melanocyte biology .................................................................................................... 22 
3.2.5. Melanocyte-relevant transcription factors and signaling pathways ..................................... 24 
3.2.5.1. FOXD3 and SOX9 ........................................................................................................ 24 
3.2.5.2. SOX10 ........................................................................................................................... 24 
3.2.5.3. PAX3 and MITF ............................................................................................................ 25 
3.2.5.4. WNT signaling .............................................................................................................. 25 
3.2.5.5. TGFβ signaling ............................................................................................................. 26 
3.2.6. Congenital neurocristopathies .............................................................................................. 27 
3.2.6.1. Waardenburg syndromes and Hirschsprung disease ..................................................... 27 
3.2.6.2. DiGeorge syndrome ...................................................................................................... 27 
3.2.6.3. Giant congenital nevus .................................................................................................. 28 
3.2.7. Acquired neurocristopathies ................................................................................................. 28 
3.2.7.1. Peripheral nerve sheath tumors ..................................................................................... 28 
3.2.7.2. Neuroblastoma .............................................................................................................. 29 
3.3. Melanoma .................................................................................................................................. 31 
3.3.1. Clinopathological classification of human melanoma ......................................................... 31 
3.3.1.1. Cutaneous melanoma .................................................................................................... 31 
3.3.1.2. Mucosal melanoma ....................................................................................................... 32 
3.3.1.3. Uveal melanoma ............................................................................................................ 32 
3.3.1.4. Acral lentiginous melanoma .......................................................................................... 32 
3.3.2. Cutaneous melanoma epidemiology and risk factors ........................................................... 33 
3.3.3. Pathogenesis of cutaneous melanoma .................................................................................. 33 
3.3.4. Molecular pathogenesis: oncogenic drivers of cutaneous melanoma .................................. 36 
3.3.4.1. Activating alterations affecting the BRAF locus ........................................................... 36 
3.3.4.2. Activating alterations affecting the NRAS locus ........................................................... 38 
3.3.5. Molecular pathogenesis: tumor suppressors in cutaneous melanoma .................................. 39 
3.3.5.1. CDKN2A as tumor suppressor ....................................................................................... 39 
3.3.5.2. PTEN as tumor suppressor ............................................................................................ 40 
 V 
3.3.5.3. TRP53 as tumor suppressor ........................................................................................... 40 
3.3.6. Transcription factors and signaling pathways relevant for cutaneous melanoma ................ 41 
3.3.6.1. SOX10 and SOX9 ......................................................................................................... 41 
3.3.6.2. MITF ............................................................................................................................. 42 
3.3.6.3. WNT signaling .............................................................................................................. 43 
3.3.6.4. TGFβ signaling ............................................................................................................. 44 
3.3.7. NCSC features in cutaneous melanoma ............................................................................... 45 
3.3.7.1. Cluster of differentiation 271 as NCSC-like melanoma stem cell marker .................... 46 
3.3.7.2. Melanoma stem cell markers beyond CD271 ............................................................... 46 
3.4. Melanoma therapies ................................................................................................................. 49 
3.4.1. BRAFV600E-targeting and MEK-targeting therapeutics ........................................................ 50 
3.4.2. MAPK-dependent mechanisms in MAPK inhibitor resistance ............................................ 51 
3.4.3. MAPK-independent mechanisms in MAPK inhibitor resistance ........................................ 53 
3.4.3.1. PI3K signaling-dependent resistance ............................................................................ 53 
3.4.3.2. CDK4-dependent resistance .......................................................................................... 53 
3.4.3.3. SOX10-dependent and MITF-dependent resistance ..................................................... 53 
3.4.3.4. Stemness-related resistance ........................................................................................... 54 
3.4.4. Immunotherapies .................................................................................................................. 55 
3.4.4.1. Interleukin 2-based therapies ........................................................................................ 55 
3.4.4.2. Adoptive T-cell transfer-based therapies ...................................................................... 56 
3.4.4.3. Immune checkpoint blockade as therapeutic approaches ............................................. 57 
3.5. Epigenetic regulation of the NC and cutaneous melanoma .................................................. 61 
3.5.1. Epigenetic regulation during NC development .................................................................... 61 
3.5.2. Epigenetic regulation of neurocristopathies ......................................................................... 63 
3.5.3. Epigenetic regulation of cutaneous melanoma ..................................................................... 64 
3.5.3.1. Aberrant function of DNMTs in melanoma .................................................................. 64 
3.5.3.2. Aberrant function of histone modifiers in melanoma ................................................... 65 
3.5.3.3. EZH2 and melanomagenesis ......................................................................................... 66 
 VI 
3.6. Accurately investigating the roles of EZH2 during melanomagenesis ................................ 67 
 
4. Results .................................................................................................................... 69 
4.1. My contributions to published articles and manuscripts in preparation ............................ 69 
4.1.1. Roles of NC development-relevant factors during melanomagenesis ................................. 69 
4.1.2. Roles of the epigenetic modifier EZH2 in melanomagenesis .............................................. 70 
4.1.3. Roles of the epigenetic modifier EZH2 in immunoediting .................................................. 70 
4.2. Roles of EZH2 in melanoma formation and metastatic progression ................................... 71 
4.2.1. EZH2 is highly expressed in samples of human and murine melanoma ............................. 71 
4.2.2. Increased EZH2 expression is linked to poor melanoma patient survival ........................... 72 
4.2.3. Ezh2 function is dispensable for homeostasis of melanocytes ............................................ 74 
4.2.4. N-RasQ61K-expressing nevus cells are Ezh2 independent ..................................................... 75 
4.2.5. Ezh2 function is essential for melanoma initiation .............................................................. 78 
4.2.6. Ezh2-targeted therapy interferes with melanoma progression ............................................. 80 
4.2.7. EZH2 is required for growth of human and murine melanoma ........................................... 83 
4.2.8. EZH2 inactivation prevents metastatic spread of melanoma ............................................... 88 
4.2.9. EZH2 propagates features favorable for melanoma metastasis ........................................... 90 
4.2.10. EZH2 represses a set of genes connected to patient survival .............................................. 92 
4.2.11. EZH2 target genes are functionally distinct suppressors of melanoma .............................. 95 
4.2.12. AMD1 suppresses EMT and metastatic spread of melanoma ............................................. 97 
4.3. Roles of EZH2 in melanoma immunoediting ....................................................................... 101 
4.3.1. EZH2 mediates immunomodulation .................................................................................. 101 
4.3.2. EZH2 inactivation promotes immune sensitivity and synergizes with immunotherapy .... 102 
 
 
 VII 
5. Discussion ............................................................................................................ 107 
5.1. EZH2 function in melanoma partly resembles its role in NC development ...................... 107 
5.2. Significance of Ezh2 activity for melanocytes and malignant melanoma .......................... 109 
5.3. Possible transcriptional effectors of EZH2 ........................................................................... 111 
5.4. Drivers of EZH2 target gene specificity ................................................................................ 112 
5.5. EZH2 target genes and their melanoma-suppressive functions ......................................... 114 
5.5.1. EZH2 target gene DCK ...................................................................................................... 114 
5.5.2. EZH2 target gene WDR19 .................................................................................................. 115 
5.5.3. EZH2 target gene AMD1 .................................................................................................... 116 
5.5.4. EZH2 target gene MPC1 .................................................................................................... 119 
5.6. Epigenetic regulation of immunoediting ............................................................................... 120 
5.7. Possible roles of EZH2 in MAPK-targeted therapy resistance .......................................... 122 
5.8. EZH2 inhibition as possible future melanoma therapy ...................................................... 123 
 
6. Materials and Methods ...................................................................................... 125 
6.1. In vivo experiments ................................................................................................................. 125 
6.1.1. Human biopsies .................................................................................................................. 125 
6.1.2. Mice .................................................................................................................................... 125 
6.1.3. In vivo Tamoxifen, GSK503, IL2-Cx, and a-CTLA4 application ..................................... 126 
6.1.4. Quantification of skin melanomas and metastases ............................................................. 126 
6.1.5. Isografting and allografting of murine melanoma cells ..................................................... 126 
6.1.6. Histological analysis and immunofluorescence ................................................................. 127 
6.1.7. Peripheral blood sample and tumor-infiltrating CTL analysis ........................................... 128 
 VIII 
6.2. In vitro experiments ................................................................................................................ 129 
6.2.1. EZH2 mutagenesis and mutation analysis .......................................................................... 129 
6.2.2. Cell cultures ........................................................................................................................ 129 
6.2.3. Cell transfections and in vitro GSK503 treatment ............................................................. 130 
6.2.4. Cell growth and apoptosis assays ....................................................................................... 130 
6.2.5. Boyden chamber invasion assay ........................................................................................ 130 
6.2.6. Immunofluorescence on cells ............................................................................................. 131 
6.2.7. Protein isolation and western blotting ................................................................................ 131 
6.2.8. RNA isolation and RT-qPCR ............................................................................................. 133 
6.2.9. Chromatin isolation and ChIP ............................................................................................ 135 
6.3. In silico analyses ...................................................................................................................... 137 
6.3.1. Microarray analysis ............................................................................................................ 137 
6.3.2. TCGA analysis ................................................................................................................... 137 
6.3.3. Statistical analyses .............................................................................................................. 137 
 
7. References ........................................................................................................... 139 
8. Curriculum Vitae ................................................................................................ 177 
 
 
  
 IX 
Table of figures and tables 
 
Figure 1: Post-translational histone modifications in normal and cancerous cells ................................ 7 
Figure 2: Histone modification readers, erasers, and writers ................................................................. 8 
Figure 3: Members and function of PRC2 ........................................................................................... 10 
Figure 4: Both EZH2 mutations and EZH2 overexpression propagate aberrant H3K27me3 .............. 13 
Figure 5: Chemical structure of GSK503 ............................................................................................ 14 
Figure 6: Epigenetic miss-regulation contributes to diverse aspects of tumorigenesis ....................... 15 
Figure 7: Embryonic NCSC progeny and NCSC locations in adult tissues ........................................ 20 
Figure 8: Melanocyte locations in human hair-bearing skin ............................................................... 23 
Figure 9: Clinopathological classifications of human malignant melanomas ..................................... 31 
Figure 10: The Clark model for melanoma progression ........................................................................ 35 
Figure 11: Relevant signaling pathways in malignant melanoma ......................................................... 37 
Figure 12: Timeline of FDA-approved melanoma therapeutics ............................................................ 49 
Figure 13: Mechanisms of resistance to MAPK-targeting therapeutics ................................................ 52 
Figure 14: IL2-Cx mediates a selective stimulation of CTLs ................................................................ 56 
Figure 15: CTL-stimulatory and CTL-inhibitory immune checkpoints ................................................ 59 
Figure 16: EZH2 protein is upregulated in human and murine melanoma ............................................ 72 
Figure 17: High EZH2 mRNA expression correlates with adverse patient survival ............................. 73 
Figure 18: EZH2 is frequently mutated in human melanoma ................................................................ 74 
Figure 19: Ezh2 is not required for normal melanocyte homeostasis .................................................... 76 
Figure 20: Ezh2 is not required for maintenance of dermal hyperplasia ............................................... 77 
Figure 21: Ezh2 is not required for dermal hyperplasia growth ............................................................ 78 
Figure 22: Ezh2 function is essential for skin melanoma initiation ....................................................... 79 
Figure 23: Ezh2 ablation in melanoma-bearing mice prevents disease progression ............................. 81 
Figure 24: Temporary GSK503 application in melanoma-bearing mice stabilizes disease .................. 82 
Figure 25: Heterogeneous high EZH2 expression correlates with KI67 positivity ............................... 84 
Figure 26: EZH2 inactivation in human melanoma cells interferes with cell growth ........................... 85 
Figure 27: Ezh2 ablation and GSK503 treatment attenuates melanoma cell proliferation in vivo ........ 86 
Figure 28: Ezh2 inactivation interferes with murine B16-F10 melanoma growth ................................ 86 
Figure 29: Ezh2 inactivation prevents growth of allografted Tyr::N-RasQ61K Ink4a-/- melanoma ......... 87 
Figure 30: RIM allografts are of a melanoma origin ............................................................................. 88 
Figure 31: Ezh2 ablation before onset of melanomagenesis prevents metastases formation ................ 89 
 X 
Figure 32: EZH2 function is required for metastatic progression of Tyr::N-RasQ61K Ink4a-/- 
 cutaneous melanoma ............................................................................................................ 90 
Figure 33: EZH2 is required for several features of metastatic progression ......................................... 91 
Figure 34: Gene expression array heat maps ......................................................................................... 92 
Figure 35: EZH2 target genes are linked to improved melanoma patient survival ............................... 93 
Figure 36: Depletion of EZH2 target genes rescues EZH2 inactivation phenotypes ............................ 96 
Figure 37: ETGs are de-repressed in vivo upon Ezh2 inactivation ........................................................ 97 
Figure 38: The ETG AMD1 is a tumor suppressor that circumvents EMT ........................................... 98 
Figure 39: Amd1 suppression promotes in vivo melanoma metastasis .................................................. 99 
Figure 40: Ezh2 inactivation promotes upregulation of immune stimulators in B16-F10 
 melanoma ........................................................................................................................... 101 
Figure 41: Ezh2 inactivation and immunotherapy synergistically abolish melanoma growth ............ 103 
Figure 42: Ezh2 inactivation and immunotherapy co-promotes CTL tumor infiltration ..................... 104 
Figure 43: Ezh2 inactivation counteracts adaptive immune evasion and resistance ........................... 105 
Figure 44: Graphical summaries of distinct roles of EZH2 during melanomagenesis ........................ 108 
Figure 45: Polyamine synthesis and connection to EZH2 activity ...................................................... 117 
Figure 46: Full scans of western blots ................................................................................................. 132 
 
 
Table 1: Roles of epigenetic modifiers during NC development and in neurocristopathies .............. 62 
Table 2: Clinical data corresponding to human nevus and melanoma biopsies ................................. 72 
Table 3: TCGA-based association of high gene expression in (Figure 35a) with melanoma 
 patient survival ..................................................................................................................... 93 
Table 4: P-values related to (Figure 35d, e) ....................................................................................... 94 
Table 5: TCGA-based association of high expression of immunogenic genes with melanoma 
 patient survival ................................................................................................................... 102 
Table 6: Mouse genotyping primers ................................................................................................. 125 
Table 7: Primary antibodies .............................................................................................................. 127 
Table 8: Secondary antibodies .......................................................................................................... 127 
Table 9: Human EZH2 mutagenesis primers .................................................................................... 129 
Table 10: Human EZH2 sequencing primers ..................................................................................... 129 
Table 11: RNAi constructs ................................................................................................................. 130 
Table 12: Mouse RT-qPCR primers ................................................................................................... 133 
Table 13: Human RT-qPCR primers .................................................................................................. 134 
Table 14: Human ChIP primers .......................................................................................................... 135 
  
 1—1 
1. Summary 
 
The epigenetic modifier EZH2 is a methyltransferase that obstructs gene expression through 
trimethylation of lysine 27 in histone 3. While EZH2 function is critical for developmental processes and 
homeostasis of several adult tissues, aberrant EZH2 activity has been connected to a variety of cancers. 
Likewise, in cutaneous melanoma, a deadly skin cancer arising from melanocytes, EZH2 levels are 
elevated and correlate with reduced patient survival. However, evidence for functional roles of EZH2 in 
the course of melanoma formation and progression remain poor. In my PhD thesis, I reveal central roles 
of EZH2 in promoting growth and especially metastasis of cutaneous melanoma. 
In a transgenic mouse model of cutaneous melanoma, conditional Ezh2 ablation counteracted growth of 
skin tumors without affecting homeostasis of physiological melanocytes and benign, nevus-like 
hyperplasia. Importantly, whether Ezh2 was ablated before or after the onset of cutaneous 
melanomagenesis, emergence of distant metastases was completely prevented. Likewise, treatment of 
melanoma-bearing mice with the preclinical EZH2 inhibitor GSK503 virtually abolished metastases 
formation, resulting in prolonged survival. In support, EZH2 inactivation in human and murine 
melanoma cells suppressed EMT and cell motility, which are both prerequisites for metastasis. 
Furthermore, interference with EZH2 activity in human melanoma cells allowed the identification of 
novel EZH2 target genes using transcriptome and methylated histone enrichment analyses. In a cohort of 
melanoma patients, high expression of these genes correlated with prolonged survival. In contrast, 
silencing of EZH2 targets promoted either melanoma cell proliferation or metastases in vivo, while a 
third group of target genes facilitated immunogenicity. These findings establish this set of EZH2 target 
genes as a functionally diverse set of tumor suppressors. 
Cutaneous melanoma is a cancer with a prominent phenotypic plasticity involving metastatic spread and 
expeditious resistance to therapy. EZH2 acts as a central node in driving melanoma growth, metastatic 
progression, and immunoediting through dynamic repression of distinct tumor suppressors. Therefore, 
targeted EZH2 inhibition might represent a highly promising strategy to interfere with these aspects of 
melanomagenesis, potentially locking tumor plasticity and augmenting therapeutic responses. 
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2. Zusammenfassung 
 
Der epigenetische Modifikator EZH2 ist eine Methyltransferase, welche durch die Methylierung von 
Lysin 27 des Histon-Proteins 3 die Expression von Genen unterdrückt. EZH2 hat die Aufgabe, 
verschiedene Prozesse während der Embryonalentwicklung sowie die Homöostase von adultem Gewebe 
zu steuern. Fehlfunktionen von EZH2 können dementsprechend zur Entstehung von Krebs beitragen. 
Das maligne Melanom, auch schwarzer Hautkrebs genannt, entwickelt sich aus Hautpigmentzellen. In 
dieser Krebserkrankung ist EZH2 häufig hochreguliert, wobei die erhöhte Expression mit einer 
verkürzten Lebenserwartung von Melanompatienten korreliert. Jedoch wurde bis heute nicht 
nachgewiesen, ob EZH2 direkt die Entstehung des Melanoms beeinflusst. In meiner Dissertation zeige 
ich auf, dass die genunterdrückende Funktion von EZH2 wesentlich zur Entstehung sowie zur 
Metastasierung des Melanoms beiträgt. 
Um das maligne Melanom in angemessener Weise zu studieren, verwendete ich transgene Mäuse, 
welche im Verlauf ihres Lebens schwarzen Hautkrebs entwickeln. Die Entfernung des Ezh2-Gens aus 
dem Genom dieser Mäuse verhinderte die Entstehung maligner Tumoren. Jedoch beeinflusste diese 
Ezh2-Gendeletion die Homöostase von physiologischen Hautpigmentzellen und gutartigen Naevuszellen 
nicht. Massgeblich war aber, dass die Ezh2-Deletion die Metastasen-Bildung in bereits an Melanomen 
erkrankten Mäusen verhinderte. Basierend auf diesen Erkenntnissen behandelte ich melanomkranke 
Mäuse mit einem pharmakologischen Hemmstoff, welcher die Aktivität von EZH2 unterdrückt. Dies 
verhinderte die Entstehung von Metastasen und verlängerte die Lebensdauer der Tiere. Zudem konnte 
ich aufzeigen, dass die Unterdrückung von EZH2 die Motilität von Melanomzellen beeinflusst. Eine 
erhöhte Motilität wird mit dem Abwandern von Krebszellen von Primärtumoren und dem Kolonisieren 
von inneren Organen, sprich der Metastasierung, in Verbindung gebracht. 
Des Weiteren analysierte ich, welche Gene EZH2 während der Melanomentstehung unterdrückt. 
Interessanterweise korrelierte eine Hochregulierung dieser Gene wiederum mit einer positiven Prognose 
für Melanompatienten. Zudem zeigten funktionelle Experimente, dass diese Gene unterschiedliche 
Vorgänge während der Melanomentstehung beeinträchtigen. Während eine Gruppe von Genen das 
 2—4 
Wachstum der Tumoren unterband, behinderten andere Gene die Motilität von Melanomzellen und 
dementsprechend die Metastasierung im Tiermodell. Ein dritter Satz von Genen aktivierte Immunzellen, 
welche die Melanomzellen angriffen.  
Das maligne Melanom ist eine Krebsart, die sich optimal an äussere, sich verändernde Gegebenheiten 
anpassen kann. Diese Plastizität trägt zu der Metastasierung wie auch zur Resistenzbildung gegenüber 
Krebstherapien bei. Meine Ergebnisse verdeutlichen, dass EZH2 die Plastizität des Melanoms durch 
dynamische Unterdrückung von Genen mit unterschiedlichsten anti-tumoralen Funktionen steuert. 
Deshalb stellt die Hemmung von EZH2 mit neuartigen Substanzen eine vielversprechende, zukünftige 
Melanomtherapie dar, möglicherweise als Ergänzung für bereits bestehende Therapien. 
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3. Introduction 
 
3.1. Epigenetic mechanisms 
During embryogenesis, programs of gene expression promote development and specification of different 
organs and tissues. These programs are initiated by distinct sets of transcription factors (Reik, 2007). 
Conceivably, re-expression of key embryonic stem cell (ESC) transcription factors in fibroblasts can 
result in reprogrammed ES-like cells. However, this process is relatively inefficient, partly due to 
silencing of POU domain class 5 transcription factor 1 (Pou5f1), one of the ESC transcription factors, 
through DNA methylation of its endogenous promoter (Epsztejn-Litman et al., 2008; Feldman et al., 
2006; Takahashi and Yamanaka, 2006). Thus, changes in gene expression are not only driven by 
transcription factors, but also accompanied or even caused by chemical alterations, such as methylation 
of DNA, one of the so-called epigenetic modifications. The term “epigenetics” is defined as all 
meiotically and mitotically heritable changes in gene expression that are not coded in the DNA sequence 
(Holliday, 1987). Among the mechanisms used to initiate and sustain epigenetic regulation, we find 
DNA methylation and post-translational modifications of histone tails (Reik, 2007). 
 
3.1.1. DNA methylation 
DNA is methylated on cytosine residues in cytosine-guanine dinucleotides (CpG). ∼80% of all CpGs are 
methylated, and DNA methylation represses transcription in a manner that depends on the location and 
density of the methyl-CpGs relative to a gene promoter. Stretches of CpGs are referred to as CpG islands 
and are present in promoter regions of ∼60% of the loci of vertebrate genomes. In contrast to isolated 
CpGs, CpG islands remain mostly unmethylated, except during development, where a few key loci 
become stably silent through corresponding CpG island methylation. During murine embryogenesis, 
global CpG methylation levels decline rapidly after zygosis to ∼30% of typical somatic levels, but de 
novo methylation restores normal levels by the time point of implantation (Bird, 2002; Reik, 2007). The 
essence of dynamic DNA de- and re-methylation during development becomes apparent with the 
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resulting embryonic lethality upon knockout of the de novo DNA methyltransferases 3a and 3b 
(Dnmt3a/b) (Hsieh, 1999; Okano et al., 1999; 1998). In contrast, ESC self-renewal is independent of 
Dnmt3a/b function (Tsumura et al., 2006). During embryogenesis, Dnmt3a/b silences pluripotency genes 
including Pou5f1 to induce lineage specifications (Feldman et al., 2006). Along serial somatic cell 
divisions, DNA methylation patterns are then maintained by Dnmt1 (Pradhan et al., 1999). Maintenance 
of these patterns is as essential as de novo methylation of genes, highlighted by embryonic lethality upon 
Dnmt1 deletion (Li et al., 1992). In most cancers, global CpG methylation levels are reduced in 
comparison to their normal tissue counterparts (Greger et al., 1989; Weber et al., 2005). Comparably, in 
a murine carcinoma model, methylation decreases during progression from benign neoplasia to 
malignant tumors (Fraga et al., 2004), while Dnmt1 attenuation in adult mice promotes various cancers 
(Eden et al., 2003; Gaudet et al., 2003). Acquired hypomethylation might sustain chromosomal 
instability through relieved mitotic recombination and activation of transposons, thus contributing to 
tumorigenesis (Bestor, 2005; Eden et al., 2003; Karpf and Matsui, 2005). In contrast, hypermethylation 
of CpG islands in promoter regions of various tumor suppressors is a major event in promoting cancer 
(Herman and Baylin, 2003). However, different cancer types usually acquire distinct hypermethylomes 
(Costello et al., 2000; Esteller et al., 2001a; Esteller, 2007). Interestingly, CpG island methylation-
mediated silencing frequently functions as secondary hit in cooperation with an already-present mono-
allelic genetic loss of a tumor suppressor resulting in homozygous abrogation (Esteller et al., 2001b). As 
a potential strategy to target cancer, forced re-expression of aberrantly silenced genes through chemical 
compounds preventing CpG methylation has been emphasized (Herman and Baylin, 2003). 5-
azanucleosides, such as azacitidine (Celgene) and decitabine (Janssen-Cilag), are cytidine analogues that 
are incorporated into DNA and covalently bind DNMTs resulting in demethylation (Jones and Taylor, 
1980). These molecules have substantial clinical activity in patients with myelodysplastic syndrome 
(Fenaux et al., 2009) and might accordingly be considered for further hematopoietic and solid 
malignancies (Azad et al., 2013). 
 
3.1.2. Post-translational histone modifications 
Apart from DNA methylation, chromatin density determines DNA accessibility. Chromatin, the 
physiological form of the eukaryotic genome, is a polymer of DNA and histone (H) proteins. 
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Hierarchical chromatin structure dynamically changes during fundamental cellular processes, such as 
DNA replication, recombination, transcription, repair, and chromosome segregation. Chromatin 
structures can be broadly divided into the loose euchromatin and the dense heterochromatin. However, 
site-specific DNA access mostly depends on local nucleosome repositioning (Elgin and Workman, 
2000). The nucleosome is the repeating core unit of chromatin built of an octamer of canonical histone 
proteins (2 of each: H2A, H2B, H3, H4) wrapped with 146 base pairs of DNA (Luger et al., 1997; 
Richmond and Davey, 2003). Apart from canonical histones, diverse histone variants confer unique 
functions within the chromatin template, thus increasing chromatin complexity and contributing to key 
developmental processes as much as tumorigenesis (Vardabasso et al., 2014). Histones are post-
translationally modified, mostly at their N-terminal tails. The great diversity of modifications includes 
acetylation (ac), methylation (me), sumoylation, and ubiquitination (ub) at lysines (K), methylation at 
arginines, and phosphorylation (P) at serines and threonines (Figure 1). 
 
 
Figure 1 #  Post-translational histone modifications in normal and cancerous cells. Histones can undergo diverse post-
translational modifications mainly along their protruding N-terminal tails, but also within their C-terminal regions. In the 
right combination and translated by the appropriate effectors, this histone modification code establishes the global and local 
chromatin density, which ultimately determines gene expression. Disruption of these normal patterns results in aberrant 
gene expression, which may contribute to cancer. “Yellow flash”, histone modifications known to be conductive to cancer. 
Ac, acetylation; Me, methylation; H, histone; P, phosphorylation; Ub, ubiquitination (adapted from: Rodríguez-Paredes and 
Esteller, 2011). 
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Depending on the position of the corresponding amino acid in the histone tail, a given modification 
might either facilitate or suppress DNA access. For instance, trimethylation of K27 in histone 3 
(H3K27me3) prevents DNA access through chromatin compaction, while H3K4me3 maintains an open 
chromatin structure. Similarly, H3K9me3 is a repressive mark, while H3K9ac induces DNA 
accessibility. Thus, the composition of such modifications at a given nucleosome ultimately defines 
accessibility of the nearby DNA sequence (Huang et al., 2014; Kouzarides, 2007). Dynamic addition and 
removal of post-translational modifications is catalyzed by two groups of enzymes termed writers and 
erasers, respectively (Jenuwein and Allis, 2001). A third group of proteins interprets the histone 
modification code and are referred to as readers (Musselman et al., 2012) (Figure 2). Proper organization 
of DNA into chromatin through the according histone modification code and its interpretation is essential 
for the integrity of lineage specifications during development and tissue homeostasis in the adult 
including maintenance of cell identities. Hence, misplacement and misinterpretation of the code can 
likely result in developmental defects and cancer (Laugesen and Helin, 2014) (Figure 1). 
 
 
Figure 2 #  Histone modification readers, erasers, and writers. (a, b) Addition of post-translational histone 
modifications is catalyzed by enzymes termed writers (a), while erasers (b) remove histone modifications. (c) A third group 
of proteins interprets the histone modification code, referred to as readers (adapted from: Constellation Pharmaceuticals, 
http://www.constellationpharma.com/research-development/). 
 
3.1.3. Histone deacetylases 
Histone deacetylases (HDAC) are enzymes that remove acetyl groups from various lysines in histone 
tails. Although HDACs by themselves do not display exquisite lysine specificity, they often operate in 
large protein complexes, which confer their lysine specificity. Acetylation predominantly confers open 
chromatin, thus HDAC activity results in more condensed chromatin leading to repression of gene 
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transcription (Kelly and Cowley, 2013). HDACs play crucial roles during development. ESC self-
renewal is dependent on Hdac1 function (Dovey et al., 2010; Lagger et al., 2002). Comparably, Hdac1 
and Hdac2 knockout is embryonically lethal (Lagger et al., 2002; Montgomery et al., 2007). 
Interestingly, interference with Hdac activity in various tissues leads to a visible phenotype, only when 
Hdac1 and Hdac2 are simultaneously depleted, indicating a partial functional redundancy between these 
homologs (Kelly and Cowley, 2013).  Among many target genes, HDACs suppress cell cycle inhibitors 
in ESCs (Lagger et al., 2002; Yamaguchi et al., 2010). Accordingly, HDAC inactivation interferes with 
growth of a variety of cancer cells (Rosato et al., 2003; Senese et al., 2007). Therefore, targeted HDAC 
inhibition has been proposed as a strategy to counteract tumorigenesis (Azad et al., 2013), and two 
HDAC inhibitors, vorinostat (Merck) and romidepsin (Celgene), have demonstrated profound clinical 
responses in cutaneous T-cell lymphoma patients (Duvic et al., 2007; Lane and Chabner, 2009; 
Whittaker et al., 2010). Interestingly, upon exposure of tumor cells to chemotherapy, HDAC inhibition 
prevents emergence of resistant sub-clones, while chemotherapy-tolerant cells regain sensitivity through 
HDAC inhibition (Sharma et al., 2010). This highlights the significance of epigenetic regulation for 
tumor plasticity.  
 
3.1.4. Histone methyltransferases 
Histone methyltransferases catalyze methylation of lysines and commonly contain a suppressor of 
variegation 3-9 - enhancer of zeste - trithorax (SET) domain, which represents their catalytic subunit. For 
instance, suppressor of variegation 3-9 H1 (SUV39H1) and enhancer of zeste homolog 2 (EZH2) sustain 
H3K9me3 and H3K27me3, respectively, which are both repressive marks (Mohan et al., 2012; Rea et al., 
2000). ESCs mostly contain euchromatin. During differentiation, however, Suv39h1 promotes chromatin 
compaction through H3K9me3, which then recruits Dnmt3a/b to stably silence pluripotency genes, such 
as Pou5f1 (Elgin and Workman, 2000; Epsztejn-Litman et al., 2008; Feldman et al., 2006; Lehnertz et 
al., 2003; Maison et al., 2002; Peters et al., 2001). Likewise, SET domain bifurcated 1 (SETDB1), 
another H3K9 methyltransferase, maintains ESC differentiation (Bilodeau et al., 2009) and is amplified 
in diverse cancers, thus inducing aberrant H3K9me3-mediated silencing of tumor suppressor genes (Ceol 
et al., 2011). Interestingly, depletion of Suv39h1 increases H3K27me3 at genomic sites usually covered 
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by H3K9me3. This underscores the plasticity of chromatin architecture and the partial redundancy 
between different histone modifications (Peters et al., 2001; 2003). 
3.1.4.1. EZH2 function in ESCs 
In contrast to H3K9me3, the repressive H3K27me3 modification is mostly present in open chromatin of 
ESCs and declines during differentiation. Accordingly, H3K9me3 and H3K27me3 are mutually 
exclusive marks at a given locus. Besides H3K27me3, H3K9ac and H3K4me3, both marks indicative of 
active transcription, are abundant in ESCs. In this cellular context, H3K27me3 allows repression of 
lineage commitment genes, while H3K9ac and H3K4me3 ensure pluripotency gene expression (Azuara 
et al., 2006; Bernstein et al., 2006; Krejcí et al., 2009; Lindroth et al., 2008; Meshorer et al., 2006; 
Mikkelsen et al., 2007; Pan et al., 2007; Xie et al., 2013). H3K27me3 is maintained by polycomb 
repressive complex 2 (PRC2), which is composed of, among others, embryonic ectoderm development 
(EED), suppressor of zeste 12 (SUZ12), and the catalytic unit EZH2 (Figure 3). 
 
 
Figure 3 #  Members and function of PRC2. (a) The PRC2 complex contains EZH2, EED, and SUZ12, while EZH2 
catalyzes H3K27 trimethylation. The SET domain of EZH2 confers this activity. (b) H3K27me3 then induces a cascade of 
events including recruitment of PRC1, which mediates ubiquitination of H2A-K119. This histone mark is thought of 
inducing chromatin compaction, thus repressing transcription. EED, embryonic ectoderm development; EZH2, enhancer of 
zeste homolog 2; H2A-K119, histone 2A lysine 119; H3K27, histone 3 lysine 27; PRC, polycomb repressive complex; 
SET, suppressor of variegation 3-9 - enhancer of zeste - trithorax; SUZ12, suppressor of zeste 12 (adapted from: Bracken 
and Helin, 2009). 
 
Ablation of any of the PRC2 members results in dampened H3K27me3, thus EZH2 can be catalytically 
active only in conjunction with all PRC2 members (Cao and Zhang, 2004; Cao et al., 2002; Ciferri et al., 
2012; Czermin et al., 2002; Kuzmichev et al., 2002; Müller et al., 2002). Surprisingly, despite de-
repression of lineage commitment genes, ESCs can be isolated from Ezh2-/-, Eed-/-, and Suz12-/- 
blastocysts, and pluripotency of these ESC cultures does not seem to be majorly affected, likely due to 
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maintained expression of stemness genes. However, PRC2-dysfunctional ESCs are more prone to 
differentiate spontaneously and incapable of giving rise to cells of all germ layers in vitro (Boyer et al., 
2006; Chamberlain et al., 2008; Lee et al., 2006; Pasini et al., 2007; Shen et al., 2008). Likewise, 
deletion of Ezh2, Eed, or Suz12 is embryonically lethal around gastrulation, thus PRC2 activity in vivo is 
absolutely required for early lineage specifications (Faust et al., 1998; 1995; O'Carroll et al., 2001; Pasini 
et al., 2004). 
3.1.4.2. EZH2 function in development and tissue homeostasis 
According to its function in ESCs, PRC2 is also regulating lineage-specific stem cell maintenance versus 
differentiation in both development and adult tissue homeostasis (Laugesen and Helin, 2014). For 
instance, depletion of Ezh2 in fetal hematopoietic stem cells (HSC) impairs self-renewal resulting in 
perinatal anemia, while adult HSCs are not immediately affected by loss of Ezh2 (Mochizuki-Kashio et 
al., 2011). However, exhaustion of HSCs in aged mice is counteracted by Ezh2 overexpression 
(Kamminga et al., 2006). In contrast, deletion of the Ezh2 homolog Ezh1 is not affecting fetal HSCs, but 
interferes with adult HSC maintenance (Hidalgo et al., 2012). Thus, PRC2 operates through EZH2 and 
EZH1, respectively, to differentially regulate fetal liver hematopoiesis and maintenance of the adult HSC 
compartment in the bone marrow. Besides HSC maintenance, PRC2 is also required for lymphopoiesis 
(Hidalgo et al., 2012; Mochizuki-Kashio et al., 2011). Ezh2 knockout impairs early stages of B-cell 
differentiation and homing of B-cells to germinal centers (Béguelin et al., 2013; Caganova et al., 2013; 
Su et al., 2003; Velichutina et al., 2010), while Ezh2 is required for proper differentiation of T-helper 
cells (Tumes et al., 2013). Apart from the hematopoietic system, the skin and the central nervous system 
(CNS) represent hierarchically structured organs with self-renewing stem cells giving rise to 
differentiating progeny (Hsu and Fuchs, 2012). Conceivably, epigenetic mechanisms are likely to also 
regulate homeostasis of these organs. Indeed, ablation of Ezh2 affects self-renewal of neonatal basal skin 
progenitors, however, without apparent consequence for skin integrity. Ezh2 expression declines in adult 
skin progenitors at the expense of elevated Ezh1, resembling the Ezh2-Ezh1 interplay in HSCs (Ezhkova 
et al., 2009). Hence, an Ezh1 Ezh2 double knockout severely compromises hair follicle and skin 
homeostasis with progressive degeneration of these tissues (Ezhkova et al., 2011). This also includes a 
restriction in fate determination towards lineage-committed Merkel cells, a progeny of basal skin 
progenitors (Bardot et al., 2013). Comparably, CNS-specific depletion of Ezh2 during embryogenesis 
alters cortical neurogenesis by shifting neural progenitor self-renewal towards basal progenitor 
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differentiation (Pereira et al., 2010), while the in vitro differentiation potential and maintenance of neural 
stem cells (NSC) is Ezh2 dependent. Ezh2 overexpression skews NSC differentiation towards 
astrogenesis (Sher et al., 2012; 2008; Sparmann et al., 2013). During cortical development, PRC2 
activity is similarly required for the neurogenic-astrogenic competence switch of neural progenitors 
(Hirabayashi et al., 2009), and changes in PRC2 activity during corticogenesis might be fine-tuned by 
microRNAs (miR) (Neo et al., 2014b). Importantly, Ezh2 does not only govern CNS development, but is 
also required for adult neurogenesis. Deletion of Ezh2 in NSCs of adult mice interferes with 
hippocampal NSC activation and neuron production, resulting in learning and memory disabilities 
(Zhang et al., 2014a). Interestingly, germline mutations in EZH2 predispose to Weaver syndrome, a 
congenital disorder composed of craniofacial malformations as well as intellectual disabilities (Gibson et 
al., 2012; Tatton-Brown et al., 2011; 2013). The latter might reflect mutated EZH2-provoked NSC 
dysfunction, in analogy to the Ezh2 knockout-induced behavioral phenotype in mice (Zhang et al., 
2014a). 
3.1.4.3. EZH2 function in hematopoietic malignancies 
In accordance to germline EZH2 mutations causing Weaver syndrome, somatic functional mutations in 
epigenetic modifiers might conceivably facilitate tumorigenesis. Indeed, mutations in epigenetic 
regulators including PRC2 members are frequently occurring in diverse cancers (Roy et al., 2014). For 
instance, ∼20% of non-Hodgkin lymphoma patients (e.g. follicular, large B-cell, or high-grade B-cell 
lymphomas) as well as T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia 
(AML) patients harbor tumor-specific EZH2 mutations, in which case EZH2 mutational status usually 
correlates with poor patient prognosis (Abdel-Wahab et al., 2011; Bödör et al., 2011; 2013; Capello et 
al., 2011; Ernst et al., 2010; Grossmann et al., 2011; Guglielmelli et al., 2011; Lohr et al., 2012; 
Makishima et al., 2010; Morin et al., 2010; 2011; Nikoloski et al., 2010; Okosun et al., 2014; Ryan et al., 
2011; Wang et al., 2013b; Zhang et al., 2012b). Furthermore, several highly recurrent mutations, such as 
EZH2Y646C/F/H/N/S, EZH2A682G, and EZH2A692V, affect the SET domain of EZH2 and confer increased 
catalytic activity, resulting in aberrant H3K27me3 (Majer et al., 2012; McCabe et al., 2012a; Ott et al., 
2014; Ryan et al., 2011; Sneeringer et al., 2010; Wigle et al., 2011; Yap et al., 2011) (Figure 4a, b).  
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Figure 4 #  Both EZH2 mutations and EZH2 overexpression propagate aberrant H3K27me3. (a) EZH2WT displays 
high efficiency to catalyze H3K27me1 and H3K27me2, but only marginal catalytic activity for H3K27me3. (b) In contrast, 
PRC2 bearing mutated EZH2, such as EZH2Y641N, has greatly enhanced capacity for H3K27me3. (c) Similarly, increased 
expression of EZH2WT leads to higher overall H3K27me3 levels, presumably due to a net increase in assembled PRC2 
complexes. Thus, both EZH2 mutations and EZH2 overexpression may propagate aberrant H3K27me3-dependent gene 
silencing potentially contributing to tumorigenesis. WT, wild type (adapted from: O'Meara and Simon, 2012). 
 
Accordingly, overexpression of wild type (wt) Ezh2 and Ezh2Y646N/F in murine HSCs and germinal center 
B-cells promotes neoplastic transformation reminiscent of myeloproliferative disease and lymphoma, 
respectively, while Ezh2 depletion prevents AML and lymphoma formation (Berg et al., 2014; Béguelin 
et al., 2013; Caganova et al., 2013; Herrera-Merchan et al., 2012; Shi et al., 2013; Tanaka et al., 2012; 
Velichutina et al., 2010). These findings establish EZH2 as an oncogenic driver of hematopoietic 
malignancies and have prompted the development of small molecules interfering with its 
methyltransferase activity. Specific EZH2 inhibitors including GSK126, GSK343, and GSK503 (Figure 
5) (GlaxoSmithKline; Béguelin et al., 2013; McCabe et al., 2012b; Verma et al., 2012), EPZ-5687 and 
EPZ-6438 (Epizyme; Knutson et al., 2013; 2012), EI1 (Novartis; Qi et al., 2012), UNC1999 (Sigma-
Aldrich; Konze et al., 2013), and “compound 3” (Constellation Pharmaceuticals; Garapaty-Rao et al., 
2013) sterically hinder the SET domain of EZH2WT and mutant EZH2, which results in reduced 
H3K27me3 and de-repression of genes with tumor suppressor potentials. These compounds induce 
apoptosis and cell cycle arrest in vitro, and counteract lymphoma and leukemia progression in 
transplantation models (Béguelin et al., 2013; Caganova et al., 2013; Garapaty-Rao et al., 2013; Knutson 
et al., 2012; Konze et al., 2013; McCabe et al., 2012b; Qi et al., 2012; Xu et al., 2015a). Comparably, 
GSK503 abrogates Ezh2Y646N-induced murine germinal center B-cell neoplasia (Béguelin et al., 2013). 
Thus, EZH2 inhibition represents a strategy with high potential to target hematopoietic malignancies and 
is currently clinically verified in phase I studies (GSK126, NCT02082977; EPZ-6438, NCT01897571). 
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Figure 5 #  Chemical structure of GSK503. GSK503 is an EZH2 methyltransferase-inhibiting compound with similar 
potency for EZH2WT and mutant EZH2 (Kiapp = 3–27nM). Importantly, GSK503 is more than 200-fold selective over EZH1 
(Kiapp = 636nM) and more than 4’000-fold selective over other histone methyltransferases. GSK503 displays favorable 
pharmacokinetics in mice, thus represents an optimal tool for in vivo experiments (adapted from: Béguelin et al., 2013). 
 
3.1.4.4. EZH2 function in solid cancers 
As originally identified in breast and prostate cancer (Bracken et al., 2003; Kleer et al., 2003; 
Varambally et al., 2002), EZH2 has been found, apart from being mutated, amplified or overexpressed in 
most cancers (Figure 4a, c), with a good correlation between high EZH2 expression levels and poor 
disease outcome. In many tissues as much as in the corresponding malignancies, EZH2 sustains stem cell 
identity and proliferation by transcriptional repression of senescence and differentiation genes (Laugesen 
and Helin, 2014). For instance, EZH2 depletion attenuates stemness features of glioblastoma cells (de 
Vries et al., 2015; Kim et al., 2013; 2015; Orzan et al., 2011; Suvà et al., 2009), akin to the role of PRC2 
in propagating neural stem cells (Hirabayashi et al., 2009; Pereira et al., 2010; Sher et al., 2008). 
Likewise, in normal and cancerous breast epithelial cells, PRC2 induces stemness features, while in vivo, 
ectopic Ezh2 expression initializes hyperplasia in murine mammary glands (Chang et al., 2011; Gonzalez 
et al., 2009; 2014; Iliopoulos et al., 2010; Kleer et al., 2003; Li et al., 2009). Interestingly, PRC2 not only 
promotes breast carcinoma growth, but is also a major regulator of a process referred to as epithelial to 
mesenchymal transition (EMT) (Iliopoulos et al., 2010; Tiwari et al., 2013), the initial step in a course of 
events required for tumor cell dissemination and distant metastasis (Tam and Weinberg, 2013). In a 
mouse model of prostate cancer, Ezh2 ablation similarly interferes with EMT and metastatic progression 
(Min et al., 2010). Suz12-deficient ESCs show an increased expression of E-cadherin (Cdh1), a major 
adhesion molecule of epithelial cells, while in breast, prostate, lung, colon, and pancreatic cancer cells, 
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PRC2 epigenetically silences CDH1, thus initializing EMT (Cao et al., 2008; Herranz et al., 2008; 
Iliopoulos et al., 2010; Oktyabri et al., 2014; Tiwari et al., 2013). Most importantly, SUZ12 and EZH2 
depletion in breast, pancreatic, and ovarian cancer cell xenotransplants has been shown to prevent tumor 
relapse after chemotherapy, thus PRC2-mediated gene silencing confers adaptive chemoresistance (Hu et 
al., 2010; Iliopoulos et al., 2010; Ougolkov et al., 2008). Hence, beyond regulating tumor growth in 
similar ways as propagating normal tissue homeostasis, aberrant PRC2 activity could be held responsible 
for tumor plasticity resulting in EMT, metastasis, and resistance to chemotherapy (Tam and Weinberg, 
2013) (Figure 6). 
 
 
Figure 6 #  Epigenetic miss-regulation contributes to diverse aspects of tumorigenesis. In the course of tumorigenesis, 
aberrant epigenetic regulation contributes to distinct processes favorable for cancer progression. Epigenetic modifiers have 
been shown to propagate cell cycle (a), suppress apoptosis (b), drive EMT resulting in metastasis (c), sustain tumor 
stemness (d), establish chemoresistance (e), and attenuate immune responsiveness (f). Accordingly, in various cancers, 
EZH2 promotes tumor progression and plasticity through silencing of tumor suppressors, such as cell cycle inhibitors, 
epithelial adhesion molecules, and differentiation genes. Consequently, an effective way in counteracting tumor progression 
and plasticity might be comprised of targeting epigenetic modifiers, such as EZH2 (adapted from: Azad et al., 2013). 
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A growing body of evidence suggests that EZH2, apart from canonically silencing genes through 
H3K27me3, mediates tumorigenesis by non-canonical mechanisms. Protein kinase B (AKT) can 
phosphorylate EZH2 at serine 21. Phospho-EZH2, in return, methylates signal transducer and activator 
of transcription 3 (STAT3), and methylated STAT3 promotes stemness features of glioblastoma (Kim et 
al., 2013). In prostate cancer, phospho-EZH2 similarly activates transcription in a PRC2-independent 
manner (Xu et al., 2012), while in breast cancer, EZH2 non-canonically regulates gene transcription 
through interaction with nuclear factor kappa-B (NF-κB) or β-catenin (CTNNB1) (Lee et al., 2011; Shi 
et al., 2007). Nevertheless, independently of the modality of EZH2-sustained oncogenesis, inhibition of 
the catalytic SET domain, the central node of EZH2 function, likely interferes with distinct aspects of 
solid cancer formation (Figure 6). Indeed, EZH2 inhibitors that have proven valid in lymphoma show 
promising features in preclinical models of diverse solid cancers (Amatangelo et al., 2013; Ferraro et al., 
2014; Kim et al., 2013; Knutson et al., 2013; Liu et al., 2015; Zingg et al., 2015), thus might conceivably 
be considered for tumor entities beyond lymphoma. 
 
3.1.5. Histone demethylases 
A biological alternative to gain-of-function mutations in EZH2, a variety of cancers including AML, T-
ALL, bladder cancer, and medulloblastoma harbor somatic loss-of-function mutations in ubiquitously 
transcribed tetratricopeptide repeat on chromosome X (UTX) (Gui et al., 2011; Jones et al., 2012; Pugh et 
al., 2012; Robinson et al., 2012; van Haaften et al., 2009), an H3K27me3 demethylase regulating diverse 
developmental processes (Van der Meulen et al., 2014). For instance, UTX emerges as a bona fide tumor 
suppressor in T-ALL. In mice, Utx deletion promotes leukemia and results in increased H3K27me3. 
Thus, the net output of UTX loss is reminiscent of increased EZH2 activity, which is supported by an 
increased sensitivity of UTX-deficient leukemia to EZH2 inhibitors (Van der Meulen et al., 2015). In 
contrast to UTX loss, H3K9me3 demethylases Jumonji domain 2 A, B, and C (JMJD2A/B/C) are 
frequently overexpressed in cancer (Young and Hendzel, 2013). Jmjd2c knockout prevents embryonic 
development beyond 4-cell-stage (Wang et al., 2010a), whereas increased JMJD2 activity in cancer 
affects de-repression of tumor promoters including pluripotency genes, resulting in enhanced tumor 
growth and stemness (Young and Hendzel, 2013). For instance, JMJD2C is amplified in breast cancer, 
and its silencing interferes with self-renewal capacity in vitro (Liu et al., 2009). Accordingly, a novel 
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pan-JMJD inhibitor counteracts breast carcinoma in mice, thus representing a possible therapeutic tool 
(Wang et al., 2013a). Yet another family of histone demethylases, Jumonji and ARID domain-containing 
protein 1A, B, C, and D (JARID1A/B/C/D), are able to erase the open chromatin mark H3K4me3, which 
enables gene repression, for instance through PRC2 (Benevolenskaya, 2007). Jarid1a/b represses 
differentiation of ESCs (Christensen et al., 2007; Lin et al., 2011), while JARID1A/B is highly expressed 
in breast and prostate cancer (Blair et al., 2011). Jarid1b knockout affects mammary gland development 
in mice and JARID1B depletion attenuates growth of human breast carcinoma cells (Catchpole et al., 
2011). Comparably, Jarid1a deletion in thyroid and pituitary cancer-prone mice mitigates tumorigenesis 
(Lin et al., 2011). Furthermore, acquired chemotolerance in lung carcinoma cells is JARID1A dependent 
(Sharma et al., 2010). Therefore, JARID1 inactivation with a novel inhibitor (Sayegh et al., 2013) 
represents a possible strategy to target cancers and especially associated chemoresistance. 
 
3.1.6. Histone modification readers 
The histone modification landscape is perceived by epigenetic readers. These recruit various components 
of the nuclear signaling network to chromatin including transcription factors and RNA polymerases, thus 
mediating chromatin accessibility and gene expression. Reader proteins contain diverse domains 
allowing the recognition of specific histone modifications. For example, the domains WD40 and 
chromodomain recognize H3K27me3 and H3K9me3, respectively, while double chromodomain detects 
H3K4me3. In contrast, bromodomain recognizes various acetylated lysines (Musselman et al., 2012). For 
instance, EED contains WD40 repeats, which allows its recognition of H3K27me3 and, through 
recruitment of EZH2, the induction of H3K27 methylation on neighboring nucleosomes (Margueron et 
al., 2009; Xu et al., 2010). Similarly, heterochromatin protein 1 (HP1) contains a chromodomain, 
allowing the protein to recognize H3K9me3 and subsequently recruit DNMTs to induce stable gene 
silencing (Bannister et al., 2001; Feldman et al., 2006; Lehnertz et al., 2003). As histone acetylation 
mostly represents an open chromatin mark, bromodomain-containing readers frequently facilitate 
transcription (Filippakopoulos et al., 2012). For example, bromodomain-containing protein 4 (BRD4) is 
a critical mediator of transcriptional elongation (Yang et al., 2005). Furthermore, in contrast to 
transcription factors, BRD4 remains bound to transcriptionally active chromatin sites during mitosis, 
thus inheriting global transcriptional patterns (Dey et al., 2009). In murine and human ESCs, BRD4 
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regulates expression of pluripotency genes (Di Micco et al., 2014; Horne et al., 2014; Liu et al., 2014; 
Wu et al., 2015), while a Brd4 knockout prevents embryogenesis beyond blastocyst stage (Houzelstein et 
al., 2002). In squamous cell carcinoma, BRD4 is recurrently a component of chromosomal translocation, 
resulting in BRD4-driven epithelial differentiation blockade and tumor growth (French et al., 2001; 
2003; 2008). Similarly, aberrant activity of bromodomain and extra terminal (BET) family members 
(BRD2, BRD3, and BRD4) promotes leukemia and multiple myeloma, partly through transcriptional 
activation of V-myc avian myelocytomatosis viral oncogene homolog (MYC), an oncogene 
overexpressed in a plethora of cancers (Dawson et al., 2011; Delmore et al., 2011). Therefore, small 
molecules sterically hindering BET family members have been developed, among which are JQ1 
(Filippakopoulos et al., 2010) and I-BET151/762 (GlaxoSmithKline; Dawson et al., 2011; Nicodeme et 
al., 2010). Such inhibitors prevent BET members from recognizing transcription-starting sites and 
especially distal enhancers. This results in suppression of oncogenes, such as C-MYC or N-MYC, and 
remarkable anti-tumor effects in a wide set of preclinical cancer models including AML (Dawson et al., 
2011), T-ALL (Knoechel et al., 2014; Ott et al., 2012; Roderick et al., 2014), lymphoma (Chapuy et al., 
2013; Trabucco et al., 2015), multiple myeloma (Delmore et al., 2011; Lovén et al., 2013), squamous 
cell carcinoma (Filippakopoulos et al., 2010), prostate cancer (Asangani et al., 2014; Wyce et al., 2013a), 
lung cancer (Shimamura et al., 2013), Merkel cell carcinoma (Shao et al., 2014), glioblastoma (Cheng et 
al., 2013; De Raedt et al., 2014; Pastori et al., 2014), medulloblastoma (Bandopadhayay et al., 2014; 
Henssen et al., 2013; Venkataraman et al., 2014), neuroblastoma (De Raedt et al., 2014; Puissant et al., 
2013; Wyce et al., 2013b), malignant peripheral nerve sheath tumors (De Raedt et al., 2014; Patel et al., 
2014), and cutaneous melanoma (De Raedt et al., 2014; Gallagher et al., 2014a; 2014b; Segura et al., 
2013). Thus, BET bromodomain inhibition represents a highly promising strategy to target various 
malignancies and is currently clinically verified in several phase I studies (AML, NCT01713582, 
NCT02158858, NCT02308761; lymphoma, NCT01949883; multiple myeloma, NCT02157636; 
glioblastoma, NCT02296476; various solid cancers, NCT02259114, NCT01987362, NCT01587703). 
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3.2. The neural crest and its derivatives 
3.2.1. The embryonic neural crest 
Originally identified in the developing chick embryo (His, 1868), the neural crest (NC) has later been 
defined as a transient cell population in the vertebrate embryo that emerges from the neural plate border 
and gives rise to a wide range of derivatives (Sauka-Spengler and Bronner, 2010). During neurulation, 
NC specification becomes apparent between the neural plate and its adjacent ectoderm, and after neural 
tube closure, NC cells localize to the dorsal neural tube. NC specification is driven by extracellular cues, 
such as ligands of the wingless/integrated (Wnt), bone morphogenic protein (Bmp), and fibroblast 
growth factor (Fgf) families. The intracellular signaling cascades induce a transcriptional network 
including v-ets avian erythroblastosis virus E26 oncogene homolog 1 (Ets1), forkhead box D3 (Foxd3), 
snail family zinc finger 1 and 2 (Snai1, Snai2), sex determining region Y-box 9 and 10 (Sox9, Sox10), 
twist family bHLH transcription factor 1 (Twist1), and zinc finger E-box binding homeobox 1 (Zeb1) 
(Betancur et al., 2010; Bronner and Ledouarin, 2012; Nelms and Labosky, 2010; Sauka-Spengler and 
Bronner, 2010). NC cells then delaminate from the dorsal neural tube through EMT and extensively 
migrate to distant locations. The same transcriptional network that is involved in NC specification also 
triggers the EMT. These transcription factors induce an EMT-typical program including expression of 
type-II cadherins, down regulation of tight junctions, loss of apico-basal polarity, and expression of 
matrix metalloproteases (MMP). The migration of NC cells to distinct target sites is established through 
a variety of signaling inputs, such as Wnts, ephrins, and semaphorins, but also Fgfs, platelet-derived 
growth factors (Pdgf), and vascular endothelial growth factor (Vegf). These signaling cascades are 
thought of commonly activating small rat sarcoma (Ras) homolog (Rho)-GTPases, key regulators of cell 
motility (Nelms and Labosky, 2010; Strobl-Mazzulla and Bronner, 2012a; Theveneau and Mayor, 2012). 
During this course of events, the NC differentiates into a plethora of cell types, such as neurons and glial 
cells of the peripheral nervous system (sensory, sympathetic, and parasympathetic), medullar cells of the 
adrenal gland, calcitonin-producing cells of the thyroid gland, adipocytes, mesenchymal cells 
(osteocytes, chondrocytes, myofibroblasts, and smooth muscle cells), and melanocytes (Figure 7a). 
However, fates of NC cells are dependent on the rostral-caudal level of emigration. For instance, the NC 
emigrating rostral to somite 7 gives rise to the peripheral nervous system and melanocytes of the trunk, 
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while NC cells emigrating caudal to somite 4 have broader fates including mesenchymal specification 
required for craniofacial structures (Dupin and Sommer, 2012; Sauka-Spengler and Bronner, 2010). 
 
 
Figure 7 #  Embryonic NCSC progeny and NCSC locations in adult tissues. (a) Embryonic NCSCs emerge from the 
neural plate border and, after extensive migration, give rise to a wide range of derivatives including neurons, glial cells, 
melanocytes, smooth muscle cells, osteoblasts, chondrocytes, and adipocytes. (b) In the adult organism, self-renewing 
NCSCs reside at post-migratory locations of the embryonic NC. These adult NCSCs have a capacity and differentiation 
potential resembling those of NCSCs during embryonic development. NCSCs have been described in diverse tissues and 
organs, such as DRG, gut, cornea, heart, bone marrow, and skin. DRG, dorsal root ganglia; NC, neural crest; NCSC, NC 
stem cell (adapted from: Shakhova, 2014; Shakhova and Sommer, 2010). 
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3.2.2. Neural crest stem cells 
While the NC gives rise to different progeny in vivo (Dupin and Sommer, 2012; Sauka-Spengler and 
Bronner, 2010), NC cells maintain the potential to differentiate into a variety of cell types in vitro, 
depending on the combination of instructive growth factors applied to the NC culture (Shakhova and 
Sommer, 2010). Importantly, NC cells can also be sustained in an undifferentiated state using a 
combinatorial application of Wnt and Bmp (Kléber et al., 2005). Due to this self-renewal capacity and 
the broad in vitro potential, NC cells were originally defined as multipotent stem cells, using first avian 
(Baroffio et al., 1991; Sieber-Blum and Cohen, 1980) and later rodent NC cultures (Stemple and 
Anderson, 1992). Likewise, the NC was described to be a stem cell population in vivo using single cell 
labeling in chicks (Bronner-Fraser and Fraser, 1989; Frank and Sanes, 1991), while NC cells have been 
associated with stem cell attributes in mouse embryos using targeted activation of a reporter gene (Jiang 
et al., 2000) and manipulation of NC-relevant transcriptional pathways, such as Sox10 (Kim et al., 2003; 
Paratore et al., 2002), Wnt (Hari et al., 2002; Lee et al., 2004), and transforming growth factor beta 
(Tgfβ) (Wurdak et al., 2005). Recently, the murine embryonic NC was proven to be a multipotent NC 
stem cell (NCSC) population both before and after delamination from the neural tube by harnessing 
multicolor-based in vivo fate-mapping (Baggiolini et al., 2015). Although it was assumed that the 
multipotent NCSC population is a transient appearance during embryogenesis, it has only recently 
become evident that multipotent and self-renewing NCSCs reside at post-migratory locations of the 
embryonic NC and persist into adulthood (Dupin and Sommer, 2012). To this day, NCSCs have been 
identified, among others, in dorsal root ganglia (Bixby et al., 2002; Hagedorn et al., 1999; Nagoshi et al., 
2008), sciatic nerves (Morrison et al., 1999), the gut (Bixby et al., 2002; Kruger et al., 2002), the heart 
(Tomita et al., 2005), the cornea (Yoshida et al., 2006), teeth (Janebodin et al., 2011), the bone marrow 
(Nagoshi et al., 2008), and the skin (Nagoshi et al., 2008; Sieber-Blum et al., 2004; Wong et al., 2006) 
(Figure 7b). Because of their broad accessibility and potential, adult NCSCs might be a potential source 
for cell and tissue replacement therapies. In fact, skin-derived NCSCs have already been applied in nerve 
(McKenzie et al., 2006), spinal cord (Biernaskie et al., 2007; Sieber-Blum et al., 2006), and bone injury 
models (Lavoie et al., 2009). 
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3.2.3. The melanocytic lineage 
Historically demonstrated with transplantation experiments of embryonic mouse tissue into the coelom 
of chick embryos (Mayer, 1973; Rawles, 1947), it is nowadays well established that melanocytes 
originate from the NC (Figure 7a). In the mouse embryo, NCSCs specify towards a melanoblastic fate 
early after delamination from the neural tube, while shortly migrating towards and then pausing in the 
so-called Migration Staging Area (MSA). Subsequently, melanoblasts migrate extensively on the 
dorsolateral pathway before invading the epidermis, where they fully differentiate into epidermal 
melanocytes or populate forming hair follicles. Apart from the skin, NC-derived melanoblasts also 
populate the uvea of the eye, the heart, the inner ear, and the leptomeninges (Pavan and Raible, 2012; 
Sommer, 2011). Recently, glial progenitors were shown to possess the potential of differentiating into 
melanocytes, representing an alternative source of pigment-producing cells during development and 
potentially during regenerative processes of the skin (Adameyko et al., 2009; 2012). Indeed, adult 
NCSCs associated with the endings of hair follicle-wrapping nerves contribute to the wound healing 
process of murine skin (Johnston et al., 2013). Although whether or not these cells also have the capacity 
of producing melanocytes remains unclear. In humans, the precise developmental origin of melanocytes 
remains a challenging question to address. However, human ESCs were recently successfully 
differentiated into NCSCs and further into pigmented melanocytes, demonstrating, at least in vitro, the 
potential of human NCSCs to give rise to the melanocytic lineage (Mica et al., 2013). 
 
3.2.4. Adult melanocyte biology 
Mature melanocytes are melanin-producing cells and responsible for pigmentation of skin and hair. 
Melanocytes deliver their melanin content to neighboring keratinocytes through melanosomes, either at 
the basal lamina of the epidermis, or in the hair matrix (bulb) of hair follicles (Figure 8). Pigment 
accumulation in keratinocytes allows protection of hairless skin from exposure to sunlight-induced 
ultraviolet (UV) damage. However, in hair coat-covered areas, epidermal melanocytes are frequently 
absent, since pigmented hair is a sufficient protection from UV radiation (Lin and Fisher, 2007). In 
agreement, epidermal inter-follicular melanocytes are completely absent in murine adult trunk skin 
(Hirobe, 1984). During mouse development, trunk skin melanoblasts solely populate hair follicles. They 
either migrate into the forming hair bulb, where they fully differentiate into pigment-producing 
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melanocytes, or they reside in the bulge (Nishimura et al., 2002a). Importantly, the hair follicle bulge is 
the concomitant stem cell niche for epidermal stem cells (Cotsarelis et al., 1990). During subsequent hair 
cycles, melanoblasts in the bulge self-renew and give rise to differentiating melanocytes to re-pigment 
newly growing hairs. Therefore, melanoblasts in the bulge have been defined as melanocyte stem cells 
(MSC) (Nishimura et al., 2002a) (Figure 8). 
 
 
Figure 8 #  Melanocyte locations in human hair-bearing skin. Human melanocytes are located either at the basal lamina 
of the epidermis or in the bulb of hair follicles, while murine trunk skin lacks interfollicular, epidermal melanocytes. A 
growing hair follicle is fueled with epithelial cells and melanocytes, which originate from epithelial (keratinocyte) stem 
cells and MSCs, respectively. These cell populations represent a stem cell reservoir that resides in the bulge area, the 
permanent niche of the hair follicle throughout the hair cycle. Accordingly, dysfunctions affecting either MSC homeostasis 
or bulge integrity result in hair graying, due to the lack of pigment-producing melanocytes in the subsequent hair cycles. 
MSC, melanocyte stem cell (adapted from: Falabella, 2009). 
 
In human skin, amelanotic melanoblasts residing in hair follicle bulges were described (Staricco, 1963), 
thus representing a potential reservoir to replenish the epidermis and hair follicles with melanocytes. In 
support, local de-pigmentation of human skin, induced through ionizing irradiation, is usually 
supplemented with pigment-producing melanocytes starting from the orifices of hair follicles (Cui et al., 
1991; Ortonne et al., 1980). Interestingly, UV irradiation of murine trunk skin similarly induces 
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migration of MSCs into hair follicle-neighboring epidermis and subsequent differentiation into melanin-
producing melanocytes in order to provide UV-protection (Chou et al., 2013). It is supposable that 
murine MSCs and amelanotic melanoblasts in human hair follicles are the corresponding cell population, 
although a formal proof is still missing. Further, it remains to be clarified, whether MSCs and NCSCs in 
the adult murine skin represent the same cell population. 
 
3.2.5. Melanocyte-relevant transcription factors and signaling pathways 
Interestingly, transcription factors and signaling pathways, critical to early NC specification and NCSC 
function, are still highly relevant for melanoblast development and adult MSC homeostasis. 
3.2.5.1. FOXD3 and SOX9 
For instance, the transcription factor Foxd3 is required for NC specification and early NCSC 
maintenance (Teng et al., 2008). However, during melanoblast specification Foxd3 is downregulated. In 
ovo, silencing of Foxd3 in early NC cells induces dorsolateral migration, while Foxd3 overexpression 
prevents melanocyte development (Kos et al., 2001). In agreement, overexpression of the NC specifiers 
Sox9 and Snai2 in early NC cells similarly represses melanocytic fate in favor of ventrally migrating NC 
cells (Nitzan et al., 2013). Likewise, Sox9 is dispensable for adult murine melanocyte homeostasis 
(Shakhova et al., 2015). 
3.2.5.2. SOX10 
In contrast, Sox10 is required for the embryonic NC as much as throughout the melanocytic lineage. 
Sox10 is expressed in NC cells upon delamination from the neural tube and highly relevant for NCSC 
survival, differentiation, and migration (Bondurand et al., 1998; Britsch et al., 2001; Kapur, 1999; Kim et 
al., 2003; Paratore et al., 2001; 2002; Southard-Smith et al., 1998). Especially extensive dorsolateral 
migration of melanoblasts is affected by aberrations affecting Sox10. This frequently results in a 
congenital melanocyte-free belly spot reminiscent of the human Waardenburg syndrome (Aoki et al., 
2003; Britsch et al., 2001; Pingault et al., 1998; Potterf et al., 2001; Southard-Smith et al., 1998). Sox10 
remains expressed in murine post-migratory melanoblasts (Osawa et al., 2005) and SOX10 is similarly 
detectable in human neonatal epidermal melanocytes (Cook et al., 2003). In murine adult hair follicles, 
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Sox10 function is essential for bulge-associated MSC homeostasis as much as retention of differentiated 
melanocytes in the bulb (Harris et al., 2013; Shakhova et al., 2015). 
3.2.5.3. PAX3 and MITF 
Sox10 drives embryonic melanoblast specification and melanocyte maintenance through an interplay 
with the transcription factors paired box 3 (Pax3) and microphthalmia-associated transcription factor 
(Mitf). Pax3 is expressed during NC specification, NC delamination, melanoblast development, and 
required for MSC homeostasis (Kubic et al., 2008; Lang et al., 2005). The synergistic function of Sox10 
and Pax3 becomes apparent in the co-activation of Mitf transcription (Bondurand et al., 2000; Potterf et 
al., 2000). Mitf itself is referred to as master regulator of the melanocytic lineage (Steingrimsson et al., 
2004). Mitf is first expressed in NC cells in the MSA, thus initializing melanoblast specification 
(Opdecamp et al., 1997). Sox10, Pax3, and Mitf then co-regulate expression of melanogenesis-relevant 
genes including dopachrome tautomerase (Dct), melan-A (Mlana), premelanosome protein (Pmel), 
tyrosinase (Tyr), and tyrosinase-related protein 1 (Tyrp1). Highlighting the essence of Mitf for 
melanocyte development, disruption of the Mitf locus leads to a complete absence of melanocytes in 
adult mice (Steingrimsson et al., 2004), while in humans, genetic alterations affecting PAX3 or MITF 
loci, similar to alterations in SOX10, result in Waardenburg syndromes (Pingault et al., 2010).   
3.2.5.4. WNT signaling 
Among critical signaling cues controlling NC development are WNTs. These ligands bind to frizzled 
receptor, which induces an intracellular signaling cascade that leads to the translocation of CTNNB1 to 
the nucleus, thus regulating transcriptional responses (Cadigan and Liu, 2006). Wnts are crucial for NC 
specification (Ikeya et al., 1997; Saint-Jeannet et al., 1997) and, in combination with Bmp, for NCSC 
maintenance (Kléber et al., 2005), while interference with Ctnnb1 function prevents fate acquisitions of 
NCSCs, such as craniofacial structures, sensory neurons, and melanocytes (Brault et al., 2001; Hari et 
al., 2002). In avian and zebrafish NC, Wnts induce melanocytic differentiation (Dorsky et al., 1998; Jin 
et al., 2001), while in the murine migratory NC, expression of a stabilized form of Ctnnb1 promotes 
melanocyte formation at the expense of other fates (Hari et al., 2012). Interestingly, expression of 
similarly stabilized Ctnnb1 in specified melanoblasts rather leads to a decreased melanocyte number 
possibly due to diminished migratory capacity (Gallagher et al., 2013). Ctnnb1 mediates Mitf 
transcription, thus inducing melanoblast specification (Takeda et al., 2000; Widlund et al., 2002). 
However, excessive Mitf levels also trigger senescence while preventing migration of melanoblasts. 
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Therefore, stabilized Ctnnb1 might over-induce Mitf and, therefore, interfere with dorsolateral migration 
of melanoblasts resulting in the reported pigmentation defect (Gallagher et al., 2013; Steingrimsson et 
al., 2004). In murine adult hair follicles, stabilized Ctnnb1 induces ectopic MSC proliferation and 
differentiation in the bulge, possibly due to aberrant Mitf induction. Likewise, MSC activation upon hair 
cycle initiation or UV irradiation is Wnt signaling dependent, such as Ctnnb1-deficient MSCs remain 
quiescent (Rabbani et al., 2011; Yamada et al., 2013).  
3.2.5.5. TGFβ signaling 
Another relevant signaling cue for NC development is TGFβ, which binds to TGFβ receptor 2 
(TGFBR2), thus inducing an intracellular signaling cascade through phosphorylation of mothers against 
decapentaplegic homologs 2 and 3 (SMAD2/3). Phosphorylated SMAD2/3 then form a complex with 
SMAD4, translocate to the nucleus, and ultimately regulate transcriptional responses (Moustakas and 
Heldin, 2009). Upon exposure to Tgfβ, NCSCs differentiate towards neuronal lineages or smooth muscle 
cells, depending on the culture conditions (Hagedorn et al., 1999; 2000; Shah et al., 1996), while 
interference with Tgfbr2 function in the NC mostly prevents mesenchymal fate acquisition crucial for  
craniofacial structures and smooth muscle cells contributing to the outflow tract of the heart (Ito et al., 
2003; Wurdak et al., 2005). Interestingly, specification of NCSCs towards mesenchymal progenitors is 
driven through Tgfβ-mediated repression of Sox10 and re-expression of Sox9 (John et al., 2011), which 
has previously been highlighted as an essential specifier for NC-derived mesenchyme (Akiyama et al., 
2004; 2002; Mori-Akiyama et al., 2003). If Tgfβ-mediated Sox10 repression was a common trait 
throughout NC development, an involvement of Tgfβ signaling in melanoblast biology would be 
surprising, since Sox10 function is essential for the melanocytic lineage (Harris et al., 2013; Shakhova et 
al., 2015). However, it was reported that adult MSCs have slightly reduced Sox10 levels compared to 
differentiated melanocytes (Osawa et al., 2005; Sharov et al., 2005). Simultaneously, Tgfβ is secreted by 
epidermal stem cells of the bulge (Tanimura et al., 2011; Tumbar et al., 2004). Remarkably, Tgfβ 
signaling is required for quiescence of MSCs. Depletion of Tgfbr2 induces premature differentiation of 
MSCs, thus the bulge provides a functional niche for MSC homeostasis (Nishimura et al., 2010; 
Tanimura et al., 2011). Similarly, Smad4 deletion mitigates MSC homeostasis resulting in hair graying 
(Zingg and Tuncer, in preparation). Whether Tgfβ-mediated quiescence of MSCs functions through 
temporal repression of Sox10 and possibly increased Sox9 expression, remains to be clarified. 
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3.2.6. Congenital neurocristopathies 
During embryonic development, abnormal specification, migration, differentiation, or survival of NC 
cells frequently leads to congenital organ and tissue dysplasia with diverse clinopathological features 
(Etchevers et al., 2006). 
3.2.6.1. Waardenburg syndromes and Hirschsprung disease 
For instance, as described above, genetic aberrations affecting SOX10, PAX3, or MITF loci regularly 
cause Waardenburg syndromes. These genes are especially relevant for melanoblast specification, 
migration, and survival. Therefore, the clinopathological features of these syndromes are, among others, 
pigmentary abnormalities of the skin as well as hearing disabilities due to absence of inner ear 
melanocytes (Pingault et al., 2010). Dependent on the type of SOX10 mutations, maintenance of NC-
derived enteric nervous system (ENS) precursors is similarly impaired, resulting in precocious 
differentiation and, therefore, aganglionosis of the most distal gut, commonly known as Hirschsprung 
disease (McKeown et al., 2013; Paratore et al., 2002; Pingault et al., 1998; Southard-Smith et al., 1998). 
Comparably, endothelins are ligands that are required for proper migration and differentiation of both 
melanoblasts and ENS precursors (Baynash et al., 1994; Hosoda et al., 1994). Therefore, mutations 
affecting endothelins or its receptors can cause a Waardenburg syndrome partly consisting of 
Hirschsprung disease (McKeown et al., 2013; Pingault et al., 2010). 
3.2.6.2. DiGeorge syndrome 
In contrast, interference with signaling pathways responsible for mesenchymal fate of the NC, such as 
Tgfβ signaling, potentially results in craniofacial and cardiovascular defects reminiscent of the 
congenital DiGeorge syndrome (Ito et al., 2003; Wurdak et al., 2005; 2006). In mice, Tgfβ signaling 
controls expression of v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl) (Wurdak et al., 
2005). Interestingly, the chromosomal region flanking CRKL is frequently deleted in DiGeorge patients 
(Driscoll et al., 1992; Scambler et al., 1991). In accordance, deletion of Crkl in mice, causes a phenotype 
again similar to the human DiGeorge syndrome (Guris et al., 2001). 
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3.2.6.3. Giant congenital nevus 
Yet another neurocristopathy is giant congenital nevus, a dermal benign hyperplasia of melanocytic cells 
that arises during embryonic melanoblast migration towards the epidermis. Formation of these nevi is 
driven by in utero-acquired gain-of-function mutations predominantly in the NRAS locus (e.g. 
NRASQ61K), resulting in permanent stimulation of mitogen-activated kinase (MAPK) signaling (Bauer et 
al., 2007; Charbel et al., 2014; Kinsler et al., 2013; Lyon, 2010) (Figure 11). Due to the constitutive 
activation of oncogenic NRAS and the large increase in melanocytic cells, congenital nevus patients 
have an increased risk of developing malignant melanoma (Lyon, 2010), a cancer arising from 
melanocytes (3.3. Melanoma). Accordingly, expression of the N-RasQ61K oncogene in the melanocytic 
lineage of mice promotes dermal melanocytic hyperplasia followed by occasional melanomagenesis 
(Ackermann et al., 2005; Shakhova et al., 2012). Interestingly, Sox10-haploinsufficient mice are devoid 
of N-RasQ61K-driven hyperplasia, thus highlighting the requirement of Sox10 for the establishment of 
congenital nevi (Shakhova et al., 2012), in analogy to its relevance for NCSCs and melanocytes (Aoki et 
al., 2003; Harris et al., 2013; Kim et al., 2003; Paratore et al., 2001; 2002; Potterf et al., 2001; Shakhova 
et al., 2015). 
 
3.2.7. Acquired neurocristopathies 
Apart from congenital neurocristopathies, a variety of acquired pathologies including cancers arise from 
NC-derived cell types. Malignancies can, for example, arise from peripheral and cranial nerves (e.g. 
peripheral nerve sheath tumors), the sympathetic nervous system (e.g. neuroblastoma), or the 
melanocytic lineage (e.g. melanoma, which will be discussed in detail in chapter (3.3. Melanoma)) 
(Dundr and Ehrmann, 2012). 
3.2.7.1. Peripheral nerve sheath tumors 
Malignant peripheral nerve sheath tumors (MPNST) are the most common malignant mesenchymal 
tumors of soft tissue. In about 50%, MPNSTs emerge de novo from NC-derived Schwann cell precursors 
of peripheral or cranial nerves. In the remaining cases, neurofibromatosis type 1, a benign syndrome 
affecting Schwann cells, progresses into MPNSTs (Carroll, 2012; Joseph et al., 2008; Mrugala et al., 
2005). A gene of importance for the peripheral glial lineage is neurofibromin 1 (NF1), which inhibits 
MAPK signaling through dephosphorylation of RAS proteins (Carroll, 2012; Wrabetz et al., 1995) 
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(Figure 11). Neurofibromatosis type 1 patients usually harbor aberrations in both NF1 loci (Legius et al., 
1993; Messiaen et al., 2000; Viskochil et al., 1990; Wallace et al., 1990), which increases MAPK 
signaling, thus promoting the disease (Basu et al., 1992). Accumulation of further driver mutations in 
distinct loci, such as cyclin-dependent kinase inhibitor 2a (CDKN2A) or transformation-related protein 
53 (TRP53), then promotes MPNSTs (Holtkamp et al., 2007; Kourea et al., 1999; Nielsen et al., 1999). 
In agreement, ablation of Nf1 in mice induces a phenotype comparable to neurofibromatosis type 1 and, 
in combination with Trp53 or Cdkn2a deficiency, promotes MPNSTs (Cichowski et al., 1999; Joseph et 
al., 2008; Mayes et al., 2011; Vogel et al., 1999; Wu et al., 2008). Untransformed peripheral glia is 
Sox10 positive, while Sox9 is repressed (Betancur et al., 2010; Sauka-Spengler and Bronner, 2010). 
However, progression of benign neurofibroma into MPNSTs is associated with a gradual increase in 
SOX9 and concomitant loss of SOX10 (Carbonnelle-Puscian et al., 2011; De Raedt et al., 2014; Lévy et 
al., 2004; Miller et al., 2009; 2006; Nonaka et al., 2008). Thus, processes driving MPNSTs might be 
reminiscent of embryonic NC development, namely differentiation of Sox10-positive NCSCs towards 
Sox9-expressing mesenchymal progenitors (John et al., 2011). In support of this, neurofibroma 
progression has been associated with EMT (Arima et al., 2010), while human MPNSTs frequently harbor 
mesenchymal components (Ducatman and Scheithauer, 1984).   
3.2.7.2. Neuroblastoma 
Neuroblastoma is the most common solid extracranial childhood tumor, and often appears within the first 
year of life (Heck et al., 2009). Neuroblastoma is a cancer frequently emerging from ganglia of the 
sympathetic nervous system including the adrenal medulla (Cheung and Dyer, 2013). During 
embryogenesis, NCSCs specify towards sympathoadrenal precursors, which then give rise to 
sympathetic ganglia including the adrenal medulla (Anderson and Axel, 1986; Anderson et al., 1991). A 
key transcription factor regulating these specification and differentiation processes is paired-like 
homeobox 2b (Phox2b). In familial and sporadic neuroblastoma, PHOX2B locus often appears to be 
disturbed (Raabe et al., 2008; Trochet et al., 2004; 2005; van Limpt et al., 2004). Interestingly, in mice 
harboring Phox2b mutations, Sox10 aberrantly remains expressed in autonomic ganglia, pointing 
towards miss-specified cells with characteristics of NCSCs or glial progenitors (Nagashimada et al., 
2012). SOX10 is also upregulated in human neuroblastoma samples (Gershon et al., 2005). However, it 
remains to be investigated, whether SOX10 promotes neuroblastoma through propagation of an 
undifferentiated NCSC-like status. 
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3.3. Melanoma 
3.3.1. Clinopathological classification of human melanoma 
Melanoma is defined as the cancer arising from the melanocytic lineage (Gray-Schopfer et al., 2007), 
which originates during embryonic development from the NC (3.2.3. The melanocytic lineage). 
However, dependent on the subtype of melanocytes and the acquired driver mutations, different classes 
of melanocytic pathologies arise. The vast majority (95%) of melanomas are derived from melanocytes 
residing at the basal lamina of the epidermis, thus referred to as cutaneous melanoma. Rarely, melanoma 
arises from mucosal (1.3%) or uveal (3.7%) melanocytes (Chang et al., 1998; McLaughlin et al., 2005) 
(Figure 9). 
 
 
Figure 9 #  Clinopathological classifications of human malignant melanomas. (a, b) Subtypes of malignant melanoma 
include cutaneous melanoma (a) and acral lentiginous melanoma (b), which originate from cutaneous melanocytes located 
in hear-bearing skin and acral hairless skin, respectively. (c, d) Furthermore, melanoma can arise from mucosal and uveal 
melanocytes resulting in mucosal (c) and uveal melanoma (d) (adapted from: Benoist and van Looij, 2013; Koh, 1991; 
Vavvas and Brodowska, 2009). 
 
3.3.1.1. Cutaneous melanoma 
Cutaneous melanoma will be discussed below (paragraphs 3.3.2. – 3.3.7.) (Figure 9a). 
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3.3.1.2. Mucosal melanoma 
Mucosal melanocytes are found at the basal lamina of squamous epithelium of mucous tissues, such as in 
the oral and the sinonasal cavity, the rectum, and the vagina (Mihajlovic et al., 2012) (Figure 9c). 
Mucosal melanoma is frequently driven by activating mutations in stem cell factor receptor (KIT) or 
through amplification of the KIT locus (Garrido and Bastian, 2010). KIT is a receptor tyrosine kinase 
(RTK) that signals, among others, through MAPK pathway (Vidwans et al., 2011) (Figure 11). During 
murine embryonic development, Kit signaling is required for survival and migration of melanoblasts, 
while differentiation of adult MSCs is dependent on functional Kit (Nishikawa et al., 1991; Nishimura et 
al., 2002a; Wehrle-Haller and Weston, 1995). It remains to be investigated, whether oncogenic mutations 
in Kit are sufficient to induce mucosal melanoma in mice.  
3.3.1.3. Uveal melanoma 
Melanocytes in the uvea of the eye (e.g. the iris) produce pigment in order to protect the eye from UV 
damage, though, in contrast to cutaneous melanocytes, without transferring the pigment to neighboring 
cells (Hu, 2000) (Figure 9d). Oncogenic mutations inducing a transformation of uveal melanocytes are 
often found in loci of the guanine nucleotide binding protein (G-protein) q polypeptide (GNAQ) or the 
G-protein alpha 11 (GNA11) (Van Raamsdonk et al., 2009; 2010). Both G-proteins similarly activate 
MAPK pathway (Vidwans et al., 2011) (Figure 11). Indeed, Gnaq or Gna11 transgenes bearing the 
human activating mutations are sufficient to transform murine melanocytes into cells giving rise to 
metastatic melanoma in recipient mice (Van Raamsdonk et al., 2009; 2010), thus confirming GNAQ and 
GNA11 as melanoma drivers. Interestingly, homozygous knockout of Gnaq and Gna11 results in 
embryos with cardiovascular and craniofacial defects (Offermanns et al., 1998), highlighting these G-
proteins as potential players during cranial NC-derived mesenchyme and, presumably, uveal melanoblast 
development. 
3.3.1.4. Acral lentiginous melanoma 
Acral lentiginous melanoma is a subclass of cutaneous melanoma. However, cutaneous melanocytes 
giving rise to acral melanoma are located at hairless acral locations of the skin, namely the palms, the 
soles, and underneath nails (Piliang, 2011) (Figure 9b). Similar to mucosal melanoma, activating 
alterations affecting the KIT locus are often found in acral melanoma (Garrido and Bastian, 2010) 
(Figure 11). Acral lentiginous melanoma, as much as mucosal and uveal melanoma, arises at areas of the 
body with little exposure to sunlight. Indeed, the UV-induced mutational burden is negligible in these 
 3—33 
melanomas in great contrast to cutaneous melanoma of hair-bearing skin. In agreement, drivers of acral 
and mucosal melanoma are frequently activated through large scale chromosomal rearrangements rather 
than UV-induced point mutations (Furney et al., 2012; 2013; 2014). 
 
3.3.2. Cutaneous melanoma epidemiology and risk factors 
5% of all new cancer cases registered in the United States in 2013 were estimated to be cutaneous 
malignant melanoma events. Over the last decades, cutaneous melanoma incidence rates have increased 
yearly about 2.5% in males and 3.9% in females. Thus, cutaneous melanoma is the most rapidly 
escalating cancer. Men are more susceptible to develop cutaneous melanoma than women (Curado et al., 
2007; Siegel et al., 2013). Apart from gender, a number of risk factors are associated with melanoma 
susceptibility. For instance, skin, hair, and eye color correlate with melanoma risk, such as persons with 
fair skin or red hair are more prone to develop melanoma. Familial melanoma history is another risk 
factor, mostly due to inactivating germ line mutations in the CDKN2A locus (Gandini et al., 2005c; 
Goldstein and Tucker, 2001). Presence of cutaneous nevi, benign melanocytic lesions with the potential 
to progress into malignant melanoma, also implies an increased risk (Gandini et al., 2005a). The highest 
risk, however, comes from repetitive exposure to sunlight or UV light (e.g. tanning bench), especially 
when causing actinic dermatitis (Gandini et al., 2005b). Indeed, melanoma-susceptible mice exposed to 
UV irradiation show a considerably shortened melanoma-free survival (Viros et al., 2014), highlighting 
UV radiation as a leading cause and, therefore, sunlight exposure as a major risk for development of 
cutaneous melanoma.  
 
3.3.3. Pathogenesis of cutaneous melanoma 
UV light is divided into three components, UVA (400nm – 320nm), UVB (320nm – 290nm), and UVC 
(290nm – 200nm). UVC is mostly absorbed by the ozone layer of the atmosphere, while 10% of UVB 
and 95% of UVA reach the surface of earth (Garibyan and Fisher, 2010). Upon penetration of the skin, 
UVB and UVA are absorbed by photosensitive molecules. UVB is directly absorbed by DNA, which 
itself is photosensitive. Photochemical reactions then induce cyclobutane pyrimidine dimers, which are 
usually corrected through the DNA damage machinery. However, incorrect repair frequently induces 
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C!T and CC!TT transition mutations (Cadet et al., 2005). In contrary, upon absorption, UVA rather 
generates reactive oxygen species causing oxidative DNA damage, and miss-repair mostly induces G!T 
transversions and G!A transitions (Besaratinia and Pfeifer, 2006). In human melanocytes, accumulation 
of such somatic mutations in loci of critical growth regulatory genes can induce proliferation while 
suppressing apoptosis (Rudolph et al., 1998). These neoplastic lesions either remain benign, commonly 
referred to as nevi, or progress into malignant melanoma (Figure 10). Nevi can be restricted to the 
epidermis (junctional nevus), the dermis (dermal nevus), or overlap both (compound nevus) (Gray-
Schopfer et al., 2007). Nevi typically remain at a certain size for decades without progressing into 
malignant melanoma through a phenomenon known as oncogene-induced senescence (Michaloglou et 
al., 2005; Serrano et al., 1997). Only further acquired mutations in tumor-suppressing senescence genes, 
such as CDKN2A, phosphatase and tensin homolog (PTEN), or TRP53 allow benign nevi cells to acquire 
dysplastic features and eventually to progress into malignancy (Box and Terzian, 2008; Sharpless and 
Chin, 2003; Wu et al., 2003). Accordingly, mice harboring dermal, nevus-like, melanocytic hyperplasia 
efficiently develop malignant melanoma only when Cdkn2a, Pten, or Trp53 is depleted (Ackermann et 
al., 2005; Dankort et al., 2009; Dhomen et al., 2009; Gembarska et al., 2012; Goel et al., 2009). 
Although presence of nevi implies an increased risk of developing melanoma (Gandini et al., 2005a), 
about 70% of melanomas develop in normal skin devoid of nevi, and less than half of the nevi associated 
with melanomas are dysplastic. Further, nevus-associated melanomas have a similar prognosis as de 
novo-developing melanomas (Bevona et al., 2003; Lin et al., 2015). Therefore, presence of multiple nevi 
might rather represent a symptom of an underlying genetic predisposition or a measure for frequent UV 
exposure, while malignant melanomas regularly arise de novo from transformed melanocytes, and not, as 
previously proposed (Clark et al., 1984), in a serial manner from senescent nevi (Figure 10). The Clark 
model of melanoma progression further suggests that malignant melanoma cells first spread radially in 
the epidermis (melanoma in situ, Clark’s clinical stage I), before starting to grow vertically to invade the 
dermis (Clark’s clinical stage II). Only upon dermal invasion, melanoma cells intravasate into the blood 
or lymph circulation and eventually disseminate to lymph nodes (Clark’s clinical stage III) and to distant 
organs (Clark’s clinical stage IV) (Balch et al., 2001; Clark et al., 1984) (Figure 10). Indeed, primary 
melanoma thickness represents the most important prognostic factor for patients. 5-year survival rate is 
highly decreased for patients bearing vertically growing lesions that reach reticular dermis or subcutis 
(Breslow depth > 4mm) in comparison to patients with melanoma in situ (Balch et al., 2001; Breslow, 
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1970). Accordingly, metastatic spread to sentinel lymph nodes correlates with Breslow depth of primary 
melanomas (Cadili and Dabbs, 2010). 
 
 
Figure 10 #  The Clark model for melanoma progression. According to the Clark model for melanoma progression, an 
epidermal melanocyte first undergoes a neoplastic transformation, which gives rise to a benign nevus. Most nevi remain 
benign. Rarely, a nevus progresses into malignant metastatic melanoma through a series of events. These include radial 
tumor expansion followed by vertical invasion into the dermis and metastasis to distant organs. However, not every 
melanoma closely follows the Clark’s course of events. A melanocyte may directly progress into a malignant tumor. 
Furthermore, metastases arising from both benign nevi and radially growing melanomas have been observed. RGB, radial 
growth phase; VGB, vertical growth phase (adapted from: Gaggioli and Sahai, 2007). 
 
However, not all melanomas closely follow Clark’s course of events. Some stage I melanomas directly 
metastasize bypassing a vertical growth phase (Haqq et al., 2005; Lomuto et al., 2004; Taran and 
Heenan, 2001), and circulating tumor cells have been measured in the peripheral blood of patients with 
radially growing melanoma (Brownbridge et al., 2001). Similarly, even benign nevus cells have been 
detected in lymph nodes (Ridolfi et al., 1977; Shenoy et al., 1987). This implies an adoption of 
disseminating features much prior to the progression into an advanced primary melanoma. In 
accordance, for a considerable number of metastatic melanoma patients (3.2%), a primary cutaneous 
tumor is untraceable (Kamposioras et al., 2011). However, these “melanomas of unknown primary” 
share a UV-typical mutational signature, suggesting an origin from UV-exposed cutaneous melanocytes 
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(Dutton-Regester et al., 2013). Thus, transformed melanocytes of early neoplasia regularly achieve the 
potential to disseminate throughout the body and to grow at distant sites. This exceptional metastatic 
capacity appears reminiscent of the excessive migratory behavior of the NC, the embryonic origin of 
melanocytes (3.2. The neural crest and its derivatives). Indeed, multiple transcription factors and 
signaling pathways known to regulate NCSC and melanocyte development have been connected to 
melanomagenesis and metastasis and will be discussed below (3.3.6. Cutaneous melanoma-relevant 
transcription factors and signaling pathways; 3.3.7. NCSC features in cutaneous melanoma). The 
aggressive metastasizing nature of melanoma becomes apparent in severely reduced 5-year patient 
survival once distant metastases are present (4%) in comparison to stage I and II patients (84%) (Curado 
et al., 2007; Siegel et al., 2013), which stresses the importance of especially investigating mechanisms 
involved in metastatic spread of cutaneous melanoma. 
 
3.3.4. Molecular pathogenesis: oncogenic drivers of cutaneous melanoma 
The series of events from neoplastic proliferation of melanocytes in the epidermis to distant metastasis is 
usually initiated through the acquirement of driver mutations in loci of proto-oncogenes. The most 
prevalent melanoma-driving signal transduction pathway is the MAPK pathway, such as the majority of 
nevi and melanomas (∼95%) harbor activity-enhancing oncogenic alterations in loci of MAPK members 
(Hodis et al., 2012; Krauthammer et al., 2012; Sullivan and Flaherty, 2013; Vidwans et al., 2011). 
Canonical MAPK signaling is initialized through RTKs (e.g. KIT), which activate RAS (HRAS, KRAS, 
NRAS), a membrane-bound GTPase. The intracellular MAPK cascade then functions through sequential 
phosphorylation of each kinase, such as RAS phosphorylates v-Raf murine sarcoma viral oncogene 
homologs (ARAF, BRAF, CRAF), RAF phosphorylates mitogen-activated protein kinase kinase (MEK), 
and MEK phosphorylates mitogen-activated protein kinase (ERK). ERK translocates to the nucleus and 
interacts with transcription factors to regulate key cellular events, such as survival and proliferation 
(Sullivan and Flaherty, 2013; Vidwans et al., 2011) (Figure 11). 
3.3.4.1. Activating alterations affecting the BRAF locus 
A majority of cutaneous melanomas (∼60%) and most acquired nevi (∼80%) harbor activating BRAF 
mutations, particularly the BRAFV600E point mutation (Curtin et al., 2005; Davies et al., 2002; Hodis et 
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al., 2012; Krauthammer et al., 2012; Omholt et al., 2003; Pollock et al., 2003) (Figure 11). The V600E 
amino acid substitution allows BRAF to bypass the inhibitory effects of negative feedback regulation by 
ERK, thus BRAFV600E remains constantly active conferring its oncogenic function (Davies et al., 2002; 
Wan et al., 2004; Wellbrock et al., 2004). In line with these findings, the kinase domain of BRAF has 
been reported to be fused in frame to N-terminal partners through genomic rearrangements, thus 
depleting the auto-inhibitory N-terminal domain of BRAF and resulting in an enhanced kinase activity 
similar to BRAFV600E (Botton et al., 2013). The uniform appearance of BRAFV600E in early melanomas 
and benign nevi suggests that the acquirement of BRAFV600E is a clonal, key-driving event in 
melanomagenesis (Omholt et al., 2003; Pollock et al., 2003; Yeh et al., 2013).  
 
 
Figure 11 #  Relevant signaling pathways in malignant melanoma. RTKs activate RAS family members, which signal 
through effector proteins, such as RAF kinases. RAF further activates a signaling cascade including MEK and ERK. Apart 
from MAPK, RAS also activates PI3K, which signals through AKT and mTOR. In the vast majority of cutaneous 
melanomas, MAPK signaling is constitutively active. Most frequent are oncogenic mutations affecting either BRAF (∼60%) 
or NRAS (∼20%). Furthermore, activating mutations affect HRAS and KRAS (∼2%), CRAF and MEK (∼1%), KIT (∼6%), 
and GNAQ / GNA11 (∼2%). KIT alterations mostly appear in mucosal and acral lentiginous melanomas, while GNAQ / 
GNA11 mutations are typical for uveal melanoma. Simultaneously inactivating alterations in CDKN2A (p16) (∼85%), 
PTEN (∼70%), and NF1 (∼4%) are frequent. Notably, NF1 loss is a major cause of neurofibromatosis, a syndrome arising 
from peripheral glia or nerves that frequently progresses into MPNSTs. MITF is the master transcriptional regulator of 
melanocytes and MITF overexpression has been linked to melanoma growth. In contrast, MITF reduction promotes 
invasion and metastatic progression of melanoma. MPNST, malignant peripheral nerve sheath tumor; RTK, receptor 
tyrosine kinase (adapted from: Lo and Fisher, 2014). 
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Indeed, expression of BRAFV600E is sufficient to transform immortalized melanocytes into tumorigenic 
cells (Wellbrock et al., 2004), and expression of B-RafV600E in the melanocytic lineage of adult mice 
induces dermal hyperplasia reminiscent of human nevi (Dankort et al., 2009; Dhomen et al., 2009; Goel 
et al., 2009). In agreement with oncogenic BRAFV600E-provoked senescence (Michaloglou et al., 2005), 
B-RafV600E-induced murine nevi mostly remain benign. Only upon loss of tumor suppressors, such as 
Cdkn2a, Pten, or Trp53, dermal hyperplasia consistently progresses to metastatic melanoma (Dankort et 
al., 2009; Dhomen et al., 2009; Goel et al., 2009), confirming somatic acquirement of BRAFV600E as 
initial melanoma-driving event. 
3.3.4.2. Activating alterations affecting the NRAS locus 
Besides BRAFV600E, activating NRAS point mutations (mostly NRASQ61K/L/R, few NRASG12D/V) are 
recurrent in melanoma (∼20%) and predominant in congenital nevi (∼80%), but mostly absent in 
acquired nevi (Albino et al., 1984; Bauer et al., 2007; Charbel et al., 2014; Curtin et al., 2005; Hodis et 
al., 2012; Kinsler et al., 2013; Krauthammer et al., 2012; Omholt et al., 2003). Notably, the majority of 
familial melanoma patients (∼95%) harbor NRASQ61K/R (Eskandarpour et al., 2003). According point 
mutations in the NRAS homologs HRAS and KRAS are also recurrent in melanoma (∼2%) and in Spitz 
nevi (Bastian et al., 2000; Hodis et al., 2012; Krauthammer et al., 2012; Milagre et al., 2010) (Figure 11). 
The Q61K/L/R amino acid substitutions lock RAS into a GTP-bound, activated conformation, whereas 
G12D/V substitutions render RAS insensitive to GTP-dephosphorylating mechanisms, both allowing 
RAS to constantly signal through MAPK (Buhrman et al., 2007; Der et al., 1986; Krengel et al., 1990). 
NRASQ61K/L/R has been found throughout all stages of melanoma progression including benign congenital 
nevi indicating that NRASQ61K/L/R might be an early melanoma driver comparable to BRAFV600E (Bauer et 
al., 2007; Charbel et al., 2014; Kinsler et al., 2013; Omholt et al., 2003; 2002). Indeed, mutant HRAS, 
KRAS, and NRAS transform immortalized melanocytes into tumor-forming cells (Whitwam et al., 2007). 
Accordingly, H-RasG12V, K-RasG12V, N-RasG12D, and N-RasQ61K promote dermal hyperplasia in mice and, 
upon depletion of Cdkn2a or Trp53, metastasizing melanoma (Ackermann et al., 2005; Bardeesy et al., 
2001; Chin et al., 1997; 1999; Gembarska et al., 2012; Huijbers et al., 2006; Milagre et al., 2010; 
Pedersen et al., 2013), establishing somatic acquirement of oncogenic RAS mutations as initial 
melanoma-driving event. 
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Apart from mutant BRAF (∼60%), NRAS (∼20%), and HRAS / KRAS (∼2%), activating mutations in 
CRAF and MEK (∼1%), KIT (∼6%), and GNAQ / GNA11 (∼2%) as well as inactivating alterations 
affecting NF1 (∼4%) occur in diverse melanoma subtypes (Garrido and Bastian, 2010; Hodis et al., 
2012; Krauthammer et al., 2012; Van Raamsdonk et al., 2009; 2010). In sum, about 95% of all malignant 
melanomas present enhanced MAPK signaling, emphasizing targeted MAPK inhibition as a valid 
strategy for melanoma therapy (Sullivan and Flaherty, 2013; Vidwans et al., 2011) (Figure 11). 
 
3.3.5. Molecular pathogenesis: tumor suppressors in cutaneous melanoma 
MAPK signaling-enhancing mutations allow a first expansion of transformed melanocytes. However, 
these hyperplastic cells usually senesce in vitro and in vivo, while malignant progression requires loss of 
tumor suppressors (Ackermann et al., 2005; Dankort et al., 2009; Dhomen et al., 2009; Gembarska et al., 
2012; Goel et al., 2009; Michaloglou et al., 2005; Serrano et al., 1997).   
3.3.5.1. CDKN2A as tumor suppressor 
For instance, loss-of-function alterations affecting the CDKN2A locus frequently occur in melanoma 
(∼60%) as much as in a plethora of different cancers, and the promoter of CDKN2A is methylated in a 
considerable amount of melanomas (∼20%), resulting in repression of CDKN2A transcription. Therefore, 
the proteins encoded by CDKN2A, p14 and p16, are absent in more than 85% of malignant melanomas 
(Hodis et al., 2012; Jonsson et al., 2010; Kamb et al., 1994; Krauthammer et al., 2012; Nobori et al., 
1994; Venza et al., 2015). p16 is an inhibitor of cyclin-dependent kinase 4 (CDK4), itself promoting G1- 
to S-phase cell cycle progression (Sharpless and Chin, 2003). Interestingly, CDK4 appears to be 
amplified in melanoma (Hodis et al., 2012; Krauthammer et al., 2012; Muthusamy et al., 2006) (Figure 
11). Loss of p16 (and CDK4 upregulation) impedes a potential DNA miss match-induced cell cycle 
arrest, which leads to genomic instability and eventually results in malignancy (Sharpless and Chin, 
2003). This becomes apparent in formation of diverse tumors in Cdkn2a knockout mice (Serrano et al., 
1996). In human melanocytes, depletion of CDKN2A is sufficient to overcome BRAFV600E- and 
HRASG12V-induced senescence (Michaloglou et al., 2005; Serrano et al., 1997), while inactivation of 
Cdkn2a in melanocytic hyperplasia-harboring mice promotes melanomagenesis (Ackermann et al., 2005; 
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Bardeesy et al., 2001; Chin et al., 1997; Dhomen et al., 2009; Goel et al., 2009; Huijbers et al., 2006), 
establishing CDKN2A as a major tumor suppressor in melanoma. 
3.3.5.2. PTEN as tumor suppressor 
Comparable to CDKN2A, a considerable number of melanomas (∼70%) harbor inactivating alterations or 
DNA methylation-mediated silencing of the PTEN locus (Guldberg et al., 1997; Hodis et al., 2012; 
Krauthammer et al., 2012; Madhunapantula and Robertson, 2009; Tsao et al., 1998; Zhou et al., 2000). 
PTEN dephosphorylates, thus inactivates, phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which is a 
cue of the phosphoinositide 3-kinase (PI3K) pathway. RTKs activate PI3K, which phosphorylates PIP2 
to PIP3. PIP3 then triggers activation of AKT, a regulator of key cellular processes including proliferation 
and survival. AKT confers its roles, among others, through activation of mechanistic target to rapamycin 
(mTOR) (Madhunapantula and Robertson, 2009; Wu et al., 2003) (Figure 11). Accordingly, copy gains 
spanning AKT3 and activating point mutations in AKT3 have been reported in melanoma (Davies et al., 
2008; Stahl et al., 2004). Therefore, loss of PTEN (and AKT3 upregulation) allows constant PI3K 
signaling contributing to malignancy, which becomes apparent in formation of diverse neoplasms in 
mice lacking a Pten allele (Di Cristofano et al., 1998; Podsypanina et al., 1999). Interestingly, PTEN 
alterations strongly correlate with BRAFV600E mutations, while PTEN inactivation and NRAS mutations 
are mutually exclusive, presumably because mutant NRAS, besides MAPK, also activates PI3K 
signaling (Goel et al., 2006; Hodis et al., 2012; Krauthammer et al., 2012; Tsao et al., 2000; 2004; 
Vidwans et al., 2011) (Figure 11). Accordingly, inactivation of Pten promotes melanomagenesis in mice 
with B-RafV600E-induced hyperplasia (Dankort et al., 2009), establishing PTEN as an important tumor 
suppressor in BRAFV600E melanoma.  
3.3.5.3. TRP53 as tumor suppressor 
Various signals activate TRP53, such as DNA damage and oncogenic, genotoxic, and oxidative stress, 
which leads to the induction of pro-apoptotic, cell cycle-regulative, or senescence genes. Therefore, 
during tumor evolution, this selective pressure results in depletion of TRP53 in most cancers (Box and 
Terzian, 2008; Vousden and Prives, 2009). In contrast, deleterious TRP53 alterations only appear in a 
relatively small cohort of melanomas (∼20%). Interestingly, mutations affecting TRP53 in cutaneous 
melanoma show UV-typical patterns (Hocker and Tsao, 2007; Hodis et al., 2012; Krauthammer et al., 
2012), and UV irradiation of mice induces loss-of-function mutations in Trp53 resulting in accelerated 
melanoma formation (Viros et al., 2014). Apart from mutational burden, loss of TRP53-upstream 
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activators, such as p14 (encoded by CDKN2A), is a frequent event in human melanoma (3.3.5.1. 
CDKN2A as a tumor suppressor). Similarly, TRP53 inhibitors, such as the E3 ubiquitin-protein ligases 
mouse double minute homologs (MDM2, MDM4), are regularly upregulated in malignant melanoma 
(Gembarska et al., 2012; Marine and Jochemsen, 2005; Muthusamy et al., 2006; Polsky et al., 2001). In 
melanoma-prone mice, overexpression of Mdm4 significantly accelerates tumor development, while 
Mdm4 depletion is sufficient to prevent melanomagenesis (Gembarska et al., 2012; Terzian et al., 2010). 
Similarly, depletion of Trp53 enhances melanocyte transformation in vitro and tumorigenesis in mouse 
models of melanoma (Bardeesy et al., 2001; Gembarska et al., 2012; Goel et al., 2009; Serrano et al., 
1997). Thus, TRP53 inactivation through various mechanisms is a key event during melanomagenesis. 
 
3.3.6. Transcription factors and signaling pathways relevant for cutaneous melanoma 
Gain of oncogenic driver mutations and loss of tumor suppressors represents key events for melanoma 
induction. Apart from these essential genetic aberrations, a plethora of transcription factors and signaling 
pathways known to regulate NCSC and melanocyte development are also involved in further promoting 
melanoma formation and metastatic progression. 
3.3.6.1. SOX10 and SOX9 
For instance, the transcription factor SOX10 is not only relevant for NCSC maintenance and adult 
melanocyte homeostasis (3.2.5.2. SOX10), but also plays pivotal roles in melanomagenesis. SOX10 is 
highly expressed in cells of nevi and malignant melanomas (Agnarsdóttir et al., 2010; Bakos et al., 2010; 
Flammiger et al., 2009; Mohamed et al., 2013; Nonaka et al., 2008; Shakhova et al., 2012; Shin et al., 
2012), while Sox10 levels are increased in the melanocytic lineage of melanoma-developing mice in 
comparison to melanocytes of wt animals (Shakhova et al., 2012). Depletion of SOX10 in human 
melanoma cells induces apoptosis and cell cycle arrest, and Sox10 haploinsufficiency counteracts 
melanoma formation in mice (Cronin et al., 2013; Graf et al., 2014; Shakhova et al., 2012). Interestingly, 
SOX10 silencing in melanoma cells results, apart from interfering with cell cycle and survival, in 
induction of a mesenchymal gene network including SOX9 (Shakhova et al., 2012; 2015). This appears 
highly reminiscent of the Sox10-Sox9 interplay during mesectodermal fate acquisition of the NC (John 
et al., 2011). In melanoma, upregulation of such mesenchymal genes might reflect acquirement of EMT-
typical features including increased cell motility and metastasis formation. Indeed, melanoma cell lines 
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with an intrinsic capacity of invading extra cellular matrix (ECM)-mimicking collagen layers have low 
SOX10 levels and express more SOX9 than cell lines devoid of this capacity (Cheng et al., 2015; 
Shakhova et al., 2015), while SOX9 overexpression in invasion-poor cells decreases SOX10 and induces 
invasive capacity. Comparably, after intravenous (i.v.) transplantation into mice, murine B16-F1 
melanoma cells with a negligible metastasizing potential only form lung nodules following 
overexpression of Sox9 (Cheng et al., 2015). In melanoma-developing mice, Sox9 ablation rescues Sox10 
deficiency-induced tumor regression resulting in normal melanoma growth (Shakhova et al., 2015). 
These findings suggest a reciprocal action in between SOX10 and SOX9. Indeed, SOX10 and SOX9 
transcriptionally repress each other in an antagonistic manner (Cheng et al., 2015; Shakhova et al., 
2015). Likely, the differential expression of SOX10 and SOX9 allows a given melanoma to tightly 
regulate growth versus dissemination and metastasis. In melanoma-harboring mice, temporal Sox10 
reduction might, therefore, induce dissemination of melanoma cells from primary tumor sites resulting in 
colonization of distant organs, while Sox9 depletion might suffice to prevent metastasis. 
3.3.6.2. MITF 
Comparably to Sox10 function, Mitf is highly relevant for melanocyte biology (3.2.5.3. PAX3 and 
MITF), and increasing evidence connects MITF to melanomagenesis. MITF is expressed in a majority of 
melanomas (Agnarsdóttir et al., 2012; King et al., 1999; Nazarian et al., 2010b; O'Reilly et al., 2001; 
Shakhova et al., 2012), while point mutations affecting MITF are substantial and frequently elevate 
MITF activity (Cronin et al., 2009). For instance, MITFE318K results in altered transcriptional activity of 
MITF and predisposes to familial and sporadic melanoma development (Bertolotto et al., 2011; 
Yokoyama et al., 2011). Comparably, the chromosomal region harboring MITF is amplified in a subset 
of melanomas (∼20%), while elevated MITF levels, in synergy with activated MAPK signaling, promote 
growth of melanoma cells (Du et al., 2004; Garraway et al., 2005; Hodis et al., 2012; Stark and Hayward, 
2007) (Figure 11). However, distant metastases show a reduced frequency in MITF positivity (Nazarian 
et al., 2010b; Shakhova et al., 2012), and advanced melanoma lesions harbor melanocytic subpopulations 
completely devoid of MITF (Goodall et al., 2008). Furthermore, reduced MITF levels correlate with 
increased invasive capacity of melanoma cells (Hoek et al., 2008; 2006). This indicates a possible role of 
MITF loss in promoting metastasis, in analogy to the low SOX10 / high SOX9-associated invasive 
behavior of melanoma cells (Cheng et al., 2015; Shakhova et al., 2015). Indeed, MITF silencing in 
human melanoma cell cultures results in diminished growth but increases invasion in collagen layers 
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(Carreira et al., 2006; Hoek et al., 2008), while depletion of Mitf in murine B16-F10 melanoma cells 
enhances metastatic potential after i.v. transplantation (Cheli et al., 2012). Likely, during melanoma 
growth and metastasis, temporal MITF repression follows the dynamic SOX10-SOX9 interplay, given 
that MITF is a direct transcriptional target of SOX10 (Bondurand et al., 2000; Potterf et al., 2000). 
Alternatively, it was proposed that MITF reduction upon gain of invasive capacity might be triggered 
through a PAX3-driven genetic program that antagonizes MITF (Eccles et al., 2013). PAX3 itself is 
expressed in nevi and malignant melanomas (Gershon et al., 2005; He et al., 2010), and PAX3 silencing 
enhances MITF expression in vitro (He et al., 2011). However, this appears conflicting in the frame of 
MITF-PAX3 synergistic roles in co-regulating embryonic melanoblast specification and melanocyte 
homeostasis (Steingrimsson et al., 2004). Independently of the cause for differential MITF expression 
along melanomagenesis, an MITF level-elevating chemical compound was demonstrated to be sufficient 
to prevent melanoma metastases in mice (Sáez-Ayala et al., 2013). However, given the role of MITF in 
promoting melanoma growth (Du et al., 2004; Garraway et al., 2005), such MITF-enhancing treatments 
had to be implicitly combined with anti-proliferation therapeutics in order to circumvent adverse clinical 
outcome. 
3.3.6.3. WNT signaling 
WNT signaling controls melanoblast specification as much as adult MSC homeostasis (3.2.5.4 WNT 
signaling). Likewise, WNT signaling has pivotal roles in melanomagenesis. In human nevi and primary 
melanoma, CTNNB1 is frequently expressed (Bachmann et al., 2005; Kageshita et al., 2001; 
Maelandsmo et al., 2003; Omholt et al., 2001). Functionally, CTNNB1 is involved in, among others, 
activating MITF (Damsky et al., 2011; Widlund et al., 2002) and suppressing CDKN2A (Delmas et al., 
2007), thus overcoming oncogene-induced senescence and promoting melanoma growth. Accordingly, 
melanoma-prone mice expressing stabilized Ctnnb1 show decreased tumor-free survival, while Ctnnb1 
depletion delays melanoma formation (Damsky et al., 2011; Delmas et al., 2007; Gallagher et al., 2013). 
However, high CTNNB1 levels in human melanoma correlate with good patient prognosis (Bachmann et 
al., 2005; Chien et al., 2009; Gould Rothberg et al., 2009), while expression and especially nuclear 
localization of CTNNB1 is reduced in metastases (Bachmann et al., 2005; Kageshita et al., 2001; 
Maelandsmo et al., 2003). Furthermore, intrinsically low CTNNB1 levels correlate with increased 
invasive capacity of melanoma cells, and CTNNB1 silencing reduces MITF and induces invasion in 
collagen layers (Arozarena et al., 2011). Thus, WNT signaling is required for melanoma growth, but the 
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pathway is down-regulated to suppress melanocytic genes including MITF, allowing dissemination and 
metastasis. Indeed, Ctnnb1 depletion in melanoma-developing mice promotes formation of amelanotic 
tumors devoid of Mitf. Against expectation, these mice do not present increased metastasis formation, 
albeit animals were not specifically screened for occurrence of unpigmented nodules (Damsky et al., 
2011). Contrariwise, expression of the stabilized Ctnnb1 allele in both B-RafV600E Pten-deficient and N-
RasQ61K mice not only promotes primary tumors, but also metastasis (Damsky et al., 2011; Gallagher et 
al., 2013). This is unexpected in the frame of stabilized Ctnnb1-induced Mitf expression, since high 
MITF levels rather connect to melanoma growth including a more differentiated / pigmented tumor 
status. However, stabilized Ctnnb1 might differentially regulate target genes beyond Mitf that would be 
responsible for driving metastasis. Indeed, stabilized Ctnnb1 activates protein peptidyl-prolyl cis/trans 
isomerase NIMA-interacting 1 (Pin1), which enhances PI3K pathway through regulation of AKT 
(Damsky et al., 2011; Liao et al., 2009). In the frame of already active PI3K due to Pten loss (Damsky et 
al., 2011) or N-RasQ61K-PI3K axis (Gallagher et al., 2013), Pin1-induced additional enhancement of PI3K 
signaling might overwrite the Mitf-dependent melanoma growth program and promote metastasis. In 
contrast, upon stabilized Ctnnb1 expression, melanoma-prone B-RafV600E mice with intact Pten (no 
enhanced PI3K signaling) develop highly differentiated melanomas devoid of metastasis (Damsky et al., 
2011). Therefore, in a PI3K pathway-dependent melanoma, WNT signaling might promote metastatic 
progression, whereas in a PI3K-independent context, temporal reduction of WNT signaling might 
support melanoma metastasis. 
3.3.6.4. TGFβ signaling 
In normal epithelial, endothelial, and hematopoietic cells, TGFβ functions as powerful tumor suppressor 
in prohibiting uncontrolled proliferation. Along tumorigenesis, however, differential transcriptional 
responses to TGFβ signaling convert TGFβ from a tumor suppressor to a promoter of tumor growth and 
especially tumor stemness, metastasis, and chemoresistance (Oshimori et al., 2015; Tian et al., 2011; Xu 
et al., 2015b). Accordingly, TGFβ suppresses proliferation of untransformed human melanocytes 
(Krasagakis et al., 1999; Rodeck et al., 1994; 1999), and Tgfβ signaling is required for quiescence of 
MSCs in vivo (Nishimura et al., 2010; Tanimura et al., 2011). In contrast, melanoma-derived cell 
cultures are resistant to TGFβ-induced senescence (Krasagakis et al., 1999; Rodeck et al., 1994; 1999). 
However, exposure of melanoma cells to TGFβ induces an EMT through activation of EMT 
transcription factors, such as SNAI1, TWIST1, and GLI family zinc finger 2 (GLI2) (Alexaki et al., 2010; 
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Javelaud et al., 2011; Menon et al., 2013), as well as novel metastatic progression genes, such as TGFβ-
Induced (TGFBI) (Lauden et al., 2014). Simultaneously, TGFβ exposure suppresses MITF (Hoek et al., 
2006; Javelaud et al., 2011; Pierrat et al., 2012; Schlegel et al., 2015). TGFβ-induced EMT in melanoma 
appears reminiscent of TGFβ-dependent mesectodermal specification of the embryonic NC (John et al., 
2011). Whether this induction of EMT also similarly functions through SOX10 suppression and SOX9 
expression, remains to be clarified. In vitro, TGFβ-induced EMT is associated with invasion of 
melanoma cells in collagen layers (Alexaki et al., 2010; Mohammad et al., 2011; Qu et al., 2014; 
Schlegel et al., 2015), while in mice, interference with SMAD2/3 activity prevents outgrowth of i.v. 
transplanted melanoma cells at distant sites (Divito et al., 2010; Javelaud et al., 2005; 2007; Mohammad 
et al., 2011). Similarly, in melanoma-developing mice, Smad4 depletion efficiently counteracts 
melanomagenesis, while depletion of the inhibitory Smad7 enhances Smad2/3 activation and accelerates 
melanoma cell dissemination from primary tumor sites, resulting in distant metastases. However, 
deletion of Tgfbr2 has no effect on metastatic melanoma progression (Zingg and Tuncer, in preparation). 
Thus, activated Smad2/3-Smad4 axis is essential for melanoma metastasis. In vivo, Tgfβ, which signals 
through Tgfbr2, might however not be the major in situ promoter of Smad2/3 activation. Other signaling 
cues, such as activin A (INHBA) or nodal growth differentiation factor (NODAL), can activate 
SMAD2/3, although through different receptors than TGFBR2 (Moustakas and Heldin, 2009). Indeed, 
NODAL expression in melanoma correlates with an aggressive metastasizing phenotype (Postovit et al., 
2008; Seftor et al., 2014; Topczewska et al., 2006; Yu et al., 2010). Comparably, in B16-F10 cells, 
Nodal induces Snai1-dependent EMT including increased invasive capacity, and upon subcutaneous 
(s.c.) transplantation, inhibition of Nodal signaling diminishes metastasis to distant organs (Fang et al., 
2013). Therefore, TGFβ has the potential to promote melanoma EMT in vitro, while NODAL might be 
the in situ ligand responsible for melanoma dissemination and metastasis formation in vivo.  
 
3.3.7. NCSC features in cutaneous melanoma 
Malignant cutaneous melanoma is a highly heterogeneous cancer. Intratumoral heterogeneity becomes 
apparent on a genomic level (Anaka et al., 2013; Ennen et al., 2014; Shi et al., 2012a), but also by 
phenotypic appearance. Apart from expressing melanocytic markers, melanomas are often composed of 
cells displaying neuronal, glial, smooth muscle-like, chondrocytic, and adipocytic features (Banerjee and 
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Eyden, 2008; Civenni et al., 2011; Cruz et al., 2003; Laga and Murphy, 2010; Mete et al., 2010; Parente 
et al., 2013). This heterogeneity resembles the plethora of derivatives, which arise from the NC during 
embryogenesis (3.2.1. The embryonic neural crest). Therefore, it has been proposed that during 
tumorigenesis transformed melanocytes reacquire embryonic NCSC-resembling features, allowing these 
cells to diverge into heterotypic NC-like progeny. Indeed, cellular melanoma subpopulations have been 
identified that express stem cell markers. Functionally, these subpopulations also show cancer stem cell-
like behaviors, which include high self-renewal capacity in vitro and enhanced tumor initiation potential 
upon xenotransplantation (Beck and Blanpain, 2013; Kreso and Dick, 2014). 
3.3.7.1. Cluster of differentiation 271 as NCSC-like melanoma stem cell marker 
For instance, the low-affinity nerve growth factor receptor cluster of differentiation 271 (CD271) labels 
embryonic and adult NCSCs (Bixby et al., 2002; Hagedorn et al., 1999; Kruger et al., 2002; Morrison et 
al., 1999; Nagoshi et al., 2008; Stemple and Anderson, 1992; Wong et al., 2006). In contrast, 
melanocytes do not express CD271 (Wilson et al., 2004). However, malignant melanomas retrieve 
positivity for CD271 in variable degrees, and CD271 positivity correlates with poor patient prognosis 
and disease progression (Boiko et al., 2010; Chesa et al., 1988; Civenni et al., 2011; Innominato et al., 
2001; Iwamoto et al., 2001). These CD271-expressing cells are frequently devoid of melanocyte 
differentiation markers including MITF, pointing towards an undifferentiated subpopulation with 
possible stem cell features (Boiko et al., 2010). Indeed, tumor-initiating cells capable of recapitulating 
the phenotypic heterogeneity observed in melanoma are mostly present in the CD271-positive tumor 
fraction (Boiko et al., 2010; Civenni et al., 2011), while CD271 depletion prevents melanoma initiation 
(Redmer et al., 2014). Therefore, CD271-positive cells might represent a melanoma subpopulation with 
NCSC characteristics that sustains melanoma initiation, heterogeneity, malignancy, and presumably 
plasticity including metastasis. 
3.3.7.2. Melanoma stem cell markers beyond CD271 
Apart from CD271, various stem cell markers have been identified in melanoma. The ESC pluripotency 
factor SOX2 (Avilion et al., 2003; Ivanova et al., 2006) is heterogeneously re-expressed in melanoma and 
functionally involved in maintaining tumor initiation and in promoting melanoma cell invasion in vitro 
(Girouard et al., 2012; Laga et al., 2010; 2011; Santini et al., 2014). Interestingly, GLI2 promotes SOX2 
re-expression (Santini et al., 2014; 2012), while MITF is suppressed by SOX2 (Adameyko et al., 2012; 
Cimadamore et al., 2012), thus establishing a melanoma stemness network likely promoting EMT and 
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metastasis. Apart from transcription factors, both cell surface receptors CD20 and CD133, previously 
associated with B-cells including B-cell malignancies (Okroj et al., 2013) and HSCs (Bauer et al., 2008), 
respectively, define melanoma subpopulations with stem cell propensities (Fang et al., 2005; Monzani et 
al., 2007). Furthermore, expression of multi-drug resistance genes, such as ATP-binding cassette sub-
family B members (ABCB1/5) or aldehyde dehydrogenase (ALDH), correlates with melanoma 
progression, and positive cells show melanoma-initiating stemness properties (Boonyaratanakornkit et 
al., 2010; Chartrain et al., 2012; Frank et al., 2005; Keshet et al., 2008; Luo et al., 2012b; Schatton et al., 
2008; Setia et al., 2012). This highlights the likely emergence of stem cell-like subpopulations during 
exposure to melanoma therapeutics eventually resulting in acquired resistance and disease relapse. 
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3.4. Melanoma therapies 
To this day, the most effective treatment for primary melanoma remains surgical excision. Similarly, 
sentinel lymph node biopsy followed by complete excision of affected lymph nodes enhances 
perspectives for patients. Even stage IV melanoma patients with oligometastatic disease show some 
benefit from radical tumor removal (Sosman et al., 2011; Testori et al., 2009). Besides surgery, treatment 
of metastatic melanoma patients has been limited to decarbazine, a DNA-alkylating chemotherapeutic 
agent (Eggermont and Kirkwood, 2004), or local radiotherapy, mostly to target non-resectable lesions, 
such as cerebral metastases (Fife et al., 2004; Testori et al., 2009). However, the ineffectiveness of these 
approaches becomes evidently apparent in stage IV patient’s median survival of 6 to 9 months, whereas 
only 4% of these patients surviving beyond 5 years (Curado et al., 2007; Eggermont et al., 2014; Siegel 
et al., 2013). This reflects the great need for novel melanoma therapies. Recently, the landscape of 
melanoma therapeutics has changed spectacularly with two distinct therapeutic advancements in the 
areas of oncogene-targeted therapy and immunomodulation, both of which show significant survival 
benefits for metastatic melanoma patients (Eggermont et al., 2014; Lo and Fisher, 2014) (Figure 12). 
 
 
Figure 12 #  Timeline of FDA-approved melanoma therapeutics. Between 1976 and 2011, decarbazine chemotherapy 
and high-dose IL-2 were the only FDA-approved melanoma therapeutics. Recently, the landscape of melanoma 
therapeutics has changed spectacularly. The novel therapeutics include MAPK signaling inhibitors and immune checkpoint 
blockade agents. Vemurafenib (Roche) and dabrafenib (GlaxoSmithKline) target BRAFV600E and were FDA-approved in 
2011 and 2013, respectively. Trametinib (GlaxoSmithKline) targets MEK and its approval took place in 2013. These 
MAPK-inactivating drugs have profound clinical activity. However, melanoma patients frequently develop resistances 
resulting in progressive disease. Ipilimumab (Bristol-Myers Squibb) is a CTLA4-blocking antibody, which was FDA-
approved in 2011. Pembrolizumab (Merck) and nivolumab (Bristol-Myers Squibb) are both antibodies targeting PD-1 and 
were approved by FDA in September and December 2014, respectively. These immune checkpoint blockade antibodies 
show surpassing clinical responses with tolerable side effects. Importantly, in a considerable fraction of patients, stable 
disease persists long after treatment discontinuation. FDA, US food and drug administration (adapted from: Lo and Fisher, 
2014).  
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3.4.1. BRAFV600E-targeting and MEK-targeting therapeutics 
The identification of BRAFV600E in a majority of melanomas and in a variety of different cancers (Davies 
et al., 2002; Tiacci et al., 2011) prompted intensive efforts to develop chemical compounds inhibiting 
RAF kinase activity. However, first-generation pan-RAF inhibitors turned out to be clinically ineffective 
at the maximal tolerable dose, which was defined by harsh side effects, likely due to systemic inhibition 
of all RAF homologs as well as PDGF and VEGF receptors (PDGFR, VEGFR) (Sullivan and Flaherty, 
2013). In contrast, PLX4032 (vemurafenib, Roche) was the first RAF inhibitor with highly increased 
selectivity towards BRAFV600E over BRAFWT, ARAF, and CRAF, resulting in efficient counteraction of 
melanoma growth in vitro, in xenografts, and in patients (Bollag et al., 2010; Sala et al., 2008; Yang et 
al., 2010). To this day, vemurafenib and a similar BRAFV600E inhibitor, GSK2118436 (dabrafenib, 
GlaxoSmithKline), have shown unprecedented clinical activity in melanoma patients with mutant BRAF 
(Chapman et al., 2011; Flaherty et al., 2010; Hauschild et al., 2012) (Figure 12). In order to block MAPK 
signaling downstream of BRAF, efforts have also led to the development of MEK inhibitors, such as 
GSK1120212 (trametinib, GlaxoSmithKline; Gilmartin et al., 2011) and MEK162 (Novartis; Ascierto et 
al., 2013). These inhibitors also demonstrate clinical benefits for BRAFV600E melanoma patients, albeit 
with lower response rates than vemurafenib and dabrafenib (Ascierto et al., 2013; Flaherty et al., 2012b) 
(Figure 12). Importantly, vemurafenib and dabrafenib efficiently inhibit MAPK signaling only in BRAF-
mutant melanoma, while BRAFWT melanomas including RAS-mutated tumors paradoxically upregulate 
MAPK signaling upon RAF inhibition. Mutant RAS does not signal through BRAF, but through CRAF, 
which is negligibly sensitive to BRAFV600E-targeting drugs. Moreover, drug-bound BRAFWT serves as a 
scaffold in recruiting CRAF to RAS, thus enhancing MAPK signaling through CRAF (Hatzivassiliou et 
al., 2010; Heidorn et al., 2010; Poulikakos et al., 2010). This phenomenon becomes apparent in highly 
increased tumor and metastases formation in melanoma-prone K-RasG12D mice, either upon genetic 
alteration of B-Raf, thus mimicking drug-bound BRAF, or upon vemurafenib treatment (Heidorn et al., 
2010; Pedersen et al., 2014; Sanchez-Laorden et al., 2014). Comparably, vemurafenib treatment of 
BRAFV600E-mutant melanoma patients occasionally stimulates proliferation and dysplastic features of 
before-benign nevi. These nevi usually turn out to be BRAFWT and NRASQ61K-positive, pointing towards 
the paradoxical MAPK stimulation (Zimmer et al., 2012). MEK inhibition represents an alternative 
strategy to target MAPK-activated, but BRAFWT melanomas (e.g. NRASQ61K). However, MEK inhibitors 
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have shown only partial efficacy in BRAFWT melanomas (Sullivan and Flaherty, 2013), possibly due to 
the ability of RAS to signal through diverse pathways aside of MAPK (Kwong et al., 2012). 
 
3.4.2. MAPK-dependent mechanisms in MAPK inhibitor resistance 
Although anti-melanoma effects of RAF and MEK inhibitors are considerable, intrinsic and mostly 
acquired resistances limit the therapeutic benefits of these approaches (Ascierto et al., 2013; Flaherty et 
al., 2010; 2012b; Sosman et al., 2012). Concomitant treatments with RAF and MEK inhibitors have 
further improved clinical benefits for BRAF-mutant melanoma patients, and have been thought of 
minimizing acquired resistances. However, patients show progressive disease even under these combo 
treatments (Flaherty et al., 2012a; Larkin et al., 2014; Long et al., 2014; Robert et al., 2015a). Resistance 
frequently results from re-established MAPK signaling, which is acquired through various mechanisms 
(Figure 13). Genetic alterations lead to BRAF splicing variants and amplification (Poulikakos et al., 
2011; Shi et al., 2014; Van Allen et al., 2014) (Figure 13e), de novo mutations in RAS, MEK, or ERK loci 
(Emery et al., 2009; Goetz et al., 2014; Nazarian et al., 2010a; Shi et al., 2014; Van Allen et al., 2014; 
Wagle et al., 2011) (Figure 13b-d), and NF1 loss (Maertens et al., 2013; Van Allen et al., 2014; 
Whittaker et al., 2013) (Figure 13f). Besides genetic MAPK signaling reactivation, altered expression of 
MAPK pathway members frequently occurs during resistance, such as RTK (e.g. epithelial growth factor 
receptor (EGFR), FGF receptor (FGFR), or PDGFR) upregulation (Girotti et al., 2013; Lito et al., 2012; 
Nazarian et al., 2010a; Sun et al., 2014; Wilson et al., 2012; Yadav et al., 2012) (Figure 13h, i), enhanced 
expression of BRAF, CRAF, or NRAS (Johannessen et al., 2010; Montagut et al., 2008; Nazarian et al., 
2010a; Shi et al., 2012b) (Figure 13g), and increased BRAF dimerization (Poulikakos et al., 2011; 
Rajakulendran et al., 2009). All these mechanisms allow the tumor to circumvent BRAFV600E and MEK 
inhibition, or even to take advantage of it (e.g. upon de novo NRASQ61K), comparable to paradoxical 
MAPK enhancement upon BRAF inhibition in NRAS-mutant melanomas (Hatzivassiliou et al., 2010; 
Heidorn et al., 2010; Nazarian et al., 2010a; Poulikakos et al., 2010; Sanchez-Laorden et al., 2014). To 
successfully counteract resistance to BRAF or MEK inhibition, it has been proposed to vertically target 
MAPK pathway with ERK inhibitors, possibly in combination with MEK inhibitors (Morris et al., 2013; 
Rebecca et al., 2014; Van Allen et al., 2014; Wong et al., 2014). However, apart from MAPK signaling 
re-enhancement, a plethora of MAPK-independent resistance mechanisms to MAPK-targeted therapy 
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have been uncovered, which postulates only limited success for future combinatorial treatments solely 
targeting canonical MAPK pathway. 
 
 
Figure 13 #  Mechanisms of resistance to MAPK-targeting therapeutics. (a) Clinical activities of vemurafenib, 
dabrafenib, and trametinib are considerable. However, intrinsic and mostly acquired resistances limit the therapeutic 
benefits of these agents. (b - d) Acquired oncogenic mutations in NRAS, MEK, or ERK are sufficient to restore MAPK 
signaling. (e, f) Similarly, BRAFV600E amplifications as well as loss of NF1 alleles re-establish MAPK pathway. Besides 
genetic aberrances, adaptive gene expression, likely due to epigenetic rewiring, contributes to resistance. (g) Increased 
expression of BRAF, CRAF, or NRAS counteracts MAPK blockade. (h, i) Furthermore, upregulation of RTKs, such as 
AXL, EGFR, FGFR, HGFR, IGFR, KIT, and PDGFR, enhances signaling through MAPK and PI3K pathways. This RTK 
induction is partly due to downregulation of SOX10 and MITF and a simultaneous upregulation of FOXD3 and TWIST1. 
Mut, mutant. 
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3.4.3. MAPK-independent mechanisms in MAPK inhibitor resistance 
3.4.3.1. PI3K signaling-dependent resistance 
For instance, increased PI3K signaling through either loss of PTEN (3.3.5.2. PTEN as tumor suppressor) 
or increased RTK (e.g. EGFR, hepatocyte growth factor receptor (HGFR), or insulin-like growth factor 
receptor (IGFR)) activity is sufficient to bypass MAPK inhibition (Girotti et al., 2013; Lito et al., 2012; 
Paraiso et al., 2011; Shi et al., 2014; Straussman et al., 2012; Van Allen et al., 2014; Villanueva et al., 
2010; Wilson et al., 2012; Xing et al., 2012) (Figure 13h, i). Furthermore, TGFβ and NODAL activate 
AKT in melanoma cells, thus SMAD2/3 signaling might also contribute to acquired MAPK resistance by 
stimulating PI3K pathway (Fang et al., 2013; Qu et al., 2014; Schlegel et al., 2015). To counteract 
resistance to MAPK inhibitors, several compounds targeting PI3K pathway have been emphasized as 
potential strategies for melanoma therapy. These inhibitors target PI3K signaling at different nodes, such 
as RTKs, PI3K, AKT, or mTOR, and are currently being tested in clinics (Deng et al., 2012; Gopal et al., 
2010; 2014; Lasithiotakis et al., 2008; Lassen et al., 2014; Roberts et al., 2012; Sarker et al., 2015; 
Schneider et al., 2014; Shi et al., 2014; 2011; Straussman et al., 2012; Tolcher et al., 2015; Van Allen et 
al., 2014; Wang et al., 2015). 
3.4.3.2. CDK4-dependent resistance 
Besides PI3K pathway, a functional screen identified CDK4 as a node potentially involved in resistance 
to MAPK-targeted therapy (Kwong et al., 2012). In RAS-mutant melanoma, loss of CDKN2A or CDK4 
amplification frequently increases melanoma progression (3.3.5.1. CDKN2A as tumor suppressor). 
Indeed, concomitant application of MEK and CDK4 inhibitors overcomes innate resistance of Ras-
mutant murine melanoma cells to Mek inhibition, resulting in tumor regression in xenograft models 
(Kwong et al., 2012), while a CDK4 inhibitor counteracts acquired vemurafenib resistance in BRAFV600E 
melanoma xenotransplants (Yadav et al., 2014). 
3.4.3.3. SOX10-dependent and MITF-dependent resistance 
Acquired resistance to vemurafenib or dabrafenib is accompanied by SOX10 (Sun et al., 2014) and MITF 
suppression (Konieczkowski et al., 2014; Müller et al., 2014). SOX10 itself represses EGFR and PDGFR 
loci. Hence, downregulation of SOX10 induces expression of these RTKs, which confers resistance to 
MAPK inhibition (Figure 13h). Depletion of SOX10 also induces TGFBR2 expression, and activated 
TGFβ signaling further enhances upregulation of RTKs (Sun et al., 2014). Silencing of MITF similarly 
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promotes expression of RTKs, such as EGFR, PDGFR, and TYR-protein kinase receptor UFO (AXL), 
that signal through MAPK, thus reactivating the pathway (Johannessen et al., 2013; Konieczkowski et 
al., 2014; Müller et al., 2014; Sensi et al., 2011) (Figure 13h). Interestingly, SOX10 / SOX9 and MITF 
transcriptional programs, which regulate melanoma growth versus invasion and metastasis, seem 
similarly involved in driving drug resistance. Indeed, AXL expression also induces invasion of melanoma 
cells (Tai et al., 2008), and therapy-resistant cells show increased ability to invade and metastasize 
(Sanchez-Laorden et al., 2014; Wang et al., 2015). Whether SOX9 is involved in SOX10-MITF 
suppression-dependent resistance to MAPK-targeted therapy, and whether this promotes melanoma 
dissemination and metastasis in vivo, remains to be deciphered.  
3.4.3.4. Stemness-related resistance 
In contrast to repression of melanocyte lineage commitment genes, NC specifier / EMT genes (Betancur 
et al., 2010; Nelms and Labosky, 2010) are re-expressed during MAPK inhibitor resistance. In 
embryonic NC, Foxd3 is silenced upon melanoblast specification (3.2.5.1. FOXD3 and SOX9), and 
FOXD3 remains mostly absent in melanoma. However, vemurafenib exposure promotes FOXD3 
expression in melanoma cells. FOXD3 transcriptionally activates RTKs including EGFR, HGFR, IGFR, 
and PDGFR, which confer resistance through enhanced MAPK and PI3K signaling (Figure 13h), while 
FOXD3 silencing sensitizes cells to MAPK inhibitors (Abel and Aplin, 2010; Abel et al., 2013; Basile et 
al., 2012). The embryonic NC mesectoderm specifier and EMT gene TWIST1 (Füchtbauer, 1995; 
Stoetzel et al., 1995) similarly mediates resistance to MAPK inhibition (Menon et al., 2013) (Figure 
13h). Interestingly, expression of TWIST1 and ZEB1, another NC / EMT gene (Cacheux et al., 2001), 
also drives EMT and metastasis in malignant melanoma, accompanied by TGFβ signaling induction and 
by SOX10 and MITF suppression (Caramel et al., 2013; Denecker et al., 2014; Weiss et al., 2012). ZEB1 
has been linked to chemoresistance in glioblastoma and lung cancer models (Fang et al., 2014; Ren et al., 
2013; Siebzehnrubl et al., 2013) and might be conceivably involved in acquiring resistances to therapies 
in cutaneous melanoma. Accordingly, the NCSC and melanoma stemness marker CD271 does not only 
mark melanoma-sustaining subpopulations, but CD271-positive cells are more abundant in biopsies of 
vemurafenib-treated melanoma patients. Indeed, CD271-positivity is greatly enriched in melanoma cells 
during vemurafenib exposure, and these drug-tolerant cells have an increased melanoma-initiating 
capacity upon xenotransplantation (Menon et al., 2014). Thus, in cutaneous melanoma, akin 
transcriptional programs propagate NCSC-like stemness, EMT, and drug resistance. This reflects 
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melanoma plasticity and emphasizes the complicacy but potentially also the opportunities in successfully 
medicating melanoma.  
 
3.4.4. Immunotherapies 
The plethora of genetic and epigenetic alterations that are typical for all cancers provide a diverse set of 
antigens used by the immune system to distinguish tumor cells from their normal counterparts. Upon 
activation through exposure to these antigens, cytotoxic T-lymphocytes (CTL) infiltrate tumors and 
ultimately destroy such antigen-positive cancer cells through the release of perforin and granzymes 
(Schatton et al., 2014). Indeed, improved melanoma patient survival correlates with an increased number 
of tumor-infiltrating T-cells (Azimi et al., 2012; Erdag et al., 2012). However, these T-cell responses 
become ineffective because of immunosuppressive and -adaptive processes occurring at the tumor sites. 
Therefore, to combat melanoma more effectively, diverse strategies have focused on reinforcing quantity 
and efficacy of tumor-infiltrating CTLs (Schatton et al., 2014). 
3.4.4.1. Interleukin 2-based therapies 
Interleukin 2 (IL2) is a potent cytokine that stimulates proliferation and maturation of T-cells (Boyman 
and Sprent, 2012). Therefore, IL2 has been applied as immunotherapeutic agent, and high-dose IL2 
immunotherapy resulted in considerable long-term survival of some melanoma patients (Figure 12). 
However, these promising features fade out in the face of the severe adverse side effects caused by IL2 
(Atkins et al., 1999; Margolin et al., 1989). IL2 toxicity is provoked by stimulation of endothelial cells 
resulting in a vascular leak syndrome (Krieg et al., 2010). Furthermore, IL2 also stimulates regulatory T-
cells (Treg) responsible for immunotolerance, thus partially canceling the anti-tumorigenic effects of 
CTLs. IL2 binds to 2 different receptor subunits, comprised of CD25, which is present on Tregs and 
endothelial cells, and CD122, which is expressed on CTLs (Boyman and Sprent, 2012). In order to 
scavenge IL2 binding towards CD122, selective antibodies blocking the CD25 binding site on IL2 have 
been developed. Complexes of IL2 and such antibodies (IL2-Cx) efficiently stimulate CTLs without 
affecting Tregs and endothelial cells (Figure 14). Administration of IL2-Cx substantially counteracts 
B16-F10 melanoma in vivo without any of the side effects observed upon treatment with IL2 (Boyman et 
al., 2006; Krieg et al., 2010; Levin et al., 2012; Létourneau et al., 2010). Therefore, IL2-Cx-based 
therapeutics might herald a second generation of more promising IL2 therapies. 
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Figure 14 #  IL2-Cx mediates a selective stimulation of CTLs. IL2 promotes proliferation and maturation of T-cells as 
well as a variety of further immune and non-immune cells, which is the cause for IL2 toxicity during high dose IL2 
immunotherapy. To scavenge this pan-activation effect towards CTLs, an antibody was developed that blocks the CD25-
binding site on IL2. CD25 is expressed on lung endothelial cells and Tregs, but is absent on CTLs and NK cells. 
Complexes of IL2 and such anti-IL2 antibodies (IL2-Cx) efficiently activate CTLs and NK cells through CD122 without 
stimulating Tregs and lung endothelium. Thus, IL2-Cx might represent a potent immunotherapeutic that strongly activates 
CTLs but minimizes the harsh side effects seen during IL2 therapy. CTL, cytotoxic T-lymphocyte; IL2, interleukin 2; NK, 
natural killer; Treg, regulatory T-cell (adapted from: Boyman and Sprent, 2012). 
  
3.4.4.2. Adoptive T-cell transfer-based therapies 
Apart from boosting the endogenous T-cell pool in vivo through systemic IL2 administration, tumor-
infiltrating CTLs have been isolated from excised lesions and expanded ex vivo. This enriched 
population of CTLs is then re-administered to patients, possibly in combination with IL2 treatment 
(Restifo et al., 2012). These approaches show durable responses in ∼50% of stage IV melanoma patients 
(Besser et al., 2010; Itzhaki et al., 2011; Rosenberg et al., 2011). Interestingly, in melanoma animal 
models and patients, such ex vivo-enriched CTLs frequently target antigens derived from melanocyte-
specific proteins, such as DCT, MLANA, PMEL, or TYR (Bloom et al., 1997; Dudley et al., 2002; 
Overwijk et al., 1998; Yee et al., 2002). This prompted the development of protocols to genetically 
engineer CTLs prior to implantation, allowing retroviral expression of T-cell receptors with high affinity 
against such antigens presented by the patient’s melanoma cells (Restifo et al., 2012). Adoptive transfer 
of genetically engineered CTLs has demonstrated success in counteracting metastatic melanoma 
(Morgan et al., 2006). However, such personalized treatments are limited by their expenses, as much as 
biosafety and ethical concerns. Furthermore, tumors are able to escape from CTL-based therapies using a 
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variety of mechanisms (Restifo et al., 2012). Melanoma sub-clones deficient of target antigens, antigen-
presenting major histocompatibility complex class 1 (MHC-I) molecules, or components of the antigen-
processing machinery have been isolated from patients that had undergone IL2 therapy or adoptive T-
cell transfer (Garrido et al., 2010; Jäger et al., 1997; Khong et al., 2004; Restifo et al., 1996). Similarly, 
in mice, transplantation of Pmel-targeting CTLs promotes silencing of Pmel in growing B16-F10 
melanomas (Wang et al., 2005). Notably, transplantation of such CTLs into a transgenic mouse model of 
melanoma first induces tumor regression followed by a relapse associated with melanoma 
dedifferentiation including Dct, Mlana, and Pmel silencing and Cd271 induction (Landsberg et al., 2010; 
2012). Furthermore, various immunosuppressive and simultaneously inflammation-promoting 
mechanisms, induced by secretion of IL6, TGFβ, and tumor necrosis factor alpha (TNFα), abrogate CTL 
function in the melanoma microenvironment, thus sustain immune evasion. (Baitsch et al., 2011; Gorelik 
and Flavell, 2001; Landsberg et al., 2012; Meyer et al., 2011; Soudja et al., 2010). Interestingly, these 
mechanisms not only promote immune escape, but also stimulate EMT and metastasis (Bald et al., 2014; 
Landsberg et al., 2012; Toh et al., 2011). Thus, malignant melanoma takes advantage of similar 
strategies, namely dedifferentiation, achieving NCSC-like stemness features, and EMT, to acquire 
resistances against MAPK-targeted therapies and to escape immunosurveillance. 
3.4.4.3. Immune checkpoint blockade as therapeutic approaches 
Besides immune evasion and immunosuppression, melanoma also coopts certain immune checkpoint 
pathways as a mechanism of immune resistance, in particular against tumor-infiltrating CTLs. Immune 
checkpoints are regulatory pathways hardwired into the immune system that are crucial for preventing 
autoimmunity and modulating the duration and amplitude of physiological immune responses in order to 
mitigate collateral tissue damage. For instance, CTL antigen 4 (CTLA4) is expressed on CTLs and 
dampens activation of these cells through binding to CD80 or CD86, which are present on antigen-
presenting cells and tumor cells (Pardoll, 2012) (Figure 15). The essence of CTLA4 for immune 
response regulation becomes apparent as a result of early lethality of Ctla4 knockout mice due to 
systemic immune hyperactivation (Tivol et al., 1995; Waterhouse et al., 1995). Surprisingly, temporal 
Ctla4 blockade with an antibody is passably tolerated by tumor-bearing mice, and leads to a significant 
anti-tumor response (Leach et al., 1996). Therefore, fully humanized anti-CTLA4 antibodies (α-CTLA4) 
have been developed, such as MDX-010 (ipilimumab, Bristol-Myers Squibb; Lipson and Drake, 2011). 
Ipilimumab has shown great clinical responses in melanoma patients, especially by increasing survival 
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beyond 2 years by ∼15%. However, ipilimumab temporally promotes considerable side effects, likely 
due to autoimmune activity (Hodi et al., 2010; Prieto et al., 2012; Robert et al., 2011) (Figure 12). 
Besides CTLA4, programmed cell death 1 (PD-1), which is present on CTLs, and its ligand (PD-L1), 
expressed on antigen-presenting cells and tumor cells, are important negative checkpoint regulators 
(Pardoll, 2012) (Figure 15). PD-L1 is frequently upregulated in human melanoma (Dong et al., 2002; 
Madore et al., 2014; Tumeh et al., 2014), while Pd-L1 overexpression in murine B16-F10 melanoma 
inhibits CTL-mediated anti-tumor responses (Blank et al., 2004). The mild Pd-1 knockout phenotype in 
mice (Nishimura et al., 1999) has prompted the development of anti-PD-1 antibodies, such as BMS-
936558 (nivolumab, Bristol-Myers Squibb; Wang et al., 2014). In melanoma patients, nivolumab has 
shown surpassing clinical responses with minor side effects. Importantly, response status is usually 
maintained long after treatment discontinuation (Robert et al., 2015b; Topalian et al., 2012; 2014) 
(Figure 12). Currently, anti-PD-L1 antibodies are clinically evaluated and show performances 
comparable to nivolumab (Brahmer et al., 2012; Herbst et al., 2014). If checkpoint blockade served only 
to temporally reverse inhibition of CTLs in the melanoma microenvironment, tumors would be expected 
to re-engage these mechanisms and progress after drug discontinuation. Instead, the persistence of stable 
disease in a considerable fraction of patients following ipilimumab or nivolumab discontinuation 
suggests that an effective melanoma-selective immune memory response may have been established, 
similar to immune memory against specific infectious organisms after antigen exposure (Allie et al., 
2011). Besides long-term responders, a notable number of melanoma patients is intrinsically resistant to 
checkpoint blockade therapies, for instance due to a complete lack of tumor-infiltrating CTLs or absence 
of PD-L1 on the tumor cells (Herbst et al., 2014; Kelderman et al., 2014; Madore et al., 2014; Tumeh et 
al., 2014). It remains to be studied, whether in a subset of melanoma patients, in analogy to adoptive 
CTL transfer, checkpoint blockade might also trigger adaptive immune evasion and local 
immunosuppression resulting in relapse. 
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Figure 15 #  CTL-stimulatory and CTL-inhibitory immune checkpoints. The primary signal activating CTLs is antigen 
presentation through peptide-MHC molecule complexes, which are present on antigen-presenting cells including tumor 
cells and bind TCRs on CTLs. This occurs either at the initiation of CTL responses in lymph nodes or in peripheral tissues, 
such as tumors, to sustain effector responses. Furthermore, a plethora of ligand–receptor interactions between CTLs and 
antigen-presenting cells tightly regulates the CTL response to antigen. For instance, CD40, CD70, CD80, CD86, and 
OX40L co-stimulate CTLs through binding to CD40L, CD27, CD28, and OX40, respectively. Activated CTLs then 
upregulate CTLA4, which also binds CD80 / CD86. Signaling through CTLA4, however, confines CTL response. An 
immune checkpoint that similarly dampens CTL response is binding of PD-L1 to PD-1. Cancers including melanoma coopt 
these immune checkpoint pathways as a mechanism of immune resistance. Tumor cells frequently downregulate MHC-I as 
much as checkpoint activators, while upregulating checkpoint inhibitors. CD, cluster of differentiation; CTLA4; CTL 
antigen 4; MHC, major histocompatibility complex; PD, programmed cell death; TCR, T-cell receptor (adapted from: 
Pardoll, 2012). 
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3.5. Epigenetic regulation of the NC and cutaneous melanoma 
3.5.1. Epigenetic regulation during NC development 
According to epigenetic modifiers regulating development, homeostasis, and cancer of various tissues 
(3.1. Epigenetics), epigenetic mechanisms are likewise participating in neural crest development and 
formation of neurocristopathies (Table 1). In human ESCs, DNMT3B loss promotes upregulation of 
NCSC genes including FOXD3, SNAI2, SOX10, and CD271 (Martins-Taylor et al., 2012). Similarly, 
upon neural tube closure in the chick embryo, both Dnmt3a and Dnmt3b silences neuroepithelial genes, 
such as Sox2 and Sox3, which induces expression of the NC specifiers Foxd3, Snai2, Sox9, and Sox10 
(Hu et al., 2014; 2012). In synergy, Jmjd2a is required for demethylation of the H3K9me3 repressive 
mark at the promoters of Snai2 and Sox10, thus promoting expression of these NC specifiers (Strobl-
Mazzulla et al., 2010). However, during EMT of the cranial NC, Dnmt3b re-induces silencing of Sox10, 
allowing the formation of Sox10-negative mesenchymal progenitors (Hu et al., 2014). EMT itself is 
promoted through Hdac and PRC2 activity. Hdacs and Ezh2 form a complex with Snai2 to repress the 
promoter of the epithelial adhesion molecules cadherin 6B (Cad6b) and Cdh1, respectively, thus 
inducing EMT (Coles et al., 2007; Strobl-Mazzulla and Bronner, 2012b; Tien et al., 2015). 
After NC delamination in zebrafish larvae, hdac1 activity is required for foxd3 repression, which induces 
mitf and melanoblast specification (Ignatius et al., 2008). In murine trunk NCSCs, Hdac1 and Hdac2 
promote Sox10 expression, while Hdac1/2 deletion attenuates NC specification towards Sox10-positive 
peripheral glia and maintenance of Schwann cells (Chen et al., 2011; Jacob et al., 2011; 2014). 
Interestingly, in cranial NC of zebrafish larvae, hdac1 activity promotes, rather than melanogenesis, 
specification of sox9-positive mesenchymal progenitors and subsequent mesectodermal differentiation 
(Ignatius et al., 2013). In contrast, different Hdac homologues than Hdac1/2 seem to induce murine NC-
derived mesectoderm. Hdac3 is required for NC differentiation towards smooth muscle cells contributing 
to the outflow tract of the heart (Singh et al., 2011), while Hdac8 ablation interferes with skull 
morphogenesis (Haberland et al., 2009). Comparably, mesectodermal differentiation of NC-derived 
mesenchymal progenitors depends on gene repression mediated by Ezh2. Importantly, apart from 
cartilage and bone formation, Ezh2 deletion affects neither NCSC proliferation nor differentiation of the 
trunk NC (Schwarz et al., 2014). Notably, in differentiated peripheral glia, PRC2 activity is again 
required for Schwann cell maturation and proper axon myelination (Heinen et al., 2012). 
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Table 1 #  Roles of epigenetic modifiers during NC development and in neurocristopathies. 
Tissue / 
Disease DNMT3A/B HDACs 
JMJD2 / 
JARID1 / SETDB1 PRC2 
NC specification 
Repress Sox2/3 
! induction of 
Foxd3, Snai2, Sox9/10 
n.a. 
Jmjd2a 
de-represses 
Snai2, Sox10 
n.a. 
NC EMT n.a. Repress Cad6b 
! EMT induction n.a. 
Represses Cdh1 
! EMT induction 
NCSCs Repress Sox10 
! cranial NCSCs n.a. n.a. Not relevant 
Melanoblast 
specification n.a. 
Repress Foxd3 
! Sox10, Mitf induction n.a. Not relevant 
Glia specification n.a. 
Induce Sox10 
! glia induction / 
maintenance 
n.a. Required for Schwann cell maturation 
Craniofacial / 
Mesenchymal 
specification 
n.a. 
Required for 
smooth muscle cells / 
skull morphogenesis 
n.a. Required for skull morphogenesis 
Waardenburg 
syndromes n.a. n.a. n.a. 
Ezh2 might repress 
Sox10, Pax3 
DiGeorge 
syndrome n.a. n.a. n.a. n.a. 
Weaver 
syndrome 
DNMT3A mutations 
! craniofacial 
anomalies 
n.a. n.a. 
EZH2 mutations 
! craniofacial 
anomalies 
ICF syndrome 
DNMT3B mutations 
! craniofacial 
anomalies 
n.a. n.a. n.a. 
MPNSTs n.a. n.a. n.a. 
SUZ12, EED loss-of-
function mutations 
! tumor progression 
Neuroblastoma Promote drug resistance 
Promote 
tumor growth / stemness n.a. 
EZH2 overexpression 
! tumor progression  
Melanoma 
Repress CDKN2A, 
PTEN, SOX9 
! tumor growth 
Promote 
tumor growth 
SETDB1 amplification 
JARID1 activity 
! growth / stemness 
EZH2Y641N / EZH2 
overexpression 
! growth / metastasis 
EMT, epithelial to mesenchymal transition; ICF, immunodeficiency - centromeric instability - facial anomalies; MPNST, 
malignant peripheral nerve sheath tumor; n.a., not available; NC, neural crest; NCSC, NC stem cell. 
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3.5.2. Epigenetic regulation of neurocristopathies 
Epigenetic modifiers do not only regulate neural crest development, but equiprobably contribute to 
neurocristopathies (Table 1). For instance, Weaver syndrome patients harbor germline EZH2 mutations, 
which are likely deleterious for EZH2 function. The Weaver syndrome partly consists of craniofacial 
malformations (Gibson et al., 2012; Tatton-Brown et al., 2011; 2013). These anomalies are presumably 
due to attenuated EZH2 function during cranial NC development, in accordance with the murine Ezh2 
knockout phenotype (Schwarz et al., 2014). Comparably, recurrent mutations in DNMT3A are associated 
with an overgrowth disorder that includes facial dysmorphism similar to the Weaver syndrome (Tatton-
Brown et al., 2014), while DNMT3B germline mutations are a cause for the immunodeficiency - 
centromeric instability - facial anomalies (ICF) syndrome (Hansen et al., 1999). Interestingly, mice 
harboring such Dnmt3b mutations show developmental defects reminiscent of the ICF syndrome (Ueda 
et al., 2006). The DNMT3A/B-related craniofacial malformations likely originate from aberrant NC 
development, as observed in Dnmt3a/b-depleted mice (Hu et al., 2012; 2014). Attenuation of adipocyte 
enhancer binding protein 2 (Aebp2) results in mice with a phenotype resembling Waardenburg 
syndromes. Interestingly, Aebp2 and Ezh2 co-maintain H3K27me3 at promoters of Sox10 and Pax3 
(Kim et al., 2011a), genes previously implicated in Waardenburg syndromes and Hirschsprung disease 
(3.2.6.1. Waardenburg syndromes and Hirschsprung disease). Thus, their aberrant epigenetic regulation 
might contribute to this congenital disorder. 
Along with its roles in congenital syndromes, epigenetic dysregulation also contributes to NC-derived 
cancers (Table 1). In most malignancies, increased PRC2 activity promotes tumorigenesis (3.1.4.3. 
EZH2 function in hematopoietic malignancies; 3.1.4.4. EZH2 function in solid cancers). Likewise, 
elevated EZH2 levels confer poor prognosis in neuroblastoma patients, and aberrant EZH2 function 
sustains neuroblastoma formation through repression of a diverse set of tumor suppressors (Wang et al., 
2012). In great contrast, somatic mutations affecting either SUZ12 or EED are recurrent in MPNSTs, 
result in abrogated PRC2 function, and are promoting the progression of NF1 loss-induced neurofibroma 
to MPNSTs. Mutational loss of PRC2 activity enforces de-repression of diverse NC specifier / EMT 
genes including ETS1, SOX9, and ZEB1 (De Raedt et al., 2014; Lee et al., 2014; Zhang et al., 2014b). In 
the context of neurofibroma, these genes might have oncogenic attributes, which would explain the 
counterintuitive appearance of PRC2 to conduct tumor suppressive activities. Besides epigenetic 
modifiers, epigenetic readers also contribute to NC-derived malignancies. In mice, Brd4 deletion 
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interferes with progression of neurofibroma to MPNSTs, and BET bromodomain inhibitors induce 
MPNST regression in xenotransplantation models. BRD4 actively stimulates transcription of the anti-
apoptosis gene B-cell leukemia/lymphoma 2 (BCL2) as well as the NC specifier / EMT genes ETS1, 
SOX9, and ZEB1, which are already disposed to transcription in the context of SUZ12 or EED loss. This 
reflects a remarkable interplay between genetic PRC2 inactivation and aberrant BRD4 activity driving 
MPNSTs (De Raedt et al., 2014; Patel et al., 2014). In neuroblastoma, however, BET bromodomain 
inhibitors promote tumor regression by attenuating expression of the N-MYC oncogene rather than 
through a PRC2-dependent mechanism (Puissant et al., 2013; Wyce et al., 2013b).  
 
3.5.3. Epigenetic regulation of cutaneous melanoma 
During cutaneous melanomagenesis, similarly as in neuroblastoma and MPNSTs, BRD4 propagates 
transcription of pro-tumorigenic genes including BCL2, MYC, and NF-κB, while BET bromodomain 
inhibitors impede melanoma growth in vitro and upon xenotransplantation (De Raedt et al., 2014; 
Gallagher et al., 2014a; 2014b; Segura et al., 2013). Beyond BRD4-mediated transcriptional activation, a 
variety of epigenetic modifiers contribute to melanoma initiation, progression, and plasticity. 
3.5.3.1. Aberrant function of DNMTs in melanoma 
For instance, DNMT3A/B expression is elevated in malignant melanoma in comparison to benign 
lesions and further increases with metastatic progression. Likewise, high DNMT3B levels correlate with 
reduced patient survival (Molognoni et al., 2011; Nguyen et al., 2011), while Dnmt3a deletion 
counteracts B16-F10 melanoma growth (Deng et al., 2009). Comparably, CpG island methylation-
induced silencing of a substantial number of tumor suppressor genes, such as CDKN2A or PTEN, has 
been identified in malignant melanoma biopsies (Bonazzi et al., 2011; Conway et al., 2011; Jonsson et 
al., 2010; Schinke et al., 2010; Venza et al., 2015; Zhou et al., 2000), and high density of promoter 
methylation correlates with poor prognosis for melanoma patients (Sigalotti et al., 2014). These findings, 
at first sight, emphasize DNMT inhibition as a possible anti-melanoma treatment. Indeed, exposure of 
melanoma cells to decitabine promotes de-repression of tumor suppressors including CDKN2A and 
apoptosis-inducing Fas cell surface death receptor (FAS) promoting a growth arrest and apoptosis. 
Furthermore, cells upregulate melanocyte differentiation genes, such as MITF and DCT, underlining the 
induced senescence phenotype (Alcazar et al., 2012; Molognoni et al., 2011). However, apart from 
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growth, melanoma plasticity is also controlled by DNMTs. In melanoma cells, decitabine triggers SOX9 
promoter demethylation leading to SOX9 expression, thus the dynamic SOX10-SOX9 interplay 
observed during melanoma progression appears to be epigenetically regulated (Alcazar et al., 2012; 
Cheng et al., 2015). Importantly, also acquired resistance to MAPK inhibitors includes epigenetic 
dynamics. During vemurafenib exposure, the promoter CpGs of EGFR are demethylated, allowing 
melanoma to upregulate EGFR and to re-establish MAPK and PI3K signaling, while decitabine 
accordingly releases EGFR repression (Wang et al., 2015). Since Sox9 overexpression enhances 
metastasis formation in B16-F10 melanoma (Cheng et al., 2015) and EGFR de-repression confers 
resistance to vemurafenib (Wang et al., 2015), DNMT inhibition as potential melanoma therapy seems 
precarious at second sight. 
3.5.3.2. Aberrant function of histone modifiers in melanoma 
Besides aberrant DNMT function, the locus of the H3K9 methyltransferase SETDB1 is recurrently 
amplified in melanoma leading to high SETDB1 expression. SETDB1 aberrantly represses tumor 
suppressors, such as CDKN2A. Accordingly, overexpression of both setdb1 and suv39h1, another H3K9 
methyltransferase, accelerates tumorigenesis in a zebrafish model of melanoma (Ceol et al., 2011; 
Kostaki et al., 2014; Miura et al., 2014). Forced expression of the H3K4me3 demethylase JARID1B in 
human melanoma cells entails a cell cycle arrest through a gain in repressive histone marks at cell cycle-
promoting loci (Roesch et al., 2006; 2008). Paradoxically, in malignant melanoma, JARID1B-expressing 
cells are more abundant than in nevi (Kuźbicki et al., 2013; Roesch et al., 2005). These JARID1B-
positive subpopulations are indeed cycling slowly compared to the tumor bulk. However, increased 
expression of JARID1B also confers stemness features to melanoma cells. JARID1B-positive cells show 
enhanced self-renewal potential in vitro and propagate tumor initiation upon xenotransplantation. 
Intriguingly, JARID1B deletion leads to in vitro exhaustion of melanoma cells and diminishes continuous 
xenotransplant growth and metastatic progression (Roesch et al., 2010). Remarkably, JARID1A/B-
positive cells are highly resistant to chemotherapy and vemurafenib (Roesch et al., 2013; Sharma et al., 
2010; Yuan et al., 2013). During exposure to vemurafenib, melanoma cells upregulate JARID1B along 
with stemness markers, such as CD271, while ablation of JARID1B interferes with CD271 enrichment 
and prevents the acquirement of resistance to MAPK inhibition (Menon et al., 2014). Thus, during 
melanomagenesis, epigenetic rewiring is responsible for tumor growth as much as plasticity resulting in 
NCSC-like stemness, metastasis formation, and resistance to therapies (Figure 6).  
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3.5.3.3. EZH2 and melanomagenesis 
Comparably to JARID1B, the expression of EZH2 mRNA and protein is incrementally increased in 
biopsies from benign nevi to metastatic melanoma (Asangani et al., 2012; Fan et al., 2011; Kampilafkos 
et al., 2015; McHugh et al., 2007). Accordingly, global H3K27me3 is enriched in human melanoma cells 
in comparison to nevus cells and melanocytes (Molognoni et al., 2011). Besides high EZH2 expression, a 
considerable number of melanomas also harbor mutations in EZH2, some of which are the gain-of-
function EZH2Y646C/F/H/N/S mutations (Alexandrov et al., 2013; Harms et al., 2014; Hodis et al., 2012; 
Krauthammer et al., 2012). According to in silico predictions, most of these non-synonymous EZH2 
mutations are thought of altering the activity of EZH2 (Tiffen et al., 2015). As observed in a variety of 
cancers (3.1.4.3. EZH2 function in hematopoietic malignancies; 3.1.4.4. EZH2 function in solid cancers), 
high EZH2 levels correlate with poor melanoma patient survival (Asangani et al., 2012; Bachmann et al., 
2006). Strong EZH2 expression in melanoma biopsies is further associated with an increased 
proliferative index of the corresponding samples (Bachmann et al., 2006), while EZH2 depletion in 
melanoma cells promotes a cell cycle arrest and interferes with growth upon xenotransplantation (Fan et 
al., 2011; Luo et al., 2012a; 2013). However, apart from regulating growth, EZH2 function also appears 
to be important for invasion in collagen layers. EZH2 ablation reduces the invasive capacity of cutaneous 
and uveal melanoma cells (Chen et al., 2013; Luo et al., 2012a; 2013). Likewise, EZH2 expression is 
increased at the invasive front of human melanomas (Kampilafkos et al., 2015), Ezh2 deletion lowers 
cell motility in s.c. growing B16-F10 tumors, and, upon i.v. transplantation, Ezh2-deficient B16-F10 
cells have reduced lung colonization potential (Manning et al., 2014; Tiwari et al., 2013). 
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3.6. Accurately investigating the roles of EZH2 during melanomagenesis 
To this day, studies investigating the roles of EZH2 in cutaneous melanoma have only been of 
correlative nature or have been gathered by means of in vitro culture and melanoma cell transplantation 
assays. Furthermore, no study has so far defined possible EZH2 target genes (ETG) that would 
accurately explain the distinct phenotypes observed upon EZH2 inactivation (3.5.3.3. EZH2 and 
melanomagenesis). It is now widely accepted that tumorigenesis is, apart from cancer cell-intrinsic 
aberrations, propagated through bidirectional interactions of tumor cells with diverse stromal 
compartments, such as the immune system, vasculature, cancer-associated fibroblasts, as well as distant 
organs upon metastatic colonization (Hanahan and Weinberg, 2011; Quail and Joyce, 2013). 
Importantly, this dynamic interference of a growing neoplasm with its microenvironment seems to 
depend on plastic reshaping of the epigenetic landscape (Azad et al., 2013; Tam and Weinberg, 2013) 
(Figure 6). Therefore, investigating the relevance of a given (epigenetic) player for various aspects of 
tumorigenesis is best achieved in physiological cancer models with undisturbed microenvironments, 
rather than in ex vivo culture systems of cancer cells or upon heterotopic transplantation of tumor cells 
into immunocompromised mice. 
Transgenic N-RasQ61K-expressing and Cdkn2a-deficient mice display dermal hyperplasia reminiscent of 
human congenital nevi and consistently develop metastatic melanoma within 6 months of age 
(Ackermann et al., 2005; Shakhova et al., 2012). Hence, this murine model represents an ideal tool to 
explore the significance of Ezh2-mediated gene repression for melanoma initiation, growth, metastatic 
progression, and the interplay of the melanoma compartment with stroma. Moreover, integration of 
global gene expression analyses, chromatin immunoprecipitation (ChIP) data, and functional 
experiments will faithfully allow the definition of melanoma-relevant ETGs. Consequently, these 
findings will deepen our understanding on the mode of EZH2-facilitated melanomagenesis and might set 
the stage to combat this deadly disease more effectively. 
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4. Results 
 
4.1. My contributions to published articles and manuscripts in preparation 
4.1.1. Roles of NC development-relevant factors during melanomagenesis 
Given the close relationship between the embryonic NC and melanoma (chapters 3.2. – 3.4.), a major 
research focus of the Sommer Lab has been on deciphering putative roles of NC development-relevant 
transcription factors and signaling pathways in the formation and metastatic progression of melanoma. In 
the course of my doctorate, I contributed to and initiated several projects investigating these questions: 
Firstly, I helped unraveling the antagonistic roles of SOX10 and SOX9 in melanoma initiation and 
metastasis. I performed a majority of the in vitro experiments deciphering the cellular and molecular 
functions of SOX10 in melanoma cells (Shakhova et al., 2012). Secondly, I contributed to the 
characterization of the SOX10-SOX9 interplay by analyzing cell cycle progression and apoptosis in the 
context of SOX10 and SOX9 depletion (Cheng et al., 2015; Shakhova et al., 2015). I also performed the 
B16-F1 i.v. transplantation assays demonstrating the in vivo potential of Sox9 in promoting lung 
metastasis (Cheng et al., 2015). Finally, I initialized and guided a project deciphering the roles of Tgfβ 
signaling in murine melanoma formation and especially metastasis. Therefore, I established a colony of 
melanoma-prone mice bearing either Smad7lox/lox or Tgfbr2lox/lox, which allowed in vivo manipulation of 
Tgfβ signaling in the context of melanomagenesis. Phenotypes have been analyzed in close collaboration 
with E. Tuncer, and results will soon be prepared for publication (Zingg and Tuncer, in preparation). 
Shakhova, O., Zingg, D., Schaefer, S.M., Hari, L., Civenni, G., Blunschi, J., Claudinot, S., Okoniewski, M., Beermann, F., 
Mihic-Probst, D., Moch, H., Wegner, M., Dummer, R., Barrandon, Y., Cinelli, P., and Sommer, L. (2012). Sox10 promotes 
the formation and maintenance of giant congenital naevi and melanoma. Nat. Cell. Biol. 14, 882–890. 
Shakhova, O., Cheng, P., Mishra, P.J., Zingg, D., Schaefer, S.M., Debbache, J., Häusel, J., Matter, C., Guo, T., Davis, S., 
Meltzer, P., Mihic-Probst, D., Moch, H., Wegner, M., Merlino, G., Levesque, M.P., Dummer, R., Santoro, R., Cinelli, P., 
and Sommer, L. (2015). Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in 
melanoma. PLoS Genet. 11, e1004877. 
Cheng, P.F., Shahkova, O., Widmer, D.S., Eichhoff, O.M., Zingg, D., Frommel, S.C., Belloni, B., Raaijmakers, M.M., 
Goldinger, S.M., Santoro, R., Hemmi, S., Hoek, K.S., Sommer, L., Dummer, R., and Levesque, M.P. (2015). Methylation-
dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced 
melanoma. Genome Biol. 16, 3016. 
Zingg, D., Tuncer, E., and Sommer, L. (2015). Tgfβ signaling promotes melanoma metastasis in vivo. In preparation. 
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4.1.2. Roles of the epigenetic modifier EZH2 in melanomagenesis 
Besides transcription factors and signaling pathways, epigenetic rewiring likely contributes to distinct 
aspects of melanomagenesis. Therefore, in the main project of my doctorate, I focused on the roles of the 
epigenetic modifier EZH2 during melanoma initiation and progression. These results are illustrated in 
my PhD thesis (4.2. Roles of EZH2 in melanoma formation and metastatic progression) and were 
recently accepted for publication (Zingg et al., 2015). I conducted the majority of these experiments and 
analyzed most of these data, with a number of exceptions, in which experiments and data analyses were 
performed in collaboration as follows: western blots with S. M. Schaefer and J. Debbache, 
immunofluorescence with E. Tuncer, qPCRs with J. Haeusel, ChIP with S. C. Frommel, and TCGA 
analyses with P. Cheng. EZH2 mutagenesis was done by J. Debbache and i.v. injections were conducted 
by N. Arenas-Ramirez. 
Zingg, D., Debbache, J., Schaefer, S.M., Tuncer, E., Frommel, S.C., Cheng, P., Arenas-Ramirez, N., Haeusel, J., Zhang, 
Y., Bonalli, M., McCabe, M.T., Creasy, C.L., Levesque, M.P., Boyman, O., Santoro, R., Shakhova, O., Dummer, R., and 
Sommer, L. (2015). The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct 
tumour suppressors. Nat. Commun. 6, 6051. 
 
4.1.3. Roles of the epigenetic modifier EZH2 in immunoediting 
Among the identified ETGs, I found CD40 to be of particular interest. CD40 is a positive immune 
checkpoint regulator. This prompted me to establish a collaboration with the Boyman Lab to decipher 
the putative role of EZH2-medited epigenetic repression in immunoediting. The so far acquired results 
are also illustrated in my PhD thesis (4.3. Roles of EZH2 in melanoma immunoediting) and are currently 
prepared for publication (Zingg, Arenas-Ramirez, and Rosalia, in preparation). In the frame of this 
collaboration, both labs contributed equally to the tumor allografting experiments. I performed most of 
the in vitro assays and tumor initiation experiments, whereas immunological analyses were done by N. 
Arenas-Ramirez and R. A. Rosalia. 
Zingg, D., Arenas-Ramirez, N., Rosalia, R.A., Haeusel, J., Boyman, O., and Sommer, L. (2015). Inhibition of the 
epigenetic modifier EZH2 synergizes with immunotherapy in abrogating melanoma formation. In preparation. 
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4.2. Roles of EZH2 in melanoma formation and metastatic progression 
4.2.1. EZH2 is highly expressed in samples of human and murine melanoma 
Previously, high EZH2 expression has been described in biopsies of malignant melanoma in comparison 
to benign nevi (3.5.3.3. EZH2 and melanomagenesis). To address whether changes in EZH2 expression 
affect cells of the melanocytic lineage rather than stromal cells in the tumor tissue, I performed co-
staining of human cutaneous melanoma sections for EZH2 in combination with SOX10 or MART1-
HMB45 (MLANA and PMEL), all markers for the melanocytic lineage (Busam et al., 1998; Gown et al., 
1986; Harris et al., 2013; Shakhova et al., 2012; 2015). In agreement with previous studies (Asangani et 
al., 2012; Fan et al., 2011; Kampilafkos et al., 2015; McHugh et al., 2007), human primary melanomas 
and metastases displayed high EZH2 expression in cells of the melanocytic lineage compared to 
epidermal melanocytes and dermal nevus cells (Figure 16a; Table 2). To study the function of Ezh2 in an 
in vivo context of melanoma development, I took advantage of a mouse model of cutaneous melanoma. 
Overexpression of the N-RasQ61K oncogene under the control of the Tyr promoter (Tyr::N-RasQ61K) drives 
formation of dermal hyperplasia reminiscent of human congenital nevi and, in combination with loss of 
Cdkn2a (hereafter referred to as Ink4a-/-), results in melanoma formation with a high penetrance (>90%) 
at around 6 months of age. Furthermore, Tyr::N-RasQ61K Ink4a-/- animals consistently develop lymph 
node and distant metastases in organs typically affected in stage IV melanoma patients, such as the liver, 
the lung, and the brain. Therefore, this murine melanoma model mimics the human disease accurately 
(Ackermann et al., 2005; Shakhova et al., 2012). Similar to human patients, Ezh2 protein was strongly 
expressed in Sox10-positive cells of murine skin melanoma and distant metastases. In contrast, Sox10-
expressing cells in hair follicle bulbs, the physiological location of melanocytes in murine trunk skin 
(3.2.4. Adult melanocyte biology), and in dermal hyperplasia only showed marginal Ezh2 expression 
(Figure 16b), consistent with the human data. 
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Figure 16 #  EZH2 protein is upregulated in human and murine melanoma. (a) Immunofluorescent staining for 
HMB45-MART1 and EZH2 on human epidermis, dermal congenital nevus, primary melanoma, and subcutaneous 
melanoma metastasis sections from biopsies described in (Table 2). (b) Immunofluorescent staining for Sox10 and Ezh2 on 
skin and lung sections of melanoma-developing Tyr::N-RasQ61K Ink4a-/- mice. E, epidermis; HF, hair follicle. Scale bars, 
50µm. 
 
Table 2 #  Clinical data corresponding to human nevus and melanoma biopsies. 
Patient ID Sex Age AJCC Nevus / Melanoma type BRAF* NRAS* MART1 HMB45 EZH2 high 
12.9648 M 48 0 Dermal nevus n.d. n.d. + - no 
12.9648 M 48 I Epidermal melanoma n.d. n.d. + + yes 
12.6190 F 61 0 Dermal nevus V600E -- + - no 
10.9640 M 36 0 Congenital nevus -- Q61K + - no 
12.13497 M 76 II Epidermal melanoma V600E -- + + yes 
12.19445 M 55 IIIA Epi- / dermal melanoma -- Q61K + + yes 
12.18389 F 65 IV Subcutaneous metastasis V600E -- + + yes 
12.14437 F n.a. IIIC Subcutaneous metastasis -- Q61R + + yes 
12.21491 F 84 IIIB Subcutaneous metastasis -- Q61R + + yes 
Immunohistochemical staining for MART1 (MLANA) and HMB45 (PMEL) was used to distinguish benign from malignant 
melanoma lesions (Busam et al., 1998; Gown et al., 1986). AJCC, American Joint Committee on Cancer; F, female; M, male;    
n.a., not available; n.d., not defined. 
 
4.2.2. Increased EZH2 expression is linked to poor melanoma patient survival 
To study the significance of high EZH2 expression for the survival of cutaneous melanoma patients, I 
established an EZH2 high and an EZH2 low patient group based on RNAseq and clinical data from The 
Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov/). These groups did not display obvious 
differences with respect to clinically relevant factors including BRAF and NRAS mutations (Figure 17a). 
 4—73 
However, patients of the EZH2 high group showed a significantly shorter overall survival as compared 
to those of the EZH2 low group (Figure 17b). Intriguingly, primary melanoma and lymph node 
metastases patients (stage I – III) of the EZH2 high group developed distant metastases (stage IV) 
significantly faster than EZH2 low-expressing stage I – III patients (Figure 17c), implying a potential 
role of EZH2 in metastatic spread of melanoma. 
 
 
Figure 17 #  High EZH2 mRNA expression correlates with adverse patient survival. (a) BRAF and NRAS mutational 
status of melanoma specimens included in EZH2 TCGA analysis. All patients, n = 274; EZH2 low, n = 60; EZH2 high, n = 
60. (b) Kaplan-Meier curves comparing overall survival of melanoma specimens (stage I – IV) with respect to EZH2 
transcript levels based on TCGA. (c) Kaplan-Meier curves comparing distant metastases-free survival of stage I – III 
melanoma specimens (primary melanoma / lymph node metastases) with respect to EZH2 transcript levels based on TCGA. 
EZH2 low / high, bottom and top 60 patients with respect to EZH2 transcript levels. TCGA, The Cancer Genome Atlas. P-
values calculated with Log-rank (Mantel-Cox) test.  
 
Apart from expression levels, mutations affecting EZH2 activity have been implicated predominantly in 
malignancies of the hematopoietic system (3.1.4.3. EZH2 function in hematopoietic malignancies), but 
also in melanoma (3.5.3.3. EZH2 and melanomagenesis). To clarify the significance of these EZH2 
mutations for melanomagenesis, I first analyzed the occurrence of EZH2 somatic mutations in cutaneous 
melanoma in comparison to 9 different cancer types using TCGA and 4 further datasets (Alexandrov et 
al., 2013; Hodis et al., 2012; Krauthammer et al., 2012; McCabe et al., 2012a). In this analysis, 
cutaneous melanoma showed the highest non-synonymous EZH2 mutation frequency besides primary 
(non-Hodgkin) lymphomas. In particular, cutaneous melanoma was the only solid cancer with non-
synonymous mutations affecting tyrosine 646 (Y646) in the SET domain of EZH2 (Figure 18a, b). 
Previously, EZH2Y646* mutations were reported to be widely present in primary lymphoma and to lead to 
increased EZH2 activity resulting in aberrant H3K27me3 (3.1.4.3. EZH2 function in hematopoietic 
malignancies). Based on in silico predictions, the collection of non-synonymous EZH2 mutations 
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occurring in melanoma patients are thought of potentially altering EZH2 function (Tiffen et al., 2015). 
To associate these EZH2 mutations present in melanoma patients with EZH2 function, I overexpressed 
selected EZH2 mutations in vitro. However, except EZH2Y646N/F, none of the mutations analyzed induced 
an increase in global H3K27me3. In fact, overexpression of EZH2P132S and EZH2D142V significantly 
reduced global H3K27me3, indicating a dominant-negative loss-of-function phenotype (Figure 18c, d). 
Further functional studies will be necessary to uncover properties of these mutations that might allow a 
functional link to cutaneous melanomagenesis. 
 
 
Figure 18 #  EZH2 is frequently mutated in human melanoma. (a) EZH2 non-synonymous mutational landscape 
including EZH2Y646*-activating mutations based on TCGA melanoma dataset and 3 further datasets (Alexandrov et al., 
2013; Hodis et al., 2012; Krauthammer et al., 2012). (b) EZH2 mutation frequencies including Y646* in different cancers 
based on TCGA and 2 further datasets (Hodis et al., 2012; McCabe et al., 2012a). (c, d) Western blot for EZH2 protein and 
H3K27me3 on HEK293T cells overexpressing different EZH2 mutants to quantify changes in H3K27me3. H3, histone 3. 
Data are mean ± s.e.m. of n = 4. P-values calculated with ANOVA and Fisher’s LSD-test. 
 
4.2.3. Ezh2 function is dispensable for homeostasis of melanocytes 
Because EZH2 was highly expressed in human and murine melanoma and linked to poor patient 
survival, I studied its function in vivo. To this end, mice carrying floxed alleles of the Ezh2 locus 
(Ezh2lox/lox) (Hirabayashi et al., 2009) were used to conditionally delete Ezh2 in the melanocytic lineage 
(Tyr promoter) by tamoxifen (TM)-induced activation of Cre-recombinase (Tyr::CreERT2) (Bosenberg et 
al., 2006). Inclusion of a Cre-reporter allele (R26R::LacZ) (Soriano, 1999) allowed fate mapping of 
recombined cells in vivo. To address a potential role of Ezh2 in maintaining normal melanocytic 
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function, Ezh2 was conditionally depleted in tumor-free Tyr::CreERT2 Ezh2lox/lox R26R::LacZ mice 
(Figure 19a). TM was applied to 1-month-old animals, and mice were monitored for hair graying (Figure 
19b). Hair graying is the phenotype predominantly arising upon interference with homeostasis of 
melanocyte stem cells in the bulge (Harris et al., 2013; Lang et al., 2005; Nishimura et al., 2010; Rabbani 
et al., 2011; Shakhova et al., 2015), the permanent niche of epithelial and melanocyte stem cells in hair 
follicles (Cotsarelis et al., 1990; Nishimura et al., 2002a). However, hair pigmentation remained normal 
up to 1 year after Ezh2 depletion (Figure 19c). Importantly, Ezh2 was efficiently and durably ablated in 
melanocytes of trunk skin hair follicles, leading to a concomitant loss of H3K27me3 (Figure 19d, e). 
 
4.2.4. N-RasQ61K-expressing nevus cells are Ezh2 independent 
This unforeseen independence of the normal melanocyte lineage from Ezh2-mediated gene repression 
prompted us to investigate a possible function of Ezh2 in maintaining benign nevus-like dermal 
hyperplasia. Therefore, Ezh2 was depleted in the genetic Tyr::N-RasQ61K Ink4a-/- Tyr::CreERT2 Ezh2lox/lox 
R26R::LacZ melanoma model (Figure 20a - c). As in tumor-free mice, conditional deletion of Ezh2 in 
Tyr::N-RasQ61K Ink4a-/- animals had no effect on hair pigmentation. Importantly, maintenance of benign 
dermal hyperplasia was also not affected (Figure 20d), despite efficient Ezh2 depletion and subsequent 
loss of H3K27me3 (Figure 20e, f). Even when aged for up to one year after conditional knockout (cKO) 
of Ezh2, Tyr::N-RasQ61K mice with functional Ink4awt loci did not show an overt reduction of recombined 
melanocytic cells in the dermis (Figure 20e). Accordingly, dermal hyperplasia grew to a similar size with 
a comparably low proliferation rate in both control and Ezh2-depleted mice (Figure 21a, b). Thus, Ezh2-
mediated gene repression is dispensable for both physiological homeostasis of normal melanocytes and 
maintenance of N-RasQ61K-transformed cells in dermal hyperplasia, independent of Ink4a-deficiency. 
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Figure 19 #  Ezh2 is not required for normal melanocyte homeostasis. (a, b) Mouse genotypes and strategy used to 
analyze the effect of conditional Ezh2 ablation in the melanocytic lineage of adult wt mice. (c) Macroscopic pictures and 
H&E staining on trunk skin sections of control and cKO mice at 5 months and 1 year post conditional Ezh2 ablation. (d) 
Immunofluorescent staining on trunk skin sections of wt mice for β-Gal to quantify recombination efficiencies 
(representative fields not shown). (e) Immunofluorescent staining on trunk skin sections of wt mice for Sox10 (control) or 
β-Gal (cKO) and H3K27me3 to quantify H3K27me3 depletion. White arrowhead, Sox10-positive cell considered 
H3K27me3-positive; White open arrowhead, β-Gal-positive cell considered H3K27me3-negative. cKO, conditional Ezh2 
knockout; H&E, haematoxylin and eosin; TM, tamoxifen. Data are mean ± s.e.m. of n = 3. P-values calculated with 
unpaired Student’s t-test. Scale bars, 50µm. 
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Figure 20 #  Ezh2 is not required for maintenance of dermal hyperplasia. (a - c) Mouse genotypes and strategy used to 
analyze the effect of conditional Ezh2 ablation in the melanocytic lineage of adult Tyr::N-RasQ61K (Ink4a-/-) mice. (d) 
Macroscopic pictures and H&E staining on trunk skin sections of control and cKO mice at 5 months post conditional Ezh2 
ablation. (e) Immunofluorescent staining on trunk skin sections of Tyr::N-RasQ61K (Ink4a-/-) mice for Dct and β-Gal to 
quantify recombination efficiencies. White arrowheads, Dct-positive cells considered β-Gal-positive; White open 
arrowheads, Dct-positive cells considered β-Gal-negative. (f) Immunofluorescent staining on trunk skin sections of Tyr::N-
RasQ61K Ink4a-/- mice for Sox10 (control) or β-Gal (cKO) and H3K27me3 to quantify H3K27me3 depletion. White 
arrowhead, Sox10-positive cell considered H3K27me3-positive; White open arrowheads, β-Gal-positive cells considered 
H3K27me3-negative. Data are mean ± s.e.m. of n = 3. P-values calculated with ANOVA and Fisher’s LSD-test (e), 
unpaired Student’s t-test (f). Scale bars, 50µm. 
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Figure 21 #  Ezh2 is not required for dermal hyperplasia growth. (a) Immunofluorescent staining for Dct on trunk skin 
sections 2 weeks after conditional Ezh2 ablation as in (Figure 20) to quantify dermal hyperplasia size. (b) 
Immunofluorescent staining for Sox10 (control) or β-Gal (cKO) and Ki67 on trunk skin sections 5 months after conditional 
Ezh2 ablation as in (Figure 20) to quantify proliferation rates. White arrowhead, Sox10-positive / Ki67-positive cell; White 
open arrowheads, Sox10- or β-Gal-positive / Ki67-negative cells. Data are median ± 100% range of n ≥ 20 interfollicular 
areas, 3 animals per group (a), mean ± s.e.m. of n = 3 (b). P-values calculated with unpaired Student’s t-test. Scale bars, 
50µm. 
 
4.2.5. Ezh2 function is essential for melanoma initiation 
To assess a possible role of Ezh2 in tumorigenesis, Ezh2 was conditionally deleted in Tyr::N-RasQ61K 
Ink4a-/- Tyr::CreERT2 Ezh2lox/lox R26R::LacZ mice before appearance of cutaneous tumors (Figure 22 a, 
b). While in control mice, many skin melanomas (Ø ≥ 2mm) emerged after approximately 5 months, 
appearance of tumors was delayed in Ezh2 cKO animals leading to an increased skin melanoma-free 
survival (Figure 22c - e). At day of sacrifice, numbers of recombined skin melanomas were drastically 
reduced in Ezh2 cKO mice compared to the total tumor load in controls (Figure 22f - h). In accordance 
with these data, melanoma-specific survival was significantly increased, independently of control type 
and sex of Ezh2 cKO mice (Figure 22i, j). 
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Figure 22 #  Ezh2 function is essential for skin melanoma initiation. (a, b) Mouse genotypes and strategy used to 
analyze the effect of conditional Ezh2 ablation in the melanocytic lineage of adult Tyr::N-RasQ61K Ink4a-/- mice. (c, d) 
Macroscopic pictures and H&E staining on skin sections of a control and a cKO littermate at 5 months post Ezh2 ablation. 
(e) Kaplan-Meier curves comparing skin melanoma-free survival (skin melanoma = lesion Ø ≥ 2mm) of control and cKO 
mice taking into count all skin melanomas (recombined and non-recombined). (f - h) H&E staining on trunk skin sections 
of control and cKO mice (f) and a section of a whole mount X-Gal stained tumor of a cKO animal (g) to quantify 
(recombined) skin melanoma numbers at day of sacrifice (h). (i, j) Kaplan-Meier curves comparing melanoma-specific 
survival after conditional Ezh2 ablation. For cKO mice only recombined skin melanomas were taken into count. Data are 
mean ± s.e.m. of n = 32 (Control), n = 23 (cKO). P-values calculated with Log-rank (Mantel-Cox) test (e, i, j), unpaired 
Student’s t-test (h). Scale bars, 500µm. 
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Next, I addressed whether Ezh2 might also be implicated in melanoma progression after the onset of the 
disease. To this end, Tyr::N-RasQ61K Ink4a-/- Tyr::CreERT2 Ezh2lox/lox R26R::LacZ mice were individually 
monitored until appearance of skin melanomas. Ezh2 deletion was then induced by TM application 
(Figure 23a, b, g). High recombination efficiency became apparent 1 month post TM application (Figure 
23c, d). Concomitantly, this also led to an efficient loss of Ezh2 protein and H3K27me3 in recombined 
tumor cells (Figure 23e, f). Frequent assessment of the animals showed a marked increase of new 
melanomas per week in control animals. In striking contrast, the tumor load was stabilized in Ezh2 cKO 
mice, in which virtually no new skin melanomas were emerging (Figure 23g). Thus, early genetic 
interference with Ezh2 activity prevents progression of benign dermal hyperplasia into malignant 
cutaneous melanoma, while Ezh2 depletion in established melanoma effectively stops emergence of 
further skin tumors. 
 
4.2.6. Ezh2-targeted therapy interferes with melanoma progression 
My findings indicate that interference with EZH2 activity might be a valid strategy for therapy of 
advanced melanoma. To test this hypothesis, I intended to treat mice with one of the preclinical EZH2 
inhibitors (3.1.4.3. EZH2 function in hematopoietic malignancies). I chose to use GSK503 (Figure 5), 
because it exhibits favorable pharmacokinetics in mice (Béguelin et al., 2013). Independent of the 
genotype (wt, Ink4a-/-, or Tyr::N-RasQ61K Ink4a-/-), mice suffered from a tolerable and reversible weight 
loss of approximately 10% and, in rare cases, from development of ascites after prolonged treatment with 
GSK503. To investigate the effect of pharmacological Ezh2 inhibition on tumor progression,        
Tyr::N-RasQ61K Ink4a-/- mice were individually monitored until skin melanomas were detectable and 
subsequently treated daily, either with vehicle or GSK503 for 35 consecutive days (Figure 24a, b, d). 
This procedure reduced H3K27me3 levels in tumor and stromal cells without affecting Ezh2 levels, 
confirming inhibition of the catalytic function of Ezh2 (Figure 24c). Comparable to genetic ablation of 
Ezh2, GSK503 treatment drastically reduced the emergence of new skin melanomas over time after 
treatment start (Figure 24d). 
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Figure 23 #  Ezh2 ablation in melanoma-bearing mice prevents disease progression. (a, b) Mouse genotypes and 
strategy used to analyze the effect of conditional Ezh2 ablation on melanoma progression in Tyr::N-RasQ61K Ink4a-/- mice. 
(c) H&E staining on skin melanoma sections and sections of whole mount X-Gal stained tumors 4 weeks after conditional 
Ezh2 ablation. (d) Immunofluorescent staining on skin melanoma sections for Dct and β-Gal 4 weeks post conditional Ezh2 
ablation to quantify a recombination efficiency. (e, f) Immunofluorescent staining on skin melanoma sections for Sox10 
(control) or β-Gal (cKO) and Ezh2 (e) or H3K27me3 (f) 4 weeks post conditional Ezh2 ablation to quantify Ezh2 and 
subsequent H3K27me3 depletion in melanoma cells. White arrowheads, Sox10-positive cells considered Ezh2- or 
H3K27me3-positive; White open arrowheads, β-Gal-positive cells considered Ezh2- or H3K27me3-negative. (g) 
Representative pictures of Tyr::N-RasQ61K Ink4a-/- mice  at time point of Ezh2 ablation and 4 weeks later to quantify 
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formation of new skin melanomas per week. Orange arrowheads, new skin melanomas. Data are mean ± s.e.m. of n = 3 (d - 
f), mean ± s.e.m. of n = 15 (Control), n = 13 (cKO) (g). P-values calculated with unpaired Student’s t-test. Scale bars, 
500µm (c), 50µm (d - f). 
 
 
 
 
Figure 24 #  Temporary GSK503 application in melanoma-bearing mice stabilizes disease. (a, b) Mouse genotypes 
and strategy used to analyze the effect of temporary GSK503 treatment on Tyr::N-RasQ61K Ink4a-/- mice with established 
melanoma. (c) Immunofluorescent staining on skin melanoma and lymph node sections for Sox10 and Ezh2 or H3K27me3 
4 weeks after treatment start with vehicle or GSK503. (d) Representative pictures of Tyr::N-RasQ61K Ink4a-/- mice treated 
with vehicle or GSK503 at time point of treatment start and 4 weeks later to quantify formation of new skin melanomas per 
week. Orange arrowheads, new skin melanomas. Data are mean ± s.e.m. of n = 17 (Vehicle) n = 15 (GSK503). P-values 
calculated with unpaired Student’s t-test. Scale bars, 50µm. 
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4.2.7. EZH2 is required for growth of human and murine melanoma 
My findings demonstrate the requirement of Ezh2 for melanoma initiation. I hypothesized whether this 
might function through regulation of proliferation, since EZH2 has previously been associated with 
proliferation of human melanoma cells in vitro (Fan et al., 2011; Luo et al., 2012a; 2013). Interestingly, I 
observed a heterogeneity with respect to EZH2 expression in melanoma cells of both human biopsies as 
well as on Tyr::N-RasQ61K Ink4a-/- skin tumors and metastases, ranging from high EZH2 expression to 
almost background levels (Figure 16). EZH2 highly expressing cells significantly correlated with KI67-
positive cells, implicating EZH2-regulated proliferation of melanoma at primary tumor and metastatic 
sites (Figure 25). To address the relevance of these findings for melanoma growth, I first blocked EZH2 
activity in human melanoma cell cultures (Zipser et al., 2011), either by RNA interference-mediated 
silencing (RNAi) or by chemical inhibition using GSK503. In agreement with my in vivo findings, RNAi 
effectively reduced EZH2, while GSK503 application did not affect EZH2 levels. Both approaches, 
however, led to a considerable loss of H3K27me3 (Figure 26a, b). Notably, neither RNAi nor prolonged 
GSK503 application for 8 days did affect cell survival (Figure 26c, d). However, suppressing EZH2 
activity stimulated a G1 cell cycle arrest (Figure 26e, f) and slowed down cell growth in culture (Figure 
26g, h). 
To functionally study EZH2-regulated proliferation in vivo, I quantified proliferative cells in tumors of 
Tyr::N-RasQ61K Ink4a-/- mice, either after Ezh2 cKO or GSK503 application. Both approaches led to a 
striking reduction of proliferative tumor cells (Figure 27). I next engrafted murine B16-F10 melanoma 
cells into C57Bl/6 mice (Figure 28a). Depletion of Ezh2 function using RNAi or GSK503 significantly 
reduced global H3K27me3 levels in vivo (Figure 28b - e). Importantly, EZH2 inactivation led to an 
inhibition of tumor growth (Figure 28b, f). Finally, I engrafted Tyr::N-RasQ61K Ink4a-/- skin melanoma 
(RIM)-derived cells into athymic nude Foxn1nu/nu mice (Figure 29a, h, k). These RIM allografts were 
confirmed to express various melanocytic markers, reassuring their melanoma origin (Figure 30). RIMs 
were first allowed to reach a considerable size for 15 to 25 days after transplantation (Figure 29a, f, j, m). 
Subsequent TM-induced Ezh2 cKO in growing RIMs completely abolished Ezh2 protein and 
H3K27me3, while GSK503 application significantly reduced H3K27me3 (Figure 29b - e). This was 
associated with an inhibition of further tumor growth in both cKO and GSK503-treated samples (Figure 
29b, f, g, i, j, l, m) highlighting Ezh2 inactivation as an efficient strategy for blocking melanoma growth. 
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Figure 25 #  Heterogeneous high EZH2 expression correlates with KI67 positivity. (a - d) Immunofluorescent staining 
on human melanoma metastases sections (a) and melanoma sections of Tyr::N-RasQ61K Ink4a-/- mice (b - d) for EZH2 and 
ΚΙ67 to quantify a correlation between high EZH2 expression and KI67 positivity. White arrowheads, EZH2-high cells 
considered KI67-positive. Data are mean ± s.e.m. of n = 5 (a, b), mean ± s.e.m. of n = 8 (c), mean ± s.e.m. of n = 4 (d). P-
values calculated with unpaired Student’s t-test. Scale bars, 50µm. 
  
 4—85 
 
Figure 26 #  EZH2 inactivation in human melanoma cells interferes with cell growth. (a) Western blot for EZH2 
protein and H3K27me3 on whole cell lysates from 2 melanoma cell cultures (M010817, M050829) after EZH2 depletion 
with 3 different siEs or EZH2 inhibition using GSK503. (b) Immunofluorescent staining on M010817 for H3K27me3 after 
GSK503 treatment. (c, d) FACS analysis of M010817 and M050829 for Annexin V positivity after EZH2 depletion with 
siE or EZH2 inhibition using GSK503 to quantify induced apoptosis. (e, f) Cell cycle profiles of M010817 and M050829 
using PI after EZH2 depletion with siE or EZH2 inhibition using GSK503 to quantify a G1 / (S + G2M) ratio. (g, h) 
Growth of M010817 and M050829 after EZH2 depletion with siE. PI, propidium iodide; Ve, vehicle. Data are mean ± 
s.e.m. of n = 3. P-values calculated with unpaired Student’s t-test (f), ANOVA and Fisher’s LSD-test (g, h). Scale bars, 
25µm. 
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Figure 27 #  Ezh2 ablation and GSK503 treatment attenuates melanoma cell proliferation in vivo. (a) Mouse 
genotypes and strategy as in (Figure 23) used to analyze the effect of conditional Ezh2 ablation on melanoma proliferation 
in Tyr::N-RasQ61K Ink4a-/- mice. (b) Immunofluorescent staining on skin melanoma sections for Sox10 (control) or β-Gal 
(cKO) and Ki67 4 weeks after conditional Ezh2 ablation to quantify a proliferation rate. White arrowheads, Sox10- or β-
Gal-positive / Ki67-positive cells. (c) Mouse genotypes and strategy as in (Figure 24) used to analyze the effect of 
temporary GSK503 treatment on melanoma proliferation in Tyr::N-RasQ61K Ink4a-/- mice. (d) Immunofluorescent staining 
on skin melanoma sections for Sox10 and Ki67 4 weeks after treatment start with vehicle or GSK503 to quantify a 
proliferation rate. White arrowheads, Sox10-positive / Ki67-positive cells. Data are mean ± s.e.m. of n = 5 (b), mean ± 
s.e.m. of n = 6 (Vehicle), n = 5 (GSK503) (d). P-values calculated with unpaired Student’s t-test. Scale bars, 50µm. 
 
 
Figure 28 #  Ezh2 inactivation interferes with murine B16-F10 melanoma growth. (a) Mouse genotypes and strategy 
used to s.c. engraft B16-F10 cells following Ezh2 silencing with shE to analyze the effect of Ezh2 depletion and GSK503 
treatment on melanoma growth. (b) Representative macroscopic pictures of shCo, shE, and GSK503-treated B16-F10 
isografts. (c) RT-qPCR for Ezh2 mRNA expression on lysed shCo, shE, and GSK503-treated B16-F10 tumors. (d, e) 
Western blot for Ezh2 protein and H3K27me3 on lysed shCo, shE, and GSK503-treated B16-F10 tumors to quantify loss of 
H3K27me3. (f) Growth of shCo, shE, and GSK503-treated B16-F10 isografts. Black arrow, GSK503 treatment start. s.c., 
subcutaneous. Data are mean ± s.e.m. of n = 3 (shCo), n = 4 (shE, GSK503) (c), mean ± s.e.m. of n = 3 (shCo, shE), n = 4 
(GSK503) (d, e), mean ± s.e.m. of n = 5 (f). P-values calculated with ANOVA and Fisher’s LSD-test. Scale bars, 1mm. 
 4—87 
 
Figure 29 #  Ezh2 inactivation prevents growth of allografted Tyr::N-RasQ61K Ink4a-/- melanoma. (a, h, k) Mouse 
genotypes and strategy used to s.c. engraft and expand Tyr::N-RasQ61K Ink4a-/- mice-derived melanoma cells in Foxn1nu/nu 
animals to analyze the effect of conditional Ezh2 ablation and GSK503 treatment on melanoma growth. (b) Representative 
macroscopic pictures of control, cKO, and GSK503-treated RIM-1 allografts. (c - e) Western blot for Ezh2 protein and 
H3K27me3 on lysed tumors to quantify loss of Ezh2 and H3K27me3. (f, g) Growth of control, cKO, and GSK503-treated 
RIM-1 allografts (f) and relative tumor volume of RIM-1, RIM-2, and RIM-3 allografts at endpoints (g). (i, j) 
Representative macroscopic pictures and growth of control, cKO, and GSK503-treated RIM-2 allografts. (l, m) 
Representative macroscopic pictures and growth of vehicle- and GSK503-treated RIM-3 allografts. Black arrows, time 
points of TM application / start of GSK503 treatment. RIM, Tyr::N-RasQ61K Ink4a-/- melanoma. Data are mean ± s.e.m. of n 
= 3 (Control), n = 4 (cKO, GSK503) (c - f), mean ± s.e.m. of n = 9 (Control, GSK503), n = 6 (cKO) (g), mean ± s.e.m. of n 
= 3 (j, m). P-values calculated with ANOVA and Fisher’s LSD-test. Scale bars, 1mm. 
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Figure 30 #  RIM allografts are of a melanoma origin. (a) RT-qPCR for melanocytic lineage genes on lysed heart tissue, 
RIM-1, RIM-2, and RIM-3 tumors. (b) Immunofluorescent staining on XB2, Melan-a, and RIM-1 cells for Sox10 and 
Tyrp1. BF, bright field. Data are mean ± s.e.m. of n = 3. P-values calculated with ANOVA and Fisher’s LSD-test. Scale 
bars, 25µm. 
 
4.2.8. EZH2 inactivation prevents metastatic spread of melanoma 
When depleting Ezh2 in my melanoma model before appearance of skin melanoma (Figure 31a, b), I 
observed that control mice, apart from skin tumors, frequently developed Sox10-positive melanoma 
metastases. However, conditional loss of Ezh2 almost fully prevented the generation of both lymph node 
and distant lung metastases, drastically increasing metastases-free survival (Figure  31c - e). Distant 
metastases likely arise from primary skin melanomas. Thus, a lack of metastases was expected, since 
early Ezh2 ablation also prevented emergence of skin tumors (Figure 22). In order to functionally 
analyze metastatic spread from skin tumors, I inactivated Ezh2 function in Tyr::N-RasQ61K Ink4a-/- mice 
already bearing skin tumors (Figure 32a - c). Strikingly, control animals consistently developed 
metastases, while Ezh2 cKO mice exhibited a significant reduction in melanoma-positive lymph nodes 
(Figure 32d) and a virtual absence of distant metastases in the lung (Figure 32e). Consequently, Ezh2 
cKO mice displayed a highly increased melanoma-specific survival compared to controls (Figure 32f). 
Likewise, GSK503-mediated Ezh2 inhibition counteracted formation of lymph node and lung metastases 
(Figure 32g, h). Importantly, temporary inhibition of Ezh2 prolonged melanoma-specific survival 
compared to vehicle-treated animals, resulting in doubling of the median survival time (Figure 32i). 
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Figure 31 #  Ezh2 ablation before onset of melanomagenesis prevents metastases formation. (a, b) Mouse genotypes 
and strategy used to analyze the effect of conditional Ezh2 ablation on metastases formation in Tyr::N-RasQ61K Ink4a-/- 
mice. (c, d) Metastases count at day of sacrifice in lymph nodes (c) and lung (d) of control and cKO animals using 
macroscopic pictures, H&E staining, and Sox10 staining on sections. Black arrowheads, lung metastases. (e) Kaplan-Meier 
curves comparing melanoma metastases-free survival after conditional Ezh2 ablation. Data are mean ± s.e.m. of n = 32 
(Control), n = 23 (cKO). P-values calculated with unpaired Student’s t-test (c, d), Log-rank (Mantel-Cox) test (e). Scale 
bars, 500µm (H&E in c, d), 100µm (immunofluorescence in c, d). 
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Figure 32 #  EZH2 function is required for metastatic progression of Tyr::N-RasQ61K Ink4a-/- cutaneous melanoma.  
(a - c) Mouse genotypes and strategies used to analyze the effect of conditional Ezh2 ablation and GSK503 treatment on 
metastatic spread of Tyr::N-RasQ61K Ink4a-/- skin melanoma. (d, e) Metastases count at day of sacrifice in lymph nodes (d) 
and lung (e) of control and cKO animals using macroscopic pictures, H&E staining, and Sox10 staining on sections. 
Macroscopic pictures and Sox10 staining performed as in (Figure 31). Black arrowheads, lung metastases. (f) Kaplan-
Meier curves comparing melanoma-specific survival after conditional Ezh2 ablation. (g, h) Metastases count at day of 
sacrifice in lymph nodes (g) and lung (h) of vehicle- and GSK503-treated animals using macroscopic pictures, H&E 
staining, and Sox10 staining on sections. Macroscopic pictures and Sox10 staining performed as in (Figure 31). Black 
arrowheads, lung metastases. (i) Kaplan-Meier curves comparing melanoma-specific survival during and after GSK503 
treatment. Data are mean ± s.e.m. of n = 15 (Control) n = 13 (cKO) (d, e), mean ± s.e.m. of n = 17 (Vehicle) n = 15 
(GSK503) (g, h). P-values calculated with unpaired Student’s t-test (d, e, g, h), Log-rank (Mantel-Cox) test (f, i). Scale 
bars, 500µm (d, e), 1mm (g, h). 
 
4.2.9. EZH2 propagates features favorable for melanoma metastasis 
Metastatic spread of a human primary melanoma is usually initialized by gain of invasive capacity, 
which allows a cell to evade from the primary tumor site (Gaggioli and Sahai, 2007; Tam and Weinberg, 
2013). Accordingly, both RNAi and drug-mediated inhibition of EZH2 significantly reduced the invasive 
capacity of human melanoma cell cultures in ECM-mimicking collagen layers referred to as Boyden 
chambers (Figure 33a). Next I used melanoma cell cultures derived from two distinct patients to perform 
a comparative global gene expression analysis of control versus EZH2-depleted cells (Figure 34). Cluster 
analysis of transcriptionally regulated genes indicated that reducing EZH2 levels affected expression of 
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genes involved, among others, in cytoskeleton remodeling, ECM remodeling, and EMT (Figure 33b). In 
support of these findings, I observed a gain of melanocyte markers and a loss of NCSC / EMT genes 
when depleting EZh2 in murine B16-F10 melanoma cells (Figure 33c). Finally, when inoculating B16-
F10 cells i.v. into C57Bl/6 mice, RNAi and importantly also GSK503 treatment drastically reduced lung 
nodule counts (Figure 33d, e). In summary, EZH2 is crucial throughout several steps of melanoma 
metastasis, such as EMT and homing to distant sites. Therefore, targeting Ezh2 in vivo efficiently 
prevented metastasis formation in the transgenic melanoma model, and pharmacological EZH2 
inhibition might represent a promising treatment strategy in preventing metastasis in patients. 
 
 
Figure 33 #  EZH2 is required for several features of metastatic progression. (a) Quantification of relative invasive 
capacity of M010817 and M050829 following EZH2 depletion with siE or EZH2 inhibition using GSK503. (b) -Log10 P-
values based on gene ontology analysis using gene signatures of M010817 and M050829 after EZH2 depletion with siE 
(Figure 34). (c) RT-qPCR for melanocyte differentiation genes and EMT genes on B16-F10 after Ezh2 depletion with shE. 
(d) Mouse genotypes and strategy used to i.v. engraft B16-F10 cells following Ezh2 silencing using shE to analyze the 
effect of Ezh2 depletion and GSK503 treatment on metastases formation. (e) Representative macroscopic pictures of lungs 
from vehicle and GSK503-treated (from day 1 on until endpoint) animals to quantify lung metastases after i.v. engraftment 
of shCo and shE B16-F10 cells. ECM, extra cellular matrix; EMT, epithelial to mesenchymal transition; i.v., intravenous. 
Data are mean ± s.e.m. of n = 4 (a), mean ± s.e.m. of n = 3 (c), mean ± s.e.m. of n = 4 (shCo), n = 5 (shE, GSK503) (e). P-
values calculated with unpaired Student’s t-test (a), ANOVA and Fisher’s LSD-test (c, e). 
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Figure 34 #  Gene expression array heat maps. Heat maps of differentially expressed genes in M010817 and M050829 
after EZH2 depletion with siE showing normalized expression values of 3 biological replicates. NCBI Gene Expression 
Omnibus archive accession code: GSE63165. 
 
4.2.10. EZH2 represses a set of genes connected to patient survival 
To further characterize the transcriptional programs controlled by EZH2 activity in melanoma, based on 
the gene expression arrays (Figure 34), I first defined genes significantly changed in both patient-derived 
cell cultures after EZH2 depletion (Figure 35a). Next, I performed TCGA-based unbiased analyses to 
determine the clinical relevance of these EZH2-regulated genes. I correlated expression levels of each of 
these genes with disease outcome in patients using RNAseq and clinical data from TCGA. Strikingly, for 
24% of all genes commonly upregulated upon EZH2 silencing, high expression levels in patients were 
associated with improved survival, while only 5.3% correlated with poor survival (Figure 35b; Table 3). 
Furthermore, for 19.6% of all genes commonly downregulated after EZH2 silencing, low expression 
levels in patients correlated with adverse survival (Figure 35c). Thus, EZH2 activity predominantly 
suppresses a transcriptional program beneficial for human patients and is associated with activation of a 
considerable fraction of genes linked to poor survival. 
The genes upregulated upon EZH2 silencing and associated with improved patient survival were, first, 
confirmed to be transcriptionally elevated after EZH2 depletion in human melanoma cell cultures. 
Indeed, mRNA of all 18 genes (24% in Figure 35b) was significantly increased after EZH2 depletion 
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(Figure 35d; Table 4). Second, ChIP assays for H3K27me3 were performed to determine whether these 
18 genes are direct targets of EZH2-mediated histone methylation. Intriguingly, 17 out of these 18 
analyzed genes exhibited promoter regions highly enriched for H3K27me3 in comparison to GAPDH 
promoter as negative control, indicating that these genes are targets of EZH2-dependent transcriptional 
repression (Figure 35e; Table 4). 
 
 
Figure 35 #  EZH2 target genes are linked to improved melanoma patient survival. (a) Gene expression signature of 
M010817 and M050829 after EZH2 depletion using siE. Average Log2 fold change values of 3 siE replicates compared to 
3 siCo replicates in (Figure 34) and significantly changed in both cell lines are shown. (b, c) Summary of TCGA-based 
unbiased analyses of genes upregulated (b; Table 3) or downregulated (c) in (a). For upregulated genes in (a), specimens 
with high RNAseq reads for the corresponding genes were compared to specimens with low RNAseq reads. For 
downregulated genes in (a), specimens with low RNAseq reads for the corresponding genes were compared to specimens 
with high RNAseq reads. (d) RT-qPCR for genes associated with improved survival in (b) on M010817 and M050829 after 
EZH2 depletion using siE (relative to GAPDH). (e) H3K27me3 ChIP and subsequent qPCR for promoters of genes 
associated with improved survival in (b) on untreated M010817 and M050829. Genes highlighted in bold were functionally 
analyzed. Data are mean ± s.e.m. of n = 3 (d), mean ± s.e.m. of n = 4 (e). P-values calculated with ANOVA and Fisher’s 
LSD-test. 
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Table 3 #  TCGA-based association of high gene expression in (Figure 35a) with melanoma patient survival. 
Gene Association with patient survival  Gene 
Association with 
patient survival 
 
TXNIP improved  MXRA7 NS  
WDTC1 NS  DIS3L NS  
ACO2 poor  NFIC NS  
DCK improved  APOBEC3D improved  
TMEM143 NS  AGPAT2 poor  
WDR34 poor  KREMEN1 NS  
CAMKK2 NS  SNAPC5 improved  
ZDHHC1 NS  GNG7 NS  
ZC3H6 improved  EIF2C4 NS  
XPOT improved  IL17RC NS  
MPC1 improved  MSRB2 NS  
CNN2 NS  FAM198B improved  
QPRT NS  SNAPC1 improved  
TCFL5 NS  TMEM129 NS  
LAMTOR1 NS  CDC42EP4 NS  
HIBADH NS  HDAC5 NS  
DDR2 NS  NNT NS  
HSBP1L1 NS  CD40 improved  
ECSIT NS  DNAJC4 NS  
MCAT NS  SAYSD1 NS  
DCAKD NS  STX8 improved  
CYP27A1 NS  SWAP70 NS  
CRYL1 NS  MUT improved  
XYLT2 NS  SCPEP1 improved  
TMEM161A NS  RETSAT poor  
REEP6 NS  PYROXD2 improved  
RBFOX2 NS  HDHD2 NS  
R3HDM2 NS  TGS1 NS  
KCTD18 improved  WBP1L NS  
BCAS3 NS  APOOL NS  
NFIA NS  MCOLN3 NS  
FAM210B NS  ANKRD44 NS  
ADAM10 NS  ST6GALNAC2 NS  
WDR19 improved  TMEM140 NS  
AMD1 improved  UBE3B NS  
STARD5 NS  GAS2L3 NS  
IER5 NS  RAB40B improved  
CTSF NS     
Genes highlighted in bold were functionally analyzed. improved, improved survival for specimens with high RNAseq reads for a 
specific gene compared to specimens with low RNAseq reads; poor, poor survival for specimens with high RNAseq reads for a 
specific gene compared to specimens with low RNAseq reads; NS, no significant difference between the high and the low group. 
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Table 4 #  P-values related to (Figure 35d, e). 
Figure 35d P-values  Figure 35e P-values 
Gene M010817 M050829  Gene M010817 M050829 
TXNIP < 0.0001 0.0047  TXNIP 0.0003 0.0030 
DCK 0.0009 0.0029  DCK 0.0051 0.0039 
AMD1 0.0080 0.0017  AMD1 0.0012 0.0045 
ZC3H6 0.0052 0.0329  ZC3H6 0.0189 0.0036 
XPOT 0.0041 0.0288  XPOT 0.0195 0.0022 
MPC1 0.0056 0.0177  MPC1 0.0018 0.0016 
APOBEC3D 0.0075 0.0125  APOBEC3D 0.0114 0.0012 
STX8 0.0065 0.0039  STX8 0.0088 0.0011 
KCTD18 0.0016 0.0002  KCTD18 0.0102 0.0080 
WDR19 0.0065 0.0001  WDR19 0.0078 0.0021 
PYROXD2 0.0012 0.0007  PYROXD2 0.0040 0.0064 
FAM198B 0.0272 0.0006  FAM198B 0.0238 0.0028 
CD40 0.0046 0.0007  CD40 0.0066 0.0002 
SNAPC5 0.0374 0.0539  SNAPC5 0.0025 0.0420 
SNAPC1 0.0162 0.0071  SNAPC1 0.0914 0.0068 
SCPEP1 0.0706 0.0058  SCPEP1 0.0083 0.0014 
MUT 0.0133 0.0033  MUT 0.0039 0.0156 
RAB40B 0.0008 0.0013  RAB40B 0.8299 0.9101 
Genes highlighted in bold were functionally analyzed. 
 
4.2.11. EZH2 target genes are functionally distinct suppressors of melanoma 
To relate these EZH2 target genes (ETG) functionally to aspects of melanomagenesis, I performed 
functional screens in human melanoma cell cultures. I focused on a potential rescue of, first, EZH2 
depletion-induced G1 cell cycle arrest and, second, EZH2 depletion-induced loss of invasive capacity. 
Among the tested ETGs, deoxycytidine kinase (DCK), adenosyl-methionine decarboxylase 1 (AMD1), 
and WD repeat domain 19 (WDR19) displayed promising features. I first established efficient RNAi-
mediated silencing of these ETGs (Figure 36a). ETG silencing did not affect the efficiency of EZH2 
knockdown achieved by siEZH2 (Figure 36b). However, EZH2 silencing-dependent upregulation of 
DCK, AMD1, or WDR19 was strongly counteracted with the double RNAi approach (Figure 36c). 
Interestingly, when simultaneously depleting EZH2 and DCK or WDR19, the G1 cell cycle arrest 
induced by EZH2 silencing was significantly reverted (Figure 36d - f). Depletion of AMD1, however, 
was not sufficient to induce such a rescue (Figure 36d). In contrary, simultaneous depletion of EZH2 and 
AMD1 efficiently led to a regain of the invasive capacity that was lost upon silencing of EZH2 alone 
(Figure 36g - i). DCK and WDR19 silencing, however, had no effect on invasion of human melanoma 
cells (Figure 36g). 
 
 4—96 
 
Figure 36 #  Depletion of EZH2 target genes rescues EZH2 inactivation phenotypes. (a) RT-qPCR for selected ETGs 
on M010817 after DCK, AMD1, or WDR19 depletion with siRNAs targeting these genes. Black arrows, siRNAs chosen for 
further experiments. (b) RT-qPCR for EZH2 on M010817 after EZH2 and DCK / AMD1 / WDR19 depletion with siE and 
siDCK / siAMD1 / siWDR19. (c) RT-qPCR for selected ETGs on M010817 after EZH2 and DCK / AMD1 / WDR19 
depletion. (d) Quantification of G1 / (S + G2M) ratio of M010817 after EZH2 and DCK / AMD1 / WDR19 depletion. (e) 
Quantification of G1 / (S + G2M) ratio of M010817, M050829, and M990514 after depletion of EZH2 and DCK / WDR19. 
(f) Cell cycle profiles of M010817 using PI, representative of quantifications in (e). (g) Quantification of relative invasive 
capacity of M050829 after EZH2 and DCK / AMD1 / WDR19 depletion. (h) Quantification of relative invasive capacity of 
M010817, M050829, and M990514 after depletion of EZH2 and AMD1. (i) Immunofluorescence fields of transvaded 
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M990514 cells after a Boyden chamber assay using Hoechst 33342, representative of quantifications in (h). White, DNA. 
ETG, EZH2 target gene. Data are mean ± s.e.m. of n = 3. P-values calculated with unpaired Student’s t-test (b), ANOVA 
and Fisher’s LSD-test (c - e, g, h). Scale bars, 1mm. 
 
I then reconfirmed these genes as direct ETGs through a ChIP assay on control and EZH2-depleted cells. 
Indeed, upon RNAi targeting EZH2, H3K27me3 mark was significantly reduced in promoter regions of 
DCK, AMD1, and WDR19 loci (Figure 37a).  Importantly, in both B16-F10 isografts and RIM-1 
allografts (Figure 28b; Figure 29b) Dck, Amd1, and Wdr19 were consistently upregulated upon Ezh2 
inactivation through either cKO (or RNAi) or GSK503 treatment (Figure 37b, c), identifying these ETGs 
as likely tumor suppressors in vivo. Thus, throughout melanomagenesis EZH2 might dynamically repress 
diverse tumor suppressor genes in order to achieve either favorable growth or invasion kinetics. 
 
 
Figure 37 #  ETGs are de-repressed in vivo upon Ezh2 inactivation. (a) H3K27me3 ChIP and subsequent qPCR for 
gene promoters of selected ETGs on M010817 and M050829 after EZH2 depletion using siE. (b) RT-qPCR for selected 
ETGs on lysed shCo, shE, and GSK503-treated B16-F10 tumors from (Figure 28b). (c) RT-qPCR for selected ETGs on 
lysed control, cKO, and GSK503-treated RIM-1 tumors from (Figure 29b). Data are mean ± s.e.m. of n = 3 (a, c), mean ± 
s.e.m. of n = 3 (shCo), n = 4 (shE, GSK503) (b). P-values calculated with ANOVA and Fisher’s LSD-test. 
 
4.2.12. AMD1 suppresses EMT and metastatic spread of melanoma 
Interestingly, silencing of AMD1 in human melanoma cultures induced an increase in invasion on its 
own (Figure 36g - i). Therefore, I further focused on the relevance of this tumor suppressor in preventing 
melanoma EMT and metastasis. Based on TCGA, patients with low AMD1 mRNA expression displayed 
a significantly shorter overall survival as compared to those with high AMD1 expression (Figure 38a). 
Further, stage I – III patients of the AMD1 low group showed a considerably reduced distant metastases-
free survival (Figure 38b). Comparably, low AMD1 expression correlated with more advanced vertical 
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invasion of primary melanomas (Figure 38c). Finally, depletion of AMD1 in human melanoma cells 
induced expression of NCSC- / EMT-relevant genes including SNAI1, TWIST1, and ZEB1 (Figure 38d). 
Similarly, when silencing Amd1 in B16-F1 (Figure 38e), a murine melanoma cell line with negligible 
metastatic potential, a comparable EMT gene set was upregulated (Figure 38f). Therefore, in order to 
functionally link loss of Amd1 to metastasis, I first i.v. transplanted Amd1-silenced B16-F1 cells into 
C57Bl/6 mice (Figure 39a).  
 
 
Figure 38 #  The ETG AMD1 is a tumor suppressor that circumvents EMT. (a) Kaplan-Meier curves comparing 
overall survival of melanoma specimens (stage I – IV) with respect to AMD1 transcript levels based on TCGA. (b) Kaplan-
Meier curves comparing distant metastases-free survival of stage I – III melanoma specimens (primary melanoma / lymph 
node metastases) with respect to AMD1 transcript levels based on TCGA. (c) Breslow depths of melanoma specimens’ 
primary melanomas with respect to AMD1 transcript levels based on TCGA. (d) RT-qPCR for EMT genes on M990514 
after AMD1 depletion with siAMD1. (e, f) RT-qPCR for Amd1 (e) and EMT genes (f) on B16-F1 after Amd1 depletion with 
shAmd1. (g) RT-qPCR for Amd1 on B16-F10 after Amd1 depletion with shAmd1. AMD1 low / high, bottom and top 60 
patients with respect to AMD1 transcript levels. Data are median ± 100% range of n = 48 (AMD1 high), n = 43 (AMD1 
low) (c), mean ± s.e.m. of n = 3 (d - g). P-values calculated with Log-rank (Mantel-Cox) test (a, b), unpaired Student’s t-
test (c), ANOVA and Fisher’s LSD-test (d - g). 
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Strikingly, loss of Amd1 strongly induced nodule formation in the lung (Figure 39b). Next, I depleted 
Amd1 in highly metastatic B16-F10 cells (Figure 38g). Comparable to B16-F1, Amd1 silencing further 
enhanced the metastatic potential of B16-F10 cells. Most importantly, when inhibiting lung nodule 
formation through Ezh2 inactivation by GSK503 treatment, depletion of Amd1 was sufficient to 
significantly re-induce metastasis (Figure 39a, c). Thus, during melanomagenesis EZH2 epigenetically 
represses the tumor suppressor AMD1 allowing metastatic spread, while EZH2-targeted therapy 
successfully counteracts disease progression. 
 
 
Figure 39 #  Amd1 suppression promotes in vivo melanoma metastasis. (a) Mouse genotypes and strategies used to i.v. 
engraft B16-F1 or B16-F10 cells following Amd1 silencing with shAmd1 to analyze the effect of Amd1 depletion and 
GSK503 treatment on metastases formation. (b) Representative macroscopic pictures of lungs from C57Bl/6 animals after 
i.v. engraftment of shCo and shAmd1 B16-F1 cells to quantify lung metastases. (c) Representative macroscopic pictures of 
lungs from vehicle- and GSK503-treated (from day 1 on until endpoint) animals to quantify lung metastases after i.v. 
engraftment of shCo and shAmd1 B16-F10 cells. shA, shAmd1. Data are mean ± s.e.m. of n = 4 (b, c), n = 3 (shCo, 
GSK503 in c). P-values calculated with ANOVA and Fisher’s LSD-test. 
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4.3. Roles of EZH2 in melanoma immunoediting 
4.3.1. EZH2 mediates immunomodulation 
Besides ETGs interfering with melanoma growth or metastasis, CD40 caught my attention. Notably, in 
contrast to DCK, AMD1, and WDR19, ablation of CD40 in EZH2-silenced human melanoma cell 
cultures was neither sufficient to revert the observed growth arrest nor capable of stimulating invasion 
(data not shown). Nevertheless, CD40 was the ETG with the highest enrichment for H3K27 promoter 
methylation and the strongest upregulation upon EZH2 silencing  (Figure 35d, e). CD40 is a positive 
immune checkpoint regulator that is expressed on tumor cells and stimulates CTLs through binding to 
CD40 ligand (Pardoll, 2012). Thus, EZH2-dependent CD40 repression might possibly be involved in 
attenuating CTL-mediated anti-melanoma responses. To test this hypothesis, I first analyzed Cd40 
expression in control and Ezh2-inactivated B16-F10 melanoma samples. Importantly, B16-F10 
melanoma was grown in syngeneic, fully immunocompetent C57Bl/6 mice (Figure 28a, b). Intriguingly, 
Cd40 as much as a set of further positive immune checkpoint regulators (Cd70, Cd80, Cd86, Fas, Ox40l) 
were upregulated upon Ezh2 depletion or GSK503-mediated Ezh2 inhibition in comparison to control 
samples. In contrast, expression of both the immunosuppressant Tgfb1 and Pd-L1, the ligand of the 
negative immune checkpoint regulator Pd-1 (Pardoll, 2012), was decreased upon Ezh2 inactivation 
(Figure 40a).  
 
 
Figure 40 #  Ezh2 inactivation promotes upregulation of immune stimulators in B16-F10 melanoma. (a, b) RT-qPCR 
for selected immune modulators (a) and members of the antigen-processing machinery (b) on lysed shCo, shE, and 
GSK503-treated B16-F10 tumors from (Figure 28b). Data are mean ± s.e.m. of n = 3 (shCo), n = 4 (shE, GSK503). P-
values calculated with ANOVA and Fisher’s LSD-test. 
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Furthermore, loss of PRC2 activity not only shifted the immune checkpoint balance towards CTL 
activation, but also promoted induction of the antigen-processing machinery including antigen-
presenting MHC-I subunits (H2-D1, H2-K1), transporters associated with antigen-shuttling into the 
endoplasmatic reticulum (Tap1, Tap2), and antigen-generating proteasome subunits (Psmb8, Psmb9) 
(Figure 40b). Importantly, based on TCGA, high expression of these immune sensitizers correlated with 
prolonged melanoma patient survival (Table 5). Thus, EZH2 likely mediates immune evasion and 
resistance through epigenetic silencing of immunostimulatory genes ultimately resulting in melanoma 
progression. 
 
Table 5 #  TCGA-based association of high expression of immunogenic genes with melanoma patient survival. 
Gene Association with patient survival  Gene 
Association with 
patient survival 
 
HLA-A improved  CD40 improved  
HLA-B improved  CD70 improved  
HLA-C improved  CD80 improved  
TAP1 improved  CD86 improved  
TAP2 NS  FAS improved  
PSMB8 improved  OX40L improved  
PSMB9 improved     
HLA-A/B/C, loci encoding human MHC-I subunits; improved, improved survival for specimens with high RNAseq reads for a 
specific gene compared to specimens with low RNAseq reads; NS, no significant difference between the high and the low group. 
 
4.3.2. EZH2 inactivation promotes immune sensitivity and synergizes with immunotherapy 
To strengthen these findings, I in vivo-stimulated CTLs in Tyr::N-RasQ61K Ink4a-/- mice by continuous 
treatment with IL2-Cx (Figure 41a, b). Activation of CTLs substantially prolonged skin melanoma-free 
survival (Figure 41c, d). Comparably, IL2-Cx as well as α-CTLA4 checkpoint blockade treatment 
interfered with B16-F10 melanoma growth (Figure 41e - i). Analysis of peripheral blood samples 
confirmed that IL2-Cx treatment promoted T-cell proliferation resulting in a highly increased number of 
CTLs and especially memory T-cells (Figure 42 a, b). Furthermore, IL2-Cx treatment stimulated tumor 
infiltration of CTL clones targeting well-established melanoma antigens, such as Dct and Pmel, while 
these clones were not enriched in tumor-draining lymph nodes (Figure 42c). Thus, CTL activation 
generated a pool of functional anti-melanoma T-lymphocytes. 
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Figure 41 # Ezh2 inactivation and immunotherapy synergistically abolish melanoma growth. (a, b) Mouse genotypes 
and strategy used to analyze the effect of prolonged IL2-Cx treatment on melanoma development in Tyr::N-RasQ61K Ink4a-/- 
mice. (c) Representative pictures of vehicle- and IL2-Cx-treated Tyr::N-RasQ61K Ink4a-/- mice 4 weeks post treatment start. 
(d) Kaplan-Meier curves comparing skin melanoma-free survival (skin melanoma = lesion Ø ≥ 2mm) of vehicle- and IL2-
Cx-treated mice. (e, f) Mouse genotypes and strategy used to s.c. engraft B16-F10 cells following Ezh2 silencing with shE 
to analyze the effect of Ezh2 depletion and GSK503 treatment in combination with IL2-Cx / α-CTLA4 application on 
melanoma growth. (g - i) Growth of shCo, shE, and GSK503-treated and IL2-Cx / α-CTLA4 co-treated B16-F10 isografts. 
α-CTLA4, anti-CTL antigen 4 antibody; IL2-Cx, Complexes of IL2 and α-IL2 antibodies. Data are mean ± s.e.m. of n = 5 
(g - i), n = 6 (Vehicle in i), n = 7 (GSK503 in i). P-values calculated with Log-rank (Mantel-Cox) test (d), ANOVA and 
Fisher’s LSD-test (g - i). 
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Figure 42 # Ezh2 inactivation and immunotherapy co-promotes CTL tumor infiltration. (a, b) Quantifications of 
proliferative T-cells (a) and composition of T-cell phenotypes (b) using BrdU labeling and FACS analysis on peripheral 
blood samples from tumor-growing mice in (Figure 41h). (c) Quantifications of Dct and Pmel antigen-specific T-cells 
using FACS analysis on tumor samples and tumor-draining lymph nodes from (Figure 41g). LN, lymph node. Data are 
mean ± s.e.m. of n = 4 (a, b), median ± 100% range of n = 5 (c). P-values calculated with ANOVA and Fisher’s LSD-test. 
 
Simultaneously, CTL stimulation promoted downregulation of melanoma antigens, members of the 
antigen-processing machinery, and positive immune checkpoint regulators in the tumor samples (Figure 
43). This partly explained the surprisingly inefficient anti-tumor responses in Tyr::N-RasQ61K Ink4a-/- and 
B16-F10-bearing mice (Figure 41). However, adaptive immune evasion and resistance was substantially 
counteracted by Ezh2 silencing, which reinforced expression of immunogenic genes (Figure 43). This led 
to a further increase in tumor-infiltrating, melanoma antigen-specific CTLs (Figure 42c). Accordingly, 
only CTL activation and concomitant ablation of Ezh2 function through either RNAi or GSK503 
completely abolished tumor growth (Figure 41e - i). Taken together, in the melanoma compartment, 
ablation of PRC2 function de-repressed a set of immunogenic genes, which re-exposed the tumor to 
CTLs, was favorable for a potent interaction with CTLs, and circumvented immune resistance. Hence, in 
melanoma patients, EZH2-targeted therapy might functionally synergize with CTL stimulating-
immunotherapy potentially resulting in a highly efficient anti-tumor response. 
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Figure 43 # Ezh2 inactivation counteracts adaptive immune evasion and resistance. (a - c) RT-qPCR for melanoma 
antigens (a), members of the antigen-processing machinery (b), and selected immune modulators (c) on lysed shCo, shE, 
and IL2-Cx co-treated B16-F10 tumors from (Figure 41g). Data are median ± 100% range of n = 6. P-values calculated 
with ANOVA and Fisher’s LSD-test. 
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5. Discussion 
 
In my PhD thesis, I demonstrate EZH2 to be a key player in promoting malignant melanoma progression 
in a genetic mouse model of cutaneous melanoma. Importantly, conditional deletion of Ezh2 did not 
interfere with normal melanocyte function and benign dermal hyperplasia, underlining the particular 
roles of Ezh2 in melanoma growth and progression to metastatic disease. Supporting these data, 
temporary pharmacological inhibition of Ezh2 counteracted growth and metastasis in vivo, and blocking 
EZH2 activity in human melanoma cells affected their growth as well as invasive capacity. In line with 
these findings, human melanoma patients showed particularly poor survival when EZH2 transcript levels 
were high or when a newly identified set of ETGs was low-expressed. Furthermore, these ETGs 
displayed tumor-suppressive functions affecting either melanoma growth or metastatic spread, while a 
third group of ETGs efficiently mediated immune sensitivity. Hence, EZH2 activity exhibits functionally 
distinct roles in driving malignant melanoma progression that appear to be highly relevant for human 
patients (Figure 44). 
 
5.1. EZH2 function in melanoma partly resembles its role in NC development 
In many tissues as much as in corresponding malignancies a central function of EZH2 is to sustain stem 
cell identity and proliferation by transcriptional repression of senescence and differentiation genes (3.1.4. 
Histone methyltransferases). In contrast, in murine embryonic NCSCs, Ezh2 regulates neither stem cell 
maintenance nor differentiation of the trunk NC. However, Ezh2 is required for mesenchymal fate 
acquisition of the cranial NC (Schwarz et al., 2014). Comparably, in ovo, Ezh2 forms a complex with 
Snai2 to repress Cdh1, which promotes EMT and NC delamination (Tien et al., 2015). In melanoma, the 
role of EZH2 function appears to be analogous, at least in part, to its function during embryonic cranial 
NC development. In line with previous reports (3.5.3.3. EZH2 and melanomagenesis), EZH2 
inactivation in human melanoma cell cultures reduced invasive capacity (Figure 33a). Furthermore, in 
B16-F10, Cdh1 and melanocyte differentiation genes including Mitf were induced upon Ezh2 silencing. 
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Figure 44 #  Graphical summaries of distinct roles of EZH2 during melanomagenesis. During melanoma growth and 
metastasis, EZH2 mediates repression of functionally distinct tumor suppressors through H3K27me3 in the promoter 
regions of these genes. The tumor suppressors are either involved in attenuating tumor growth (a) or EMT and metastasis 
(b). A third group of tumor suppressors is involved in stimulating CTLs, which in turn release perforin and granzymes 
triggering tumor cell apoptosis (c). Therefore, EZH2 represents a central node that propagates diverse aspects of 
melanomagenesis. Importantly, these processes can be targeted effectively through GSK503-mediated EZH2 inhibition, 
potentially in combination with immunotherapy. 
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Simultaneously, this promoted a reduction in EMT transcription factor expression, among which was 
Snai1, Twist1, and Zeb1 (Figure 33c). Thus, EZH2 sustains EMT resulting in melanoma cell motility, 
which is reminiscent of embryonic NC delamination. The process of melanoma metastasis is thought to 
be triggered by acquisition of mesenchymal features (Gaggioli and Sahai, 2007; Tam and Weinberg, 
2013). Indeed, when inactivating Ezh2 in melanoma-bearing Tyr::N-RasQ61K Ink4a-/- mice, distant 
metastases formation was drastically impaired (Figure 32). 
However, apart from driving metastatic spread, Ezh2 has further roles during melanomagenesis that do 
not resemble its function in embryonic NC. When deleting Ezh2 in benign hyperplasia of Tyr::N-RasQ61K 
Ink4a-/- mice, emergence of cutaneous tumors was almost completely prevented (Figure 22). Likewise, 
Ezh2 function was required for Tyr::N-RasQ61K Ink4a-/- melanoma growth (Figure 29). In carcinomas of 
breast and prostate, EZH2 similarly propagates tumor initiation and growth, and at later stages, EZH2 
activity is necessary for EMT and metastasis (3.1.4.4. EZH2 function in solid cancers). Thus, the abilities 
of EZH2 to drive functionally distinct aspects of tumorigenesis seem to be a common trait among 
different cancers entities. Likely, this is achieved through dynamic repression of specific sets of genes 
with either growth- or EMT-suppressive attributes. Indeed, in human melanoma cells, EZH2 regulated 
functionally distinct target genes, which will be discussed below (5.5. EZH2 target genes and their 
melanoma-suppressive functions). 
 
5.2. Significance of Ezh2 activity for melanocytes and malignant melanoma 
In Tyr::N-RasQ61K Ink4a-/- mice, melanoma is initiated and grows spontaneously in an undisturbed 
environment without prior ex vivo manipulation of tumor cells. Thus, an inducible and conditional 
knockout strategy in these mice allowed studying functional implications of Ezh2 for different stages of 
melanomagenesis in an intact environment. A few previous in vivo studies have also taken advantage of 
the cKO technique in genetic mouse models of melanoma, although most reports on gene function in 
melanoma are based on cell culture and xenotransplantation assays. However, up to date, genes shown to 
be involved in melanoma formation turned out to be also important for normal melanocytes and benign 
hyperplasia cells. For instance, Sox10 haploinsufficiency affects embryonic melanoblast development 
and similarly counteracts hyperplasia and melanoma formation in Tyr::N-RasQ61K Ink4a-/- mice, while 
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Sox10 cKO completely abrogates the melanocytic lineage (Harris et al., 2013; Shakhova et al., 2012; 
2015). Likewise, Wnt and Tgfβ signaling are required for MSC homeostasis, while both Ctnnb1 and 
Smad4 ablation interferes with melanomagenesis in transgenic mouse models (Damsky et al., 2011; 
Delmas et al., 2007; Gallagher et al., 2013; Nishimura et al., 2010; Rabbani et al., 2011; Zingg and 
Tuncer, in preparation). 
I found Ezh2 function to be relevant for malignant tumor growth at initial stages of melanoma formation, 
while a striking effect of Ezh2 inactivation was on metastatic spread of melanoma. However, in great 
contrast to the above-mentioned studies, Ezh2 was required neither for normal melanocyte function nor 
maintenance of benign hyperplasia (Figure 19; 20; 21). This suggests that in melanoma, Ezh2 plays a 
unique tumor-specific role, in accordance with the strong upregulation of its expression during malignant 
melanoma progression (Figure 16; Table 2). Thus, unlike in many other cancers and their respective 
tissues of origin (3.1.4. Histone methyltransferases), EZH2 function appears to be of no relevance for the 
cells from which melanoma arises. In HSCs, Ezh2 and its homolog Ezh1 have partially redundant 
functions. Likewise, in basal skin progenitors, only simultaneous depletion of Ezh1 and Ezh2 severely 
compromises skin homeostasis (3.1.4.2. Ezh2 function in development and tissue homeostasis). 
Therefore, Ezh1 might functionally compensate loss of Ezh2 in the melanocytic lineage. However, when 
inactivating Ezh2 during melanomagenesis, Ezh1 is apparently incapable of compensating the 
tumorigenic function of Ezh2 in a sufficient manner. 
During lymphomagenesis, both EZH2WT and EZH2Y646* act as oncogenes and drive neoplastic 
transformation of germinal center B-cells (3.1.4.3. EZH2 function in hematopoietic malignancies). Based 
on TCGA and 2 further datasets (Hodis et al., 2012; McCabe et al., 2012a), cutaneous melanoma was 
defined as the only solid cancer with recurrent EZH2Y646* gain-of-function mutations (Figure 18b). 
EZH2Y646N enhances in vitro proliferation and motility of a human melanoma cell line (Barsotti et al., 
2015). Therefore, it will be of high interest to investigate whether EZH2WT and especially EZH2Y646* 
operate as de novo oncogenic drivers of metastasizing melanoma in vivo. To do so, we plan to cross 
Tyr::N-RasQ61K or B-RafV600E-inducible mice with Ezh2Y646N-inducible animals (Béguelin et al., 2013). 
Mice solely expressing N-RasQ61K or B-RafV600E rarely develop malignant melanoma (3.3.4. Molecular 
pathogenesis: oncogenic drivers of cutaneous melanoma). Thus, a gain in cutaneous melanoma and 
metastasis events upon Ezh2Y646N overexpression would confirm Ezh2Y646N to be a melanoma-driving 
oncogene in vivo.  
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5.3. Possible transcriptional effectors of EZH2 
During malignant melanoma progression, EZH2 expression is highly increased (Figure 16; Table 2). 
However, so far no transcriptional effectors of EZH2 have been described that might accurately explain 
this upregulation upon melanoma malignancy. In breast carcinoma, CRAF amplifications sustain 
oncogenic MAPK signaling, which induces EZH2 transcription (Chang et al., 2011; Fujii et al., 2011). 
Likewise, in cancers of the prostate and the pancreas, KRASG12D/V mutations are recurrent and promote 
MAPK signaling, which enhances EZH2 expression (Cai et al., 2012; Fujii et al., 2012). Furthermore, 
EZH2 epigenetically represses disabled homolog 2-interacting protein (DAB2IP), which is a suppressor 
of RAS (Min et al., 2010). Thus, EZH2 promotes MAPK signaling, which in turn further enhances EZH2 
transcription. In the vast majority of cutaneous melanomas, MAPK pathway is activated (3.3.4. 
Molecular pathogenesis: oncogenic drivers of cutaneous melanoma). In analogy to MAPK-driven 
carcinomas, MAPK signaling might, therefore, also trigger EZH2 upregulation in melanoma. However, 
human nevi never displayed high levels of EZH2 expression, despite the presence of either BRAFV600E or 
NRASQ61K in these tissues. Likewise, N-RasQ61K promotes dermal hyperplasia in mice. In spite of 
activated MAPK signaling, Ezh2 was marginally expressed in hyperplasia and only upregulated upon 
tumorigenesis (Figure 16; Table 2). Furthermore, MEK inhibition does not reduce EZH2 levels in human 
melanoma cell cultures (Zingg and Schaefer, unpublished data). Thus, in melanoma, MAPK signaling 
unlikely acts as a transcriptional enhancer of EZH2. 
Several transcription factors independent of MAPK pathway have been indicative of increasing EZH2 
expression. For instance, NF-κB induces EZH2 transcription in lymphocytes and similarly enhances 
EZH2 in multiple myeloma and leukemia cells (Neo et al., 2014a). In prostate cancer cells, both ETS and 
MYC transcription factors activate EZH2 expression (Koh et al., 2011; Kunderfranco et al., 2010), while 
FOXM1 maintains glioblastoma stem cells through transcriptional upregulation of EZH2 (Kim et al., 
2015). In breast carcinoma, TGFβ signaling induces SOX4, which activates EZH2 transcription and 
promotes EMT (Tiwari et al., 2013). Comparably, TGFβ signaling sustains EED expression in lung 
cancer cells. This results in aberrant PRC2 activity-mediated EMT (Oktyabri et al., 2014). In Tyr::N-
RasQ61K Ink4a-/- mice, enhanced Smad2/3 activity promotes metastatic spread of cutaneous melanoma 
(Zingg and Tuncer, in preparation), while Ezh2 ablation prevented metastasis (Figure 31; 32). Therefore, 
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in resemblance of carcinomas, activated SMAD complexes might drive EZH2 overexpression in 
melanoma, thus promoting EMT and metastasis. 
Apart from transcriptional activators, loss of transcriptional repressors conceivably induces EZH2. 
Indeed, miR-31, miR-101, miR-124, and miR-137 have been shown to suppress EZH2 in several 
melanoma cell lines (Asangani et al., 2012; Chen et al., 2013; Luo et al., 2012a; 2013). It remains to be 
deciphered, whether a decrease in miRs is causative for EZH2 upregulation during melanoma formation 
in vivo. Besides transcriptional regulation, post-translational modifications alter EZH2 activity during 
tumorigenesis (Yamaguchi and Hung, 2014). For instance, AKT phosphorylates EZH2 at serine 21 
resulting in aberrant EZH2 activity in prostate cancer and glioblastoma (Kim et al. 2013; Xu et al., 
2012). A considerable number of melanomas harbor activated PI3K signaling, especially in response to 
MAPK-targeted therapy (3.3.5.2. PTEN as tumor suppressor; 3.4.3.1. PI3K signaling-dependent 
resistance). In these melanomas, activated AKT might likewise phosphorylate EZH2. Hence, PI3K 
signaling possibly propagates melanoma progression and adaptive MAPK resistance through phospho-
EZH2-mediated epigenetic rewiring. 
 
5.4. Drivers of EZH2 target gene specificity 
In melanoma samples, I found high EZH2 expression to correlate with KI67-positive, proliferative cells 
(Figure 25), while others have described connections between increased EZH2 levels and the invasive 
front of human melanomas or motile cells in B16-F10 tumors, respectively (Kampilafkos et al., 2015; 
Manning et al., 2014). Thus, EZH2 might dynamically regulate target genes that suppress either 
proliferation or motility of melanoma cells. Indeed, I identified ETGs with distinct functions favorable 
for either growth inhibition or cell immotility (Figure 36). This raises the question of how PRC2 is 
recruited to such defined loci in the course of melanomagenesis. In Drosophila, polycomb response 
elements (PRE), short cis-regulatory DNA sequences in gene promoters, recruit PRC2 to specific loci, 
thus initiating and mediating gene repression. In contrast, the very existence of PRE-like elements also in 
mammals remains controversial (Ringrose and Paro, 2007; Simon and Kingston, 2009). In fact, in 
murine ESCs, absence of the transcriptional machinery recruits PRC2 to maintain transcriptional 
repression rather than gene silencing would be initiated by PRC2 through recognition of in cis DNA 
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motifs (Riising et al., 2014). Notably, during tumorigenesis, aberrant PRC2 function might still enforce 
gene repression. 
Independent of the mode of PRC2-dependent gene repression, transcription factors have been reported to 
guide PRC2 in trans to specific loci. For instance, a considerable number of loci, which are H3K27me3-
repressed during murine ESC differentiation towards neural progenitors, share a Snai1 binding motif in 
their promoter region. In addition, Snai1 has been shown to mediate, through PRC2 recruitment, the 
repression of these genes, among which is Cdh1 (Arnold et al., 2013). Interestingly, in nasopharyngeal 
carcinoma and pancreatic cancer, PRC2 similarly forms a complex with SNAI1 to repress CDH1, thus 
promoting EMT (Herranz et al., 2008; Tong et al., 2012). Likewise, in ovo, Snai2 recruits Ezh2 to the 
Cdh1 promoter, and Cdh1 silencing enables NC delamination (Tien et al., 2015). Comparably, TWIST1 
is able to recruit PRC2 to the CDKN2A locus in human mesenchymal stem cells, thus propagating self-
renewal and mesenchymal identity (Cakouros et al., 2012). Notably, PRC2 silences CDKN2A in several 
cancers (Popov and Gil, 2010), while TWIST1 regulates metastatic progression of basal cell carcinoma 
and melanoma (Beck et al., 2015; Caramel et al., 2013; Weiss et al., 2012). In murine B16-F10 
melanoma cells, ablation of Ezh2 induced Cdh1 and melanocyte differentiation genes, accompanied by a 
reduction in Snai1 and Twist1 expression (Figure 33c). It remains to be deciphered, whether TWIST1 
and SNAI1 propagate melanoma EMT and metastasis in cooperation with PRC2-mediated gene 
repression. 
In murine ESCs, the pluripotency factor Sox2 binds to a large number of gene promoters that are 
enriched in H3K27me3 (Boyer et al., 2006; Lee et al., 2006). Therefore, Sox2 might recruit PRC2 in a 
comparable fashion as Snai1. Interestingly, SOX2 is re-expressed in a fraction of melanomas (3.3.7.2. 
Melanoma stem cell markers beyond CD271), while SOX2 deletion in melanoma cell cultures induces 
CDH1 and melanocyte differentiation genes. Remarkably, SOX2 ablation also promotes a global 
H3K27me3 reduction, albeit EZH2 expression remains intact (Zingg and Schaefer, unpublished data). 
Therefore, SOX2 likely mediates repression of CDH1 and melanocyte differentiation genes through 
PRC2 recruitment, which may result in tumor stemness and metastasis. 
Besides transcription factor-based PRC2 recruitment, putative histone modification readers might guide 
PRC2 to specific loci. Previously, H2A-K119ub was thought to be established by PRC1 in a subsequent 
manner to H3K27me3 (Bracken and Helin, 2009) (Figure 3). However, recent studies in murine ESCs 
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have challenged this model and propose that H2A-K119ub is placed by PRC1 prior to PRC2 activity. 
PRC2 is then recruited to H2A-K119ub through a so far unidentified reader subunit to maintain gene 
repression by H3K27me3 (Blackledge et al., 2014; Cooper et al., 2014; Kalb et al., 2014). In a 
conceptually similar way, in murine ESCs, Jarid2 can recruit PRC2 to target loci, possibly through 
binding to yet unknown DNA motifs or nucleosome components (Pasini et al., 2010; Peng et al., 2009; 
Son et al., 2013). This cascade might include methylation of Jarid2 by Ezh2 as much as long non-coding 
RNAs (lncRNA) functioning as scaffolds between Jarid2, PRC2, and chromatin (Kaneko et al., 2014; 
Sanulli et al., 2015). Conceivably, Jarid2 is relevant for adult tissue stem cell homeostasis (Kinkel et al., 
2015; Mejetta et al., 2011), whereas JARID2 incorporates TGFβ signaling resulting in an EMT of 
several carcinoma cell lines (Tange et al., 2014). These findings emphasize the significance of 
unraveling the precise recruitment paths encircling PRC2, which might help uncovering how PRC2 
perturbations contribute to tumorigenesis. 
 
5.5. EZH2 target genes and their melanoma-suppressive functions 
Since EZH2 acts as a transcriptional repressor (3.1.4. Histone methyltransferases), genes upregulated 
upon EZH2 silencing are likely candidates for being direct targets of EZH2-mediated H3K27me3. In 
agreement with this, promoters of genes selected based on my TCGA analyses were indeed confirmed to 
be enriched in H3K27me3 (Figure 35e), while EZH2 ablation led to a loss of H3K27me3 at these 
promoters (Figure 37a). This defined a number of direct ETGs, while functional characterizations of 
these ETGs allowed assignment of growth-suppressive, metastasis-suppressive, or immunostimulatory 
features (Figures 36 - 40). 
 
5.5.1. EZH2 target gene DCK 
For instance, following EZH2 ablation, silencing of the ETG DCK was sufficient to significantly re-
induce melanoma cell proliferation (Figure 36). Thus, epigenetic repression of DCK might sustain 
cutaneous melanoma growth. DCK is required for the phosphorylation of several deoxyribonucleosides 
and their nucleoside analogs (Spasokoukotskaja et al., 1995). In several cancers, DCK expression is 
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reduced, which confers resistance to DNA-demethylating agents, such as azacitidine and decitabine (Qin 
et al., 2009; Saiki et al., 2012). Likewise, inactivation of Dck enhances resistance to these cytidine 
analogues in a rat model of AML (Stegmann et al., 1995). Importantly, the melanoma cell cultures used 
to define ETGs were never exposed to cytidine analogues. Therefore, loss of DCK function appears to 
have biological relevance for melanoma cell proliferation independent from any cytidine analog 
resistance mechanism. Interestingly, efficiency of nucleoside transporters is attenuated in pancreatic 
adenocarcinoma, while overexpression of these transporters counteracts tumor growth (Pérez-Torras et 
al., 2013). In line with these data, enhanced degradation of pyrimidine deoxynucleosides promotes EMT 
and metastasis in breast cancer (Shaul et al., 2014). Thus, dynamic influx, turnover, and phosphorylation 
of nucleosides seem to influence tumorigenesis. However, the underlying mechanisms of this appearance 
remain to be deciphered. 
 
5.5.2. EZH2 target gene WDR19 
Comparably to DCK, depletion of the ETG WDR19 counteracted an EZH2 inactivation-provoked growth 
arrest of melanoma cells (Figure 36). WDR19 is a critical component required for the structural and 
functional integrity of the intraflagellar transport machinery of primary, immotile cilia (Efimenko et al., 
2006; Wei et al., 2012). Wdr19-defficient mouse embryos have patterning defects affecting the limbs, the 
skeleton, and the nervous system (Ashe et al., 2012; Wainwright et al., 2014). These anomalies appear 
reminiscent of a broad spectrum of human ciliopathies. Indeed, patients affected by these disorders 
frequently harbor WDR19 mutations (Bredrup et al., 2011; Coussa et al., 2013; Fehrenbach et al., 2014; 
Schmidts et al., 2013). A primary cilium is a non-motile, microtubule-based organelle that is maintained 
by the intraflagellar transport machinery and projects from the surface of vertebrate cells. Primary cilia 
function as sensory antennae that coordinate a large number of signaling pathways coupled to cell 
division and differentiation. Hence, they play critical roles in embryonic patterning, organogenesis, and 
tissue homeostasis (Goetz and Anderson, 2010). Interestingly, upon differentiation-induced quiescence, 
melanocytes form primary cilia in vitro (Le Coz et al., 2014), in accordance with the observation that 
human epidermal melanocytes harbor these organelles (Wandel et al., 1984). Primary cilia are similarly 
detectable in melanocytic cells of nevi. However, these structures are completely absent in samples of 
malignant melanoma (Kim et al., 2011b; Snedecor et al., 2015). Comparably, primary cilia are lost in 
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advanced prostate carcinoma (Hassounah et al., 2013), while low WDR19 expression is connected to 
poor prostate cancer patient survival (Lin et al., 2008). Therefore, EZH2 might dynamically repress 
members of the intraflagellar transport machinery including WDR19 resulting in disassembly of the 
primary cilium, which sustains melanomagenesis through yet unidentified mechanisms. 
 
5.5.3. EZH2 target gene AMD1 
In contrast to DCK and WDR19, the ETG AMD1 was not relevant for melanoma growth, but AMD1 loss 
promoted melanoma EMT and metastasis (Figure 36; 38; 39). AMD1 is an enzyme that catalyzes the 
conversion of S-adenosyl-methionine (SAM) to decarboxylated SAM (dcSAM), which serves as a 
substrate for the biosynthesis network of the polyamines spermine and spermidine. Spermidine itself is 
required for the conversion of lysine 50 in eukaryotic translation initiation factor 5A (EIF5A) into the 
non-canonical amino acid hypusine, which is critical for EIF5A function. EIF5A initiates and elongates 
translation of proteins through recruitment of initiator methionyl-tRNA as well as prolyl-tRNAs to 
ribosomes (Gutierrez et al., 2013; Park et al., 2010; Scuoppo et al., 2012) (Figure 45a). Besides EIF5A 
activation, spermine and spermidine directly influence a variety of biological processes including 
transcription, translation, diverse signaling cascades, and cytoskeleton remodeling (Pegg, 2009). 
Likewise, SAM, apart from being decarboxylated by AMD1, interacts with lncRNAs and influences 
transcription and translation. But most importantly, SAM is also the methyl group donor for DNMTs and 
histone methyltransferases including EZH2. Catalysis of SAM results in methylated DNA and histones 
and produces S-adenosyl-homocysteine (SAH) as by-product (Loenen, 2006) (Figure 45b). 
The relevance of AMD1 and polyamine metabolism becomes apparent in early lethality of Amd1-
deficient embryos, while Amd1 deletion abolishes self-renewal of ESC cultures, which is restored by 
spermidine application (Nishimura et al., 2002b; Zhang et al., 2012a; Zhao et al., 2012). This 
proliferation defect is thought of resulting from impaired protein synthesis due to a lack in functional 
EIF5A. Indeed, EIF5A depletion affects growth of xenotransplanted pancreatic cancer and melanoma 
cells (Fujimura et al., 2014, Jasiulionis et al., 2007). Notably, AMD1 ablation similarly induced a G1 cell 
cycle arrest in melanoma cell cultures (Figure 36d). In contrast, Amd1 and Eif5a function as tumor 
suppressor genes in a murine lymphoma model (Scuoppo et al., 2012), while I saw an Amd1 depletion-
dependent increase in melanoma EMT and metastasis (Figure 39). 
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Figure 45 #  Polyamine synthesis and connection to EZH2 activity. (a) Schematic representation of the polyamine-
hypusine metabolic network. SAM is the substrate for AMD1, which produces dcSAM. This intermediate metabolite serves 
as substrate to generate the polyamines spermine and spermidine. Spermidine is essential to convert lysine 50 in EIF5A into 
hypusine. This non-canonical amino acid is critical for EIF5A function. (b) SAM is also the methyl group-donating 
substrate for methyltransferases, such as EZH2, which results in methylated DNA or proteins and SAH as by-product. (c) 
Hypothetical working model of AMD1 repression influencing increased EZH2 activity: EZH2 mediates AMD1 repression, 
which reduces AMD1 protein. This increases SAM availability for EZH2, which sustains EZH2 efficacy in silencing target 
genes, such as EMT / metastasis suppressors. Hence, melanoma cells secure availability of EZH2 substrate through 
epigenetic repression of substrate-competing metabolic networks. AMD1, adenosyl-methionine decarboxylase 1; EIF5A, 
eukaryotic translation initiation factor 5A; SAH, S-adenosyl-homocysteine; SAM, S-adenosyl-methionine; dcSAM, 
decarboxylated SAM (adapted from: Scuoppo et al., 2012). 
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Thus, polyamine metabolism is required for proliferative cells due to its relevance in sustaining protein 
synthesis through EIF5A. However, diminutions in protein synthesis seem to be critical for EMT and 
metastatic tumor progression. Indeed, in prostate cancer, mTOR promotes metastasis by steering a pro-
metastatic translational landscape (Hsieh et al., 2012). Likewise, reduction in the translation initiation 
factor family member EIF3E in breast cancer cells causes a global loss of protein synthesis but 
unexpectedly enhances SNAI1 and ZEB2 translation, thus promoting EMT (Gillis and Lewis, 2013).   
AMD1 depletion likely increases the abundance of SAM. Therefore, in an alternative scenario, AMD1 
reductions might influence EMT through accumulation of SAM, rather than by attenuating protein 
synthesis. An increase in SAM would facilitate aberrant EZH2 function, as EZH2-mediated H3K27me3 
is dependent on SAM as methyl group-donating substrate (Loenen, 2006). Hence, in this proposed 
model, EZH2 represses AMD1, which elevates SAM abundance, thus ultimately enhancing EZH2 
efficacy in silencing further EMT- / metastasis-suppressive genes (Figure 45c). Interestingly, in 
rheumatoid arthritis, increased SAM-dependent polyamine synthesis leads to DNA hypomethylation 
(Karouzakis et al., 2012). Thus, AMD1 and methyltransferases indeed directly compete for SAM usage. 
Previously, changes in metabolites have been connected to epigenetic rewiring. For instance, elevated 
levels of the tricarboxylic (TCA) cycle metabolite alpha ketoglutarate (αKG) maintain ESC 
pluripotency. Histone demethylases including JMJD3 and UTX utilize αKG as substrate. Therefore, an 
increase in αKG promotes demethylation of H3K9me3 and H3K27me3, which sustains pluripotency 
(Carey et al., 2015). Interestingly, the locus encoding the TCA cycle enzyme isocitrate dehydrogenase 1 
(IDH1) harbors recurrent mutations in diverse cancers (Lu and Thompson, 2012). Under physiologic 
conditions, IDH1 catabolizes isocitrate to αKG. However, mutant IDH1 displays neomorphic activity of 
converting αKG to 2-hydroxyglutarate (2HG) (Dang et al., 2009; Ward et al., 2010). αKG serves as 
histone demethylase substrate, whereas 2HG sterically hinders these enzymes (Chowdhury et al., 2011; 
Xu et al., 2011). Therefore, mutant IDH1 causes a vast increase in H3K9me3 and H3K27me3, which 
contributes to aberrant epigenetic gene silencing. Likewise, loss-of-function mutations affecting the TCA 
cycle enzyme succinate dehydrogenase (SDH) lead to an accumulation of succinate. Succinate inhibits 
histone demethylases similarly as 2HG, thus inducing global hypermethylation, which promotes tumor 
growth and especially EMT in several malignancies (Aspuria et al., 2014; Cervera et al., 2009; Letouzé 
et al., 2013). Thus, in a conceptually similar mode, an AMD1 repression-provoked raise in SAM levels 
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might indeed give rise to EZH2-mediated metastatic melanoma progression (Figure 45c). It will be of 
high interest to further decipher the interplay between abundance of metabolites and epigenetic gene 
regulation and its significance for aspects of tumorigenesis. 
 
5.5.4. EZH2 target gene MPC1 
Another ETG that caught my attention is mitochondrial pyruvate carrier 1 (MPC1). Comparably to 
AMD1, depletion of MPC1 enhances melanoma cell invasion. Mpc1 loss also promotes s.c. tumor 
growth of B16-F1 melanoma and, importantly, induces distant metastasis arising from these transplants 
(Zingg, Leu, and Antunes, unpublished data). MPC1 is a transporter that shuffles pyruvate, the end 
product of glycolysis, into mitochondria, thus providing the organelle with oxidative fuel (Bender et al., 
2015; Bricker et al., 2012; Herzig et al., 2012). Cancer cells, however, divert pyruvate to fuel other 
anabolic processes or convert it to lactate for excretion from the cell, a phenomenon referred to as 
Warburg effect (Warburg, 1956; Warburg et al., 1927). In accordance with Warburg effect, depletion of 
MPC1 reroutes metabolism to, first, increased glycolysis at the expense of pyruvate oxidation and, 
second, an increase in glutaminolysis and fatty acid oxidation to maintain TCA cycle (Schell et al., 2014; 
Vacanti et al., 2014; Yang et al., 2014a). Indeed, in several cancers, MPC1 is low-expressed, thus 
conferring Warburg effect-associated growth advantages (Schell et al., 2014). Conceivably, Mpc1 
silencing promotes B16-F1 melanoma growth. However, it is less apparent, how such a Warburg-like 
metabolic rerouting would trigger melanoma cell invasion resulting in distant metastasis (Zingg, Leu, 
and Antunes, unpublished data). 
In support of these observations, expression of the TCA cycle malic enzyme 2 (ME2) is increased in 
invasive melanoma, while ME2 depletion interferes with cell motility. ME2 maintains constant 
anaplerosis by replenishing pyruvate from glutamine (Chang et al., 2015). Comparably, pyruvate 
dehydrogenase (PDH) is the enzyme that converts pyruvate into acetyl co-enzyme A (acetyl-CoA), 
which is fueled into TCA cycle. Pyruvate dehydrogenase kinases (PDK) inhibit PDH. Interestingly, in 
melanoma-bearing mice, Pdk1 cKO enhances acetyl-CoA production, which drives oxidative 
phosphorylation, thus reversing the Warburg effect. Importantly, loss of Pdk1 abolishes metastasis 
formation (Kaplon et al., 2013; Scortegagna et al., 2014). Similarly, SNAI1 represses PDH in canine 
kidney cells, while in lung cancer cells, TGFβ signaling represses lipogenesis in a SNAI1-dependent 
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manner. Suppression of both PDH activity and lipogenesis promotes EMT (Haraguchi et al., 2013; Jiang 
et al., 2014). Thus, metabolic rewiring, for instance by EZH2-dependent repression of MPC1, is 
sufficient to promote EMT and metastasis, while EMT transcription factors reshape the metabolic 
landscape in favor of cell motility and metastasis. Intriguingly, dynamic epigenetic regulation might be 
at the source of guiding this complex interplay between metabolism and phenotypic plasticity of cancer. 
 
5.6. Epigenetic regulation of immunoediting 
I found ETGs to suppress either melanoma growth or metastasis. However, in B16-F10 melanoma 
samples, Ezh2 inactivation also promoted upregulation of an immunostimulatory gene signature. In 
contrast, immunotherapy in B16-F10 melanoma-bearing mice led to a downregulation of these 
immunogenic genes, which was significantly counteracted by Ezh2 depletion (Figure 40 - 43). 
Previously, immunogenicity has been connected to chemical blockade of epigenetic modifiers. For 
instance, DNMT and HDAC inhibition induces FAS de-repression in melanoma cells, osteosarcoma 
cells, and H-Ras-transformed fibroblasts. FAS is a death receptor recognized by FAS ligand on CTLs, 
which in turn triggers apoptosis of the target cells (Maecker et al., 2002; Molognoni et al., 2011; Rao-
Bindal et al., 2012). Likewise, Dnmt3a silencing promotes upregulation of MHC-I subunits in B16-F10 
melanoma cells (Deng et al., 2009), while both DNMT and HDAC inhibition is sufficient to similarly 
induce the antigen-processing machinery in human and murine cell lines of melanoma and further 
cancers (Chou et al., 2012; Coral et al., 2012; Gregorie et al., 2009; Khan et al., 2008; Krishnadas et al., 
2014; Kumari et al., 2013; Magner et al., 2000; Manning et al., 2008; Setiadi et al., 2008; Woods et al., 
2013; Wrangle et al., 2013; Xiao et al., 2013). Furthermore, epigenetic inhibitors also promote de-
repression of immune checkpoint effectors, such as CD40, CD80, CD86, and OX40L, but also PD-L1 
(Kumari et al., 2013; Magner et al., 2000; Woods et al., 2013; Wrangle et al., 2013; Yang et al., 2014b). 
Importantly, PD-L1 is an immune checkpoint inhibitor, thus PD-L1 upregulation might rather attenuate 
CTL efficacy (3.4.4.3. Immune checkpoint blockade as therapeutic approaches). In contrast, Ezh2 
inactivation only induced expression of positive immune checkpoint regulators, while expression of Pd-
L1, as well as of the immunosuppressant Tgfβ, was reduced (Figure 40a). Therefore, EZH2-targeted 
therapy might represent a more efficient strategy to reinforce immunogenicity than DNMT or HDAC 
inhibition. 
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In mice bearing B16-F10 melanoma or renal cell carcinoma tumors, combinatorial treatment with HDAC 
inhibitors and IL2 synergistically attenuates tumor growth through concomitant stimulation of 
lymphocytes by IL2 and reinforced immune sensitivity in the tumor compartment (Kato et al., 2007; 
2014). Comparably, we observed a synergistic growth reduction of B16-F10 melanoma upon Ezh2 
inactivation and simultaneous administration of immunotherapeutics (Figure 41). However, in contrast to 
previous studies, we provide direct evidence that the synergistic growth mitigation was based on, first, 
selective CTL stimulation through IL2-Cx or α-CTLA4, second, melanoma antigen-specific CTL 
infiltration into the tumor, and third, Ezh2 inactivation-dependent upregulation of immunogenic surface 
receptors in the tumor cells. Furthermore, we demonstrate that PRC2 mediated de novo repression of 
immune modulators in the course of immunotherapeutic pressure resulting in adaptive immune evasion 
and resistance (Figure 42; 43). This provides a rationale for combining immunotherapy and EZH2-
targeting agents likely resulting in an effective anti-melanoma response. 
Noteworthy, in activated Tregs, Ezh2 stabilizes the transcriptional program including Foxp3 expression, 
while Ezh2 deletion in Tregs impairs immunotolerance resulting in autoimmunity (Arvey et al., 2014; 
DuPage et al., 2015; He et al., 2014). Furthermore, an Ezh2 knockout in the T-cell compartment 
promotes spontaneous leukemogenicity in aged mice (Simon et al., 2012), while T-ALL patients 
frequently harbor EZH2 and SUZ12 loss-of-function mutations (Ntziachristos et al., 2012; Zhang et al., 
2012b). Therefore, melanoma patients, which would undergo a prolonged systemic therapy with EZH2 
inhibitors, had to be carefully monitored for possible autoimmunity side effects, especially in the case of 
simultaneous immunotherapy. Furthermore, dependent on genetic predispositions, systemic EZH2 
blockade might promote T-cell proliferations possibly advancing to leukemia. 
 
5.7. Possible roles of EZH2 in MAPK-targeted therapy resistance 
Efficacy of current melanoma treatments, such as MAPK-targeted therapy, is limited because of acquired 
resistances resulting in tumor relapse (3.4. Melanoma therapies) (Figure 13). In xenotransplantation 
models of human melanoma, continuous vemurafenib administration rapidly causes drug resistance. 
However, these resistant tumors become drug dependent, such as cessation of drug administration leads 
to a temporary tumor regression, while a discontinuous dosing strategy exploits this vemurafenib 
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dependency and forestalls the onset of progressive disease (Thakur et al., 2013). This plastic behavior of 
melanoma upon intermittent vemurafenib exposure supposedly underlies dynamic epigenetic 
rearrangements. Likewise, the acquirement of resistances to MAPK-targeting therapy is prevalently 
based on transcriptional dynamics (3.4. Melanoma therapies) (Figure 13), thus might depend on aberrant 
PRC2 activity. 
Indeed, in a set of solid tumor entities, inactivation of PRC2 function synergizes with chemotherapy in 
attenuating tumorigenesis, while PRC2 activity is required to establish chemoresistance (Hu et al., 2010; 
Iliopoulos et al., 2010; Ougolkov et al., 2008). Comparably, increased EZH2 activity protects 
glioblastoma stem cells from radiation therapy, while EZH2 inhibition extenuates radioresistance (Kim 
et al., 2015). Therefore, to more efficiently medicate malignant melanoma, apart from combining EZH2 
inhibitors with immunotherapy, a possibly highly effective treatment strategy might incorporate MAPK-
targeting therapeutics and EZH2 inhibition. 
A considerable number of melanomas harbor damaging alterations in the NF1 locus (De Raedt et al., 
2014; Hodis et al., 2012; Krauthammer et al., 2012), while NF1 is frequently lost upon MAPK 
inhibition, thus re-establishing MAPK signaling (Maertens et al., 2013; Van Allen et al., 2014; Whittaker 
et al., 2013). Importantly, in several cancers including MPNSTs and cutaneous melanoma, NF1 
aberrances co-occur with EED or SUZ12 loss, which expedites tumorigenesis (3.5.2. Epigenetic 
regulation of neurocristopathies). Comparably, I observed a subset of the EZH2 mutations occurring in 
melanoma specimens to be damaging for PRC2 function (Figure 18). Interestingly, in NF1-deficient 
melanoma cells, SUZ12 depletion enhances growth, while SUZ12 ablation counteracts growth of NF1WT 
cells. Therefore, in melanoma patients bearing loss of PRC2 function, EZH2 inhibition might exacerbate 
tumorigenesis rather than counteracting it. However, loss of EED or SUZ12 sensitizes tumors to BET 
bromodomain inhibitors (De Raedt et al., 2014). Hence, careful genomic screening would be absolutely 
prudent prior to subjecting melanoma patients to an EZH2-inhibiting therapy to minimize adverse 
clinical responses, while BRD4 inhibition might represent an alternative treatment strategy for the 
PRC2-inactivated subset of melanoma patients. 
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5.8. EZH2 inhibition as possible future melanoma therapy 
In a murine model of glioblastoma, Ezh2 depletion first abolishes tumor growth, but prolonged Ezh2 
ablation epigenetically redirects remaining tumor cells to an undifferentiated, stem cell-like state, which 
eventually results in tumor progression. In this model, stemness of glioblastoma cells upon Ezh2 loss is 
promoted by de-repression of pluripotency genes, which confers tumor aggressiveness. However, release 
from Ezh2 depletion abolishes the acquired stemness features and attenuates the growth advantages (de 
Vries et al., 2015). A small group of Tyr::N-RasQ61K Ink4a-/- mice similarly developed Ezh2-deficient 
melanomas despite knockout of Ezh2 in benign hyperplasia long prior to tumor initiation (Figure 23g, h). 
Therefore, also in melanoma, cells rarely escape Ezh2 dependence and form progressing tumors. These 
observations highlight the importance of carefully establishing regimens for possible future EZH2 
inhibition-based therapies, potentially including intermittent EZH2 blockade.   
Dependent on the mutational landscape, levels of oxidative and metabolic stress, the stromal context 
including the immune system, and the history of exposure to melanoma therapeutics, the set of aberrantly 
silenced tumor suppressor genes might be assembled differently in a given melanoma and at a given time 
point (Figure 6). However, I have demonstrated that EZH2 itself represents a central node in the control 
of melanoma progression through epigenetic regulation of such genes (Figure 44). In support of this, 
pharmacological inhibition of Ezh2 using the preclinical drug GSK503 in melanoma-bearing mice 
efficiently counteracted metastatic melanoma progression, resulting in a doubled survival time (Figure 
32). Therefore, my PhD thesis reveals that EZH2 inhibition, likely in combination with 
immunotherapeutics or MAPK-targeting therapeutics, might be a promising strategy for future therapies 
of human melanoma patients. 
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6. Materials and Methods 
 
6.1. In vivo experiments 
6.1.1. Human biopsies 
Human biopsies were isolated and genotyped as described (Zipser et al., 2011). Usage of nevus and melanoma biopsies as 
well as melanoma-derived cell cultures was approved by the official ethical authorities of Canton of Zurich, Switzerland. 
Written informed consent was obtained from all subjects and approved by the local institutional review boards (EK647, 
EK800). 
 
6.1.2. Mice 
Tyr::N-RasQ61K animals and Ink4a-defficient mice have previously been described (Ackermann et al., 2005; Serrano et al., 
1996; Shakhova et al., 2012; 2015). The Tyr::CreERT2 line (Bosenberg et al., 2006; Harris and Pavan, 2013; Harris et al., 
2013; Shakhova et al., 2012; 2015), Ezh2lox animals (Hirabayashi et al., 2009; Schwarz et al., 2014), and R26R::LacZ mice 
(Soriano, 1999) have been analyzed elsewhere. Mouse genotyping was performed according to a standard DNA isolation 
protocol (Laird et al., 1991), followed by PCR using a Taq PCR Core Kit (201225, Qiagen) and primers indicated in (Table 
6). Genetic background of (Tyr::N-RasQ61K Ink4a-/-) Tyr::CreERT2 Ezh2lox/lox R26R::LacZ mice was mixed, while background 
of Tyr::N-RasQ61K Ink4a-/- animals was Black 6. Mice were born with the expected ratio of Mendelian inheritance, and no 
changes in gender ratios were observed. Transgenic mice used were of both genders and were subjected to experiments 
either at the age of 1 month, or upon tumor development (5 to 7 months). Melanoma-developing mice were frequently 
monitored and sacrificed at an endpoint defined by adverse clinical symptoms, such as multiple skin tumors (Ø > 5mm), 
weight loss (Δm > 15%), or hunched back. 3-month-old female C57Bl/6J and athymic nude Foxn1nu/nu mice were 
purchased (Charles River Laboratories). Mice engrafted s.c. with melanoma cells were sacrificed at an endpoint defined by 
tumor volume (V > 1’000mm3). Tumor volume was calculated as follows: V = 2/3 × π × ((a + b) / 4))3, a (mm) was the 
length and b (mm) was the width of the tumor. Mice engrafted i.v. with melanoma cells were sacrificed 12 days post 
engraftment. All animal experiments have been approved by the veterinary authorities of Canton of Zurich, Switzerland, 
and were performed in accordance with Swiss law and the GlaxoSmithKline policy on the Care, Welfare, and Treatment of 
Animals. 
 
Table 6 #  Mouse genotyping primers. 
Allele Forward sequence Reverse sequence 
Cre CTATCCAGCAACATTTGGGCCAGC CCAGGTTACGGATATAGTTCATGAC 
Ezh2wt AAGGCTGTGTACAGGAAACAATC AGTACTCCAGAGGTACTGAAGTTTG 
Ezh2lox AAGGCTGTGTACAGGAAACAATC TCACCTTAATATGCGAAGTGGAC 
Ink4awt ATGATGATGGGCAACGTTC CAAATATCGCACGATGTC 
Ink4a-knockout CTATCAGGACATAGCGTTGG AGTGAGAGTTTGGGGACAGAG 
LacZ GGTCGGCTTACGGCGGTGATTT AGCGGCGTCAGCAGTTGTTTTT 
N-RasQ61K GATCCCACCATAGAGGATT CTGGCGTATTTCTCTTACC 
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6.1.3. In vivo Tamoxifen, GSK503, IL2-Cx, and α-CTLA4 application 
In order to conditionally ablate Ezh2, (Tyr::N-RasQ61K Ink4a-/-) Tyr::CreERT2 Ezh2lox/lox R26R::LacZ mice were subjected to 
treatment with tamoxifen (TM, T5648, Sigma-Aldrich), which was diluted (10mg/ml) in ethanol and sunflower oil (1:9 
ratio). Conditional ablation of Ezh2 was achieved by daily intraperitoneal injections of 2mg TM for 5 consecutive days. 
Mice were either 4 weeks old or at an age of 5 to 7 months, when first skin melanomas had become macroscopically 
detectable (Ø ≥ 2mm). In order to pharmacologically inhibit Ezh2 activity, Tyr::N-RasQ61K Ink4a-/-, Ink4a-/-, and C57Bl/6 
mice were subjected to treatment with GSK503 (Béguelin et al., 2013), which was diluted (15mg/ml) in 20% Captisol 
solution (Cydex). Efficient Ezh2 inhibition was achieved by daily intraperitoneal injections of 150mg/kg GSK503 over 35 
consecutive days. Ink4a-/- and C57Bl/6 mice were 5 months old. Tyr::N-RasQ61K Ink4a-/- animals were at an age of 5 to 7 
months, when first skin melanomas had become macroscopically detectable (Ø ≥ 2mm). Mice were monitored during and 
after treatment to measure GSK503-induced reversible weight loss. Moreover, a few GSK503 treated animals developed 
ascites, independently of the genotype, and had to be excluded from the studies. C57Bl/6 and Foxn1nu/nu mice engrafted 
with melanoma cells were subjected to TM and GSK503 treatment as described above. C57Bl/6 mice engrafted with 
melanoma cells were subjected to IL2-Cx and α-CTLA4 treatment as previously specified (Krieg et al., 2010; Létourneau 
et al., 2010). 
 
6.1.4. Quantification of skin melanomas and metastases 
When Ezh2 ablation was done at 1 month, developing trunk skin lesions were considered as melanomas above a diameter 
of 2mm (Ø ≥ 2mm). At day of sacrifice, a final skin melanoma count was established. In conditional Ezh2 knockout mice 
(cKO) whole mount X-Gal staining was used to quantify recombined tumors, and X-Gal negative tumors were excluded 
from cKO melanoma count. To quantify metastases, accessory axillary, proper axillary, sciatic, and subiliac lymph nodes 
(total of 8) (Van den Broeck et al., 2006) as well as the lung were subjected to further analyses. Lymph nodes were 
considered melanoma-positive, when Sox10-positive cells were found on histological sections. Black dots on lung surface 
were counted and confirmed as melanoma metastases using Sox10 staining on histological sections. Melanoma-specific 
survival curves were based on presence of (recombined) skin melanomas and/or metastases. When Ezh2 ablation or 
GSK503 treatment was done in established melanoma, newly forming skin melanomas (Ø ≥ 2mm) were counted weekly. 
At day of sacrifice, skin melanoma and metastases counts were established as described for early Ezh2 ablation, except skin 
melanoma numbers were not based on recombination but solely on tumor numbers. Melanoma-specific survival curves 
were based on presence of newly formed skin melanomas and/or metastases. 
 
6.1.5. Isografting and allografting of murine melanoma cells 
Skin melanomas from Tyr::N-RasQ61K Ink4a-/- (Tyr::CreERT2 Ezh2lox/lox R26R::LacZ) animals were dissociated into small 
pieces using forceps and scissors. Tissue was digested using 0.25mg/ml Liberase DH Research Grade (05401054001, 
Roche) in RPMI 1640 (42401, Life Technologies) for 45min at 37°C followed by a treatment with 0.55mg/ml Dispase II 
(17105, Life Technologies) and 0.2mg/ml DNase I (10104159001, Roche) for 15min at 37°C. Single cells were separated 
from remaining tissue using a 70µm cell strainer and engrafted s.c. into Foxn1nu/nu mice in PBS or cultured in vitro using 
growth medium as described below. Foxn1nu/nu mice were s.c. engrafted with either 500’000 Tyr::N-RasQ61K Ink4a-/- 
Melanoma (RIM)-1 cells, 500’000 RIM-2 cells, or 1 Mio RIM-3 cells. C57Bl/6 mice were either s.c. engrafted with 1 Mio 
B16-F10 cells or tail vein-injected with 400’000 B16-F1 cells / 100’000 B16-F10 cells.   
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6.1.6. Histological analysis and immunofluorescence 
Human and mouse tissue samples were fixed in 4% buffered formaldehyde and embedded in paraffin, except for whole 
mount X-Gal staining. Therefore, mouse tissue samples were fixed in formaldehyde for 20min and subjected to X-Gal 
staining as described (Shakhova et al., 2012). Human samples were processed into sections of 3mm thickness, while mouse 
samples were processed into 5mm sections. Slides were stained with haematoxylin and eosin (H&E) according to standard 
protocols. Sections were subjected either to immunohistochemical analyses or to immunofluorescent analyses. Briefly, 
immunohistochemical stainings were performed using primary antibodies (Table 7) in combination with the iVIEW DAB 
Detection Kit (760-091, Ventana) or the ChemMate Detection Kit (K5006, Dako) according to manufacturers’ protocols. 
For immunofluorescence, protocols described elsewhere were applied (Shakhova et al., 2012). Briefly, sections were 
deparaffinized and subjected to an antigen retrieval step using citrate buffer (S2369, Dako). Primary antibodies (Table 7) 
were applied in blocking buffer (1% BSA in PBS and 0.05% Triton X-100) overnight at 4°C and visualized using 
secondary antibodies (Table 8) in blocking buffer for 1h at room temperature. For visualization of β-Gal, a biotin α-chicken 
(1:300, AP194B, Merck Millipore) secondary antibody was combined with further signal amplification using HRP-
streptavidin (1:300, 016-030-084, Jackson ImmunoResearch) and the TSA Plus Cy3 Kit (1:50, NEL744001KT, 
PerkinElmer) according to manufacturer’s protocol. Subsequently, nuclei were stained with Hoechst 33342 (14533, Sigma-
Aldrich) and slides were mounted with Fluorescent Mounting Medium (S3023, Dako). Immunohistochemical / -fluorescent 
sections were analyzed using either a Mirax Midi Slide Scanner (Zeiss) or a DMI 6000B microscope (Leica). 
 
Table 7 #  Primary antibodies. 
Anitgen Specificity Company Serial number Applications / Dilutions 
b-Actin human / mouse Sigma-Aldrich A5316 WB, 1:10’000 / IF, 1:1’000 
DCT human / mouse Santa Cruz Biotechnology sc-10451 IF, 1:200 
EZH2 human / mouse Cell Signaling Technology 3147 WB, 1:1’000 / IF, 1:200 
b-Gal mouse Abcam ab9361 IF, 1:1’000 
Histone 3 human / mouse Cell Signaling Technology 3638 WB, 1:1’000 
H3K27me3 human / mouse Cell Signaling Technology 9733 WB, 1:1’000 / IF, 1:500 
HMB45 human Dako IS052 IHC, 1:50 
KI67 human Abcam ab156956 IF, 1:50 
Ki67 mouse BioLegend 652402 IF, 1:100 
MART1 human Novocastra PA0233 IHC, 1:50 
MART1-HMB45 human Abcam ab732 IF, 1:200 
SOX10 human / mouse Santa Cruz Biotechnology sc-17342 IF, 1:100 
Tyrp1 mouse V. Hearing Lab, NIH (Kobayashi and Hearing, 2007) aPEP1 IF, 1:500 
 
Table 8 #  Secondary antibodies. 
Fluorophore Specificity Company Serial number Applications / Dilutions 
Alexa488 goat Jackson ImmunoResearch 705-545-147 IF, 1:500 
Alexa488 rabbit Jackson ImmunoResearch 711-545-152 IF, 1:500 
Alexa488 rat Jackson ImmunoResearch 712-545-153 IF, 1:500 
Alexa546 mouse Life Technologies A-11030 IF, 1:500 
Cy3 goat Jackson ImmunoResearch 705-165-147 IF, 1:500 
Cy3 rat Jackson ImmunoResearch 712-165-153 IF, 1:500 
IRDye-800CW mouse LI-COR Biosciences 926-32212 WB, 1:10’000 
IRDye-680LT rabbit LI-COR Biosciences 926-68023 WB, 1:10’000 
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6.1.7. Peripheral blood sample and tumor-infiltrating CTL analysis 
Blood samples, tumors, and tumor-draining lymph nodes were collected and processed as previously described (Krieg et 
al., 2010; Létourneau et al., 2010). BrdU, immunophenotype, and CTL antigen-specific clone labeling for flow cytometry 
was performed according to previous reports (Krieg et al., 2010; Létourneau et al., 2010) and cell populations were 
quantified using a BD FACSCanto II flow cytometer (BD Biosciences) and FlowJo software (Tree Star). 
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6.2. In vitro experiments 
6.2.1. EZH2 mutagenesis and mutation analysis 
EZH2 mutations were chosen based on specimens in the Somatic Mutations dataset for Skin Cutaneous Melanoma (SKCM) 
as described below. Specimens showing non-synonymous mutations in the coding sequence of EZH2 and for which clinical 
data was available were selected. A previously validated pRetro-X construct containing human EZH2WT, EZH2Y646N, or 
EZH2Y646F cDNA was used (Béguelin et al., 2013). Further mutations were introduced into EZH2WT cDNA using a 
QuikChange II Site-Directed Mutagenesis Kit (200523, Agilent Technologies) according to manufacturer’s protocol. For 
each mutation, 10ng of template EZH2WT cDNA was used with the appropriate primers containing the corresponding 
sequence modification (Table 9), and constructs were sequenced using 3 pairs of primers covering the EZH2 sequence 
(Table 10). 
 
Table 9 #  Human EZH2 mutagenesis primers. 
EZH2 mutation Sequence 
EZH2P132S   forward CTAAAACTTCATCTCCCATATAAGAAATGTTATGTAAAACAGTTTCATCTTC 
EZH2P132S   reverse GAAGATGAAACTGTTTTACATAACATTTCTTATATGGGAGATGAAGTTTTAG 
EZH2D142V forward TAGTTCTTCAATGAAAGTACCAACCTGATCTAAAACTTCATCTCC 
EZH2D142V reverse GGAGATGAAGTTTTAGATCAGGTTGGTACTTTCATTGAAGAACTA 
EZH2R216Q forward TCAAAAATTTTATCAGAAGGAAATTTTTGAGGTGGGCGGCTTTCTTTATCATC 
EZH2R216Q reverse GATGATAAAGAAAGCCGCCCACCTCAAAAATTTCCTTCTGATAAAATTTTTGA 
EZH2A226V forward CTTATCTGGAAACATTGAGGAAATGACTTCAAAAATTTTATCAGAAGGAAAT 
EZH2A226V reverse ATTTCCTTCTGATAAAATTTTTGAAGTCATTTCCTCAATGTTTCCAGATAAG 
EZH2P431S forward CCACATTCTCAGGAGATTCAATATTTGGCTTCATCTTTATTGGT 
EZH2P431S reverse ACCAATAAAGATGAAGCCAAATATTGAATCTCCTGAGAATGTGG 
EZH2K515R forward GAGGAGCCGTCCCTTTTCAGCTGTATCTTTCTGCAG 
EZH2K515R reverse CTGCAGAAAGATACAGCTGAAAAGGGACGGCTCCTC 
EZH2C535W forward GGCACGAACTGTCCCAAGGCTGCCGTG 
EZH2C535W reverse CACGGCAGCCTTGGGACAGTTCGTGCC 
 
Table 10 #  Human EZH2 sequencing primers. 
Gene location Forward sequence Reverse sequence 
EZH2 N-term TGTTCGGTGACCAGTGACTT TTTGGTCCATCTATGTTGGGG 
EZH2 middle ATACAGACAGTGATAGGGAAGCA CATCCCGGAAAGCGGTTTTG 
EZH2 C-term CAAGAACTGCAGTATTCAGCG CCGACATACTTCAGGGCATC 
 
6.2.2. Cell cultures 
Human melanoma cell cultures were characterized before (Zipser et al., 2011), XB2 and Melan-a cell lines were previously 
described (Bennett et al., 1987), and HEK293T, B16-F1, and B16-F10 cell lines were purchased (ATCC). All cells 
(including primary RIM cells) were cultured in growth medium, which was RPMI 1640 (42401, Life Technologies) 
supplemented with 10% FCS (16140, Life Technologies), 4mM L-Glutamine (25030, Life Technologies), Penicillin-
Streptomycin (15070, Life Technologies), and Fungizone Antimycotic (15290, Life Technologies) as previously specified 
(Shakhova et al., 2012; Zipser et al., 2011). 
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6.2.3. Cell transfections and in vitro GSK503 treatment 
In order to overexpress EZH2WT and mutated EZH2, HEK293T cells were grown in growth medium devoid of antibiotics 
and transfected with 10µg EZH2-expressing plasmids using 2.5M CaCl2 in HEPES buffer according to standard protocols, 
and cells were subjected to functional analyses after 36h. In order to temporarily deplete EZH2, DCK, AMD1, and 
WDR19, human melanoma cells were transfected with small interfering RNAs (siRNA) indicated in (Table 11). 25nM 
siRNA was applied in combination with jetPRIME siRNA Transfection Reagent (114-15, Polyplus Transfection) according 
to manufacturer’s guidelines. Growth medium was exchanged after 24h and cells were subjected to further assays after 72h, 
unless specified. For all functional assays the most efficient siRNAs underlined in (Supplementary Table 9) were used. In 
order to stably deplete Ezh2 and Amd1, murine melanoma cells were transfected with small hairpin RNA (shRNA)-
expressing plasmids indicated in (Table 11). 10µg plasmid was applied in combination with jetPEI DNA Transfection 
Reagent (101-10N, Polyplus Transfection) according to manufacturer’s guidelines. Transfected cells were selected using 
1µg/ml puromycin (A11138-02, Life Technologies) for 1 week before subjection to further assays. Efficiency of shEzh2 
was previously validated (Tiwari et al., 2013). In order to pharmacologically inhibit EZH2, melanoma cells were treated 
either with vehicle (DMSO) or 1µM GSK503. Cells were treated for 8 days before subjection to further assays. Drug was 
only replenished when cells were passaged during the 8-day period. 
 
Table 11 #  RNAi constructs. 
Target gene si/shRNA name Specificity Company Serial numbers 
none siCo human Life Technologies 12935-112 
EZH2 siE human Life Technologies HSS176653, HSS176652, HSS103462 
DCK siDCK human Life Technologies HSS141795, HSS175996, HSS175997 
AMD1 siAMD1 human Life Technologies HSS100444, HSS178141, HSS178142 
WDR19 siWDR19 human Life Technologies HSS126737, HSS126738, HSS184043 
none shCo mouse Sigma-Aldrich SHC002 
Ezh2 shE mouse Sigma-Aldrich TRCN0000039040 
none shCo mouse GE Healthcare RHS4346 
Amd1 shAmd1 mouse GE Healthcare V2LMM_71494, V2LMM_72222 
 
6.2.4. Cell growth and apoptosis assays 
To establish growth curves, cell counts were measured daily starting 48h after transfection. For cell cycle analysis, cells 
were 50% ethanol-fixed, and labeled with propidium iodide including RNase A (F10797, Life Technologies). To measure 
apoptosis, an Annexin V Apoptosis Detection Kit (559763, BD Biosciences) was used. Cell cycle and apoptotic cells were 
quantified using a BD FACSCanto II flow cytometer (BD Biosciences) and FlowJo software (Tree Star). 
 
6.2.5. Boyden chamber invasion assay 
After 24h of transfection or 8d of GSK503 treatment, cells were starved for 48h in starvation medium containing all 
supplements except 1% FCS. Subsequent Boyden chamber invasion assays were done according to manufacturer’s 
protocol. Briefly, 150’000 cells were subjected to Matrigel-coated well inserts (354480, BD Biosciences) in empty medium 
(0% FCS, 0% L-Glutamine). Growth medium was used as chemoattractant for 24h. Transvaded cells were 4% buffered 
formaldehyde-fixed and visualized using Hoechst 33342 (14533, Sigma-Aldrich). Membranes were mounted to glass 
slides, and cell numbers were quantified using a DMI 6000B microscope (Leica) and CellProfiler software (Carpenter et al., 
2006). 
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6.2.6. Immunofluorescence on cells 
Cells were grown on cover slips, 50% ethanol-fixed, and subjected to immunofluorescent labeling using primary antibodies 
(Table 7) in blocking buffer (1% BSA in PBS) overnight at 4°C and secondary antibodies (Table 8) for 1h at room 
temperature. Nuclei were stained with Hoechst 33342 (14533, Sigma-Aldrich), and cells were recorded with a DMI 6000B 
microscope (Leica). 
 
6.2.7. Protein isolation and western blotting 
Protein isolation and western blotting was done as previously described (Shakhova et al., 2012), unless specified. Briefly, 
cells were lysed in RIPA buffer (89900, Thermo Scientific) containing Halt Phosphatase and Protease Inhibitor Cocktail 
(78420, 87786, Thermo Scientific), while tumor biopsies were homogenized in such buffer using a tissue homogenizer 
(Polytron). SDS-PAGE was carried out on 4-20% Mini-PROTEAN TGX Gels (456-1094, Bio Rad). Primary antibodies 
(Table 7) were applied in Odyssey blocking buffer (927-40000, LI-COR Biosciences) overnight at 4°C and visualized using 
secondary antibodies (Table 8) in Odyssey blocking buffer (927-40000, LI-COR Biosciences) for 45min at room 
temperature. Blots were scanned and quantified with an Odyssey imaging system (LI-COR Biosciences). Quantified band 
intensities were normalized using either β-Actin or Histone 3 as housekeeping protein. Full scans are shown in (Figure 46). 
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Figure 46 #  Full scans of western blots. (a) Full scans corresponding to (Figure 18c). (b - d) Full scans of M010817 (b, 
d) and M050829 (c, d) after siE (b, c) or GSK503 (d) corresponding to (Figure 26a). (e) Full scans corresponding to 
(Figure 28d). (f) Full scans corresponding to (Figure 29c). 
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6.2.8. RNA isolation and RT-qPCR 
RNA extraction and DNase treatment of samples was performed using the RNeasy Mini Kit (74104, Qiagen) and the 
RNase-Free DNase Set (79254, Qiagen) according to manufacturer’s guidelines. Purified RNA was quantified using 
nanodrop and subjected to reverse transcriptase reaction using Maxima First Strand cDNA Synthesis Kit (K1641, Thermo 
Scientific) followed by an RNase H (EN0202, Thermo Scientific) digestion step according to manufacturer’s 
recommendations. Quantitative real-time PCR was performed on a LightCycler 480 System (Roche) using LightCycler 480 
SYBR Green I Master (4707516001, Roche). Primers used are indicated in (Table 12; 13). Each sample was analyzed in 
technical triplicates, and relative quantified RNA was normalized using USF1 or GAPDH, when specified, as housekeeping 
transcript.  
 
Table 12 #  Mouse RT-qPCR primers. 
Gene Forward sequence Reverse sequence 
Acta2 TGACAGAGGCACCACTGAAC AGAGGCATAGAGGGACAGCA 
Amd1 TGTGGAAGTCTTCAAGCCAGG CGAAGAAAGCACTGTGCGAC 
Cd40 TCCTCATCACCATTTTCGGGG TCCATCTCCTGGGGATCTTG 
Cd70 CGCACACAGCTGAGTTACAG CTCTGGTCCGTGTGTGAAGG 
Cd80 CGACTCGCAACCACACCAT GCTATCAGGAGGGTCTTCTGG 
Cd86 AGCTTCAGTTACTGTGGCCC TGTCAGCGTTACTATCCCGC 
Cdh1 CTGCTGCCACCAGATGATGA CTGTGCAGCTGGCTCAAATC 
Cdh2 GCGCCATCATCGCTATCCTT TCCCGCCGTTTCATCCATAC 
Dck AAGCTGGCTCCTTCATCGGA TAACATCCAGTGTGAGGACGG 
Dct CCTGAATGGGACCAATGCCT AGGCATCTGTGGAAGGGTTG 
Ets1 GCCAACCCTACCTACCCAGA GAGGGAGGAACACACTGAGC 
Ezh2 GTGACCACAGGATAGGCATCT CAAGGGATTTCCATTTCTCG 
Fas (Cd95) TCCCAGAAATCGCCTATGGT CCTGTCTCCTTTTCCAGCACT 
H2-D1 GGAGCTATGGCCATCATTGGA TCTCGGAGAGACATTTCAGAGC 
H2-K1 CTGGAGCTGTGGTGGCTTT GACAGATCAGAGGTCTGGGAG 
Mitf CCCCAAGTCAAATGATCCAG GCAACTTCCGGATGTAGTCC 
Mmp1 GAACACGGGGAAGACCCTCT TTCCTCTTCTATGAGGCGGGG 
Mmp3 GACTCAAGGGTGGATGCTGT CCAACTGCGAAGATCCACTG 
Ox40l (Tnfsf4) GGACCCTCCAATCCAAAGACT CCGAATTGTTCTGCACCTCC 
Pd-L1 (Cd274) GGACTACAAGCGAATCACGC TTCTGGATAACCCTCGGCCT 
Pmel GGGGATGCATTTGAGCTGAC CTGGCACCCTGGTGATGAAA 
Psmb8 AGCATCCAAGCTGCTTTCCAA CCGAGTCCCATTGTCATCTACG 
Psmb9 GGTTCCGGAAGCTCCTACAT AGAGCCATCTCGGTTCATGG 
Snai1 GTGGAAAGGCCTTCTCTAGGC GGTTGGAGCGGTCAGCAAAA 
Sox10 GAAGAAGGCTCCCCCATGTC GCTCTGTCTTTGGGGTGGTT 
Tap1 TCCCTCAGGGCTATGACACA ATAAGCAGGAGTGGCTTCCG 
Tap2 ACTGTGAGGACGCTCAAGTG TAACTGGCCCCCTTTTTCCC 
Tgfb1 ATGCCAACTTCTGTCTGGGAC CGGGTTGTGTTGGTTGTAGAG 
Twist1 CGGCCAGGTACATCGACTTC TGCAGCTTGCCATCTTGGAG 
Tyr GTACTTGGGAGGTCGTCACC GTCCCTCAGGTGTTCCATCG 
Usf1 CAGGGCTCAGAGGCACTACT GCTCCCTCCCTGCAATACTT 
Vim GCGAGGAGAGCAGGATTTCT TGAGTGGGTGTCAACCAGAG 
Wdr19 ACCACCCCATGTCCATTCTG CGTCTTTCAACATGTGTCGGC 
Zeb1 GATCCAGCCAAACGGAAACC TGGCGTGGAGTCAGAGTCAT 
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Table 13 #  Human RT-qPCR primers. 
Gene Forward sequence Reverse sequence 
ACTA2 GGCAAGTGATCACCATCGGA GTGGTTTCATGGATGCCAGC 
AMD1 CCAGGAAAATTTGTGACCACCT ACTCTGGCAATCAAGACGCT 
APOBEC3D AAGCACCACTCAGCTGTCTTC CCAGGTGACCTCGTAGTTTGT 
CD40 AGTCAGTGCTGTTCTTTGTGC TTCGCTTTCACCGCAAGGA 
CDH2 ACAGTGGCCACCTACAAAGG CCGAGATGGGGTTGATAATG 
DCK AAAGCTGGCTCCTGCATAGG TCCAGTGTTAAGATAGGCACCTC 
ETS1 GATAGTTGTGATCGCCTCACC GTCCTCTGAGTCGAAGCTGTC 
EZH2 CCCTGACCTCTGTCTTACTTGTGGA ACGTCAGATGGTGCCAGCAATA 
FAM198B AGCGAAAGCATGACCCAAGG CCGTAAGTGCTGGCTCTTCAA 
GAPDH ACCCAGAAGACTGTGGATGG TCTAGACGGCAGGTCAGGTC 
KCTD18 TGCGTCACATGGCTCCAAT CTGAGGCCGAGTTCTTGACTT 
MMP1 TTGTGGCCAGAAAACAGAAA TTCGGGGAGAAGTGATGTTC 
MMP3 CAATTTCATGAGCAGCAACG AGGGATTAATGGAGATGCCC 
MPC1 ATCAGTGGGCGGATGACATT GGCATGCAAACAGAAGCCAG 
MUT ACTTAACTCCCTTGGACGGC CGAGTCCCAGGACCAAATACA 
PYROXD2 AGCAGGAGAGAGACGCTTATG TGAGGATGTCTCTGCCAACC 
RAB40B ATGGGATGGACCGGCTCT TTAAGGCAATGGGGAGCGG 
SCPEP1 AGCATTGTGGACGAGTTGCT ACTTCAGTTTCCGCACCCAG 
SNAI1 CCTCCCTGTCAGATGAGGAC CCAGGCTGAGGTATTCCTTG 
SNAPC1 TGAAAGGGCAGAATCATTAGCG TTGACTTGCCCTTGACCAGA 
SNAPC5 GAAGAGGGGATGAGATGCTGTC CAGCTCCAGGGTTGTTTGGT 
STX8 TCGCCAAAAACAAATGGGGC TGTTTACCCGCCTGGTTTCA 
TWIST1 GTCCGCAGTCTTACGAGGAG CCAGCTTGAGGGTCTGAATC 
TXNIP TATCCTGGGCTGCAACATCC TCTGCTGCCAATTACCAGGG 
USF1 TACTACCCAGGGCTCAGAGG TCCCTGCAGTACTTCTTGTGG 
VIM GAGAACTTTGCCGTTGAAGC GCTTCCTGTAGGTGGCAATC 
WDR19 TGATGAGGCCTGAATACCGC AATGGACATGGAGTCGTGGC 
XPOT GACCTGGCAGATGCACAAAC GCAAGGAGGGCAGGTATTCT 
ZC3H6 ATGAGTCCCTGCAAAACCCAG TGGGCAAATTCACCATGCCA 
ZEB1 GCACAACCAAGTGCAGAAGA CATTTGCAGATTGAGGCTGA 
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6.2.9. Chromatin isolation and ChIP 
Chromatin isolation and ChIP was done as previously described (Santoro, 2014). Briefly, an antibody against H3K27me3 
(1:250, 9733, Cell Signaling Technology) and Dynabeads Protein A (10002D, Life Technologies) were used. Quantitative 
real-time PCR was performed on a Rotor Gene RG-3000A (Qiagen) using the SensiFAST Probe Hi-ROX Kit (BIO-82005, 
Bioline). Primers were designed to amplify genomic DNA from a region flanking the transcriptional starting site -500bp to 
+100bp devoid of local CpG islands using CpG island prediction (Li and Dahiya, 2002). Primers used are indicated in 
(Table 14). Relative promoter enrichment was normalized to chromatin inputs and to GAPDH promoter as negative control. 
 
Table 14 #  Human ChIP primers. 
Promoter Forward sequence Reverse sequence 
AMD1 ACAGCTGGAACAATCCGCAG CGTGAGACTAGCGAACAACCA 
APOBEC3D TTTGCAATTGCCTTGGGTCC GCCCTGGGACGCTTTATCTT 
CD40 GAGTTGTTTTTGCCCCGACC CTGCCCCCACAAAAATCAGC 
DCK CAGCCTGGCTCTCTAAGTGG CATCTGGGGAGAAGGCACTG 
FAM198B CCCTGTCCCCTTTCTGTCTTC TGTCCTAGCACAAAGGCAGG 
GAPDH TACTAGCGGTTTTACGGGCG TCGAACAGGAGGAGCAGAGAGCG 
KCTD18 AGTGACCTTGGACAATCGCA CACACGGTAGAGAAGGCCAG 
MPC1 GAGAGGGTGCGCTTGTCAG CACTGTCACCGGCTCTCTAC 
MUT CGCGCCCAAACATTCGTAAA AGGGTTAGATGCCCGTTTCC 
PYROXD2 GCATGGAGTTGGAGCAGAGT CAGAGTGGAGCTCGAAAGGG 
RAB40B AACTGGACCGACCCCGA GAACTCGCTCCCACGGTC 
SCPEP1 TGGTCTGAGTGCTTCCGTTC CGGGGAAACCTCATTGACCA 
SNAPC1 AGACCTAAAACCGCTCGTGA TTGCTTTCACCCAGAGTGCT 
SNAPC5 AGGTATTGACCAGCAGCCTC CTGGCTTTGTCATGCCTGTG 
STX8 TACAGAGAGGTCTTGCAGCG CTGCGGACAGTACACTGGAG 
TXNIP AAGGAGTGCTTGTGGAGATCG TACGCCGCTGGTTACACTAAG 
WDR19 CTCCTCCCTTCTACCCCAGA GGAGGCAGGATGGGCTAAAT 
XPOT CTGCTGTACTCGGGACACTT GGATTCACGAATCAGGATGACG 
ZC3H6 AAACTGCATGGCAAGCTATTTTCC AAGGCGGCTGTAGAGTCCTTA 
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6.3. In silico analyses 
6.3.1. Microarray analysis 
Total RNA was isolated as described for RT-qPCR. Total RNA was amplified and biotin-labeled using the MessageAmp 
II-Biotin Enhanced aRNA Amplification Kit (AM1791, Life Technologies). Biotin-labeled RNA was hybridized to Human 
Gene 2.1 ST Array (902136, Affymetrix) following the manufacturer’s protocol. After hybridization, microarrays were 
washed and stained using a GeneChip Fluidics Station 450 (Affymetrix), and scanned with a GeneChip Scanner 7G 
(Affymetrix). Differential gene expression was determined by R package limma (Smyth, 2005). Microarray data have been 
deposited in the NCBI Gene Expression Omnibus (GEO) archive under the accession code GSE63165. Gene ontology 
network analysis was performed with MetaCore (Thomson Reuters). 
 
6.3.2. TCGA analysis 
The RNAseq, Somatic Mutations, and Clinical datasets for Skin Cutaneous Melanoma (SKCM), and the Somatic Mutations 
datasets for Colon Adenocarcinoma (COAD), Lung Squamous Cell Carcinoma (LUSC), Lung Adenocarcinoma (LUAD), 
Glioblastoma Multiforme (GBM), Kidney Renal Clear Cell Carcinoma (KIRC), Acute Myeloid Leukemia (LAML), Head 
And Neck Squamous Cell Carcinoma (HNSC), Breast Invasive Carcinoma (BRCA), and Prostate Adenocarcinoma 
(PRAD) were downloaded on September 29, 2013 from The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov/). 
Somatic mutation data was annotated using ANNOVAR (Wang et al., 2010b). Non-synonymous EZH2 mutations were 
mapped to functional EZH2 domains based on previous reports (Ciferri et al., 2012; Tiffen et al., 2015). Raw RNAseq 
reads were normalized with edgeR (Robinson et al., 2010) and differential RNA expression was analyzed with voom from 
R package limma (Smyth, 2005). Specimens with top and bottom transcript levels for a gene of interest were used for 
analysis. Patient numbers were gradually increased from a minimum of top and bottom 7% (19 out of 274) to a maximum 
of top and bottom 25% (69 out of 274), in order to optimize potential segregation of Kaplan-Meier curves. This procedure 
was performed for EZH2 and all commonly differentially expressed genes form the microarray datasets (Figure 35a) in an 
unbiased way. 
 
6.3.3. Statistical analyses 
Quantifications of immunofluorescent stainings were done on sections of at least 3 different mice. Therefore, at least 150 
hair follicles or at least 300 label-positive cells were counted. Cell culture-based experiments were done at least in 
biological triplicates. P-values for comparison of 2 groups were calculated with unpaired Student’s t-test, except for paired 
data (follow-up measurements on the same mouse). Therefore, paired Student’s t-test was applied. P-values for comparison 
of multiple groups were calculated with ANOVA and Fisher’s LSD-test. P-values for comparison of Kaplan-Meier curves 
were calculated with Log-rank (Mantel-Cox) test. P < 0.05 was considered significant. 
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